<?xml version="1.0" encoding="utf-8"?>
<add>
	<doc>
		<field name="docid">BR-TU.23951</field>
		<field name="filename">8233_000876978.pdf</field>
		<field name="filetype">PDF</field>
		<field name="text">
1 
 

 
UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL 

FACULDADE DE MEDICINA 

PROGRAMA DE PÓS-GRADUAÇÃO EM MEDICINA: CIÊNCIAS MÉDICAS 

 

 

 

 

 

ASPECTOS CLÍNICOS E BIOQUÍMICOS DA DOENÇA DE MACHADO-JOSEPH: 

DA DESCRIÇÃO DE NOVOS BIOMARCADORES À BUSCA DE UM TRATAMENTO 

EFETIVO 

 

 

 

 

JONAS ALEX MORALES SAUTE 

 

 

Orientador: Profa. Dra. Laura Bannach Jardim 

Tese apresentada ao Programa de Pós-Graduação 

em Medicina: Ciências Médicas, UFRGS, como 

requisito para obtenção do título de Doutor  

 

Porto Alegre, janeiro de 2013 

 



2 
 

Dedicatória 

 

À minha mãe, Loiva. 

  



3 
 

Agradecimentos 

 

À minha orientadora Dra. Laura Bannach Jardim pelo exemplo como médica, 

professora e pesquisadora, e pelo apoio dado em todas as etapas deste trabalho 

bem como em minha formação em Neurogenética.  

Aos meus mestres do Departamento de Bioquímica da UFRGS, Prof. Luis Valmor 

Cruz Portela e Prof. Diogo Souza por me abrirem as portas do mundo científico. 

À professora Márcia Chaves, chefe do Serviço de Neurologia do HCPA, por ter 

permitido a simultaneidade da realização da residência médica em Neurologia e do 

doutorado em Ciências Médicas. 

A todos os meus colegas de residência médica em Neurologia e Genética Médica, 

em especial para Carlos, Lenise e Antonette que me acompanharam em boa parte 

deste percurso e o tornaram ainda mais agradável. 

À equipe de pesquisa em Neurogenética, em especial para Artur Schuh, Thais 

Monte, Carlos Rieder, Raphael Castilhos, Gabriele Souza, Aline Russo, Karina, 

Donis, Rui D‘Ávila, Gabriel Furtado, Tailise Gheno, Maria Luiza Saraiva-Pereira e 

Andrew Chaves pela inestimável colaboração. 

À Vanessa Torman e Suzi Camey pelo auxílio estatístico, literalmente express. 

Aos professores, contratados, funcionários e bolsistas dos serviços de Neurologia e 

Genética Médica do HCPA por todo apoio e aprendizado. 

Aos colaboradores e colegas do Departamento de Bioquímica da UFRGS, 

especialmente para Alexandre Muller, Júlia Moreira, Marcelo Ganzella e Prof. Diogo 

Lara, pela inestimável cooperação e incentivo.  

À Janine, que me acompanhou durante toda esta jornada, pelo amor e compreensão 

e por me mostrar um olhar mais crítico e mais bonito sobre vários aspectos da vida, 

inclusive da ciência. 

Aos meus pais, Newton e Loiva e ao meu irmão, Edson pelo imensurável apoio, 

incentivo, carinho e compreensão em mais este percurso que se encerra. 



4 
 

Aos pacientes e seus familiares. 

 

 

   

  



5 
 

Resumo  

Introdução: A doença de Machado-Joseph (DMJ) ou ataxia espinocerebelar tipo 3 

(SCA3) é causada por uma expansão de trinucleotídeos CAG no gene ATXN3,  que 

leva à degeneração de múltiplos sistemas neurológicos. Seu curso é invariavelmente 

progressivo, não havendo tratamento específico.  

Objetivos: Descrever novos biomarcadores, aspectos não motores e definir quais 

escalas clínicas devem ser utilizadas como desfechos principais nos futuros ensaios 

clínicos randomizados (ECR) para a DMJ/SCA3. Além de avaliar se o tratamento 

com carbonato de lítio é seguro e efetivo em reduzir a progressão desta condição. 

 Métodos: Em estudo caso-controle avaliamos: 1) a relação dos sintomas 

depressivos na DMJ/SCA3, pelo inventário de Beck (BDI), com aspectos de 

gravidade clínica e molecular; 2) alterações no índice de massa corporal (IMC) e sua 

correlação com aspectos clínico-moleculares e de neuroimagem; e 3) o Sistema 

Insulina/ IGF-1 (IIS) e o potencial de seus componentes como biomarcadores. 

Fizemos uma revisão sistemática sobre os aspectos psicométricos das escalas 

clínicas de SCAs já descritas, para em seguida iniciarmos um ECR, duplo-cego, 

paralelo, placebo-controlado de fase 2/3. Para este estudo foram randomizados 62 

pacientes com diagnóstico molecular prévio de DMJ/SCA3 com marcha 

independente e ? 10 anos de doença (1:1) para tratamento com carbonato de lítio 

(0.5-0.8mEq/L) ou placebo.  

Resultados: Os escores do BDI foram mais elevados na DMJ/SCA3 (p= 0.012) e 

correlacionaram-se significativamente apenas com as escalas SARA (R=0.359, 

p=0.01) e NESSCA (R=0.412, p=0.003). Os pacientes com DMJ/SCA3 (N=46) 

apresentaram IMC menor (24.4 ± 4.1) do que os indivíduos controle (N=42, 27.1± 

4.5, p=0.01), havendo correlação inversa (R=?0.396, p=0.015) entre o IMC e o 

tamanho da sequencia repetitiva CAG (CAGn). Encontramos uma maior 

sensibilidade periférica à insulina (HOMA2-%S, p=0.003, corrigido pelo IMC) e níveis 

séricos mais elevados da proteína ligante do IGF-1, IGFBP-1 (p=0.001) na 



6 
 

DMJ/SCA3. A IGFBP1 correlacionou-se diretamente à CAGn (R=0.452; p = 0.006) e 

a sensibilidade à insulina inversamente à idade de início dos sintomas (R=-0.444; P 

= 0.003). Concluímos, na revisão sistemática, que as escalas semi-quantitativas 

SARA e NESSCA, e as quantitativas SCAFI e CCFS seriam os melhores desfechos 

para um ECR.  O uso de lítio foi seguro após 24 semanas de tratamento, não 

havendo diferenças no número total de eventos adversos entre os grupos lítio 

(50,3%) e placebo (49,7%, p=1.00). O grupo placebo apresentou maior progressão 

(que não foi significativa) nos escores NESSCA (0.35 pontos, 95% IC -1.0 a 1.7, 

p=0.222, desfecho primário de efetividade) e SARA (0.96 pontos, 95% IC -0.46 a 

2.38, p=0.329), após 48 semanas de tratamento. A gravidade da ataxia de marcha 

(p=0.008), as provas funcionais quantitativas: PATA rate (p=0.002) e Click Test ND 

(p=0.023), e os escores compostos SCAFI (p=0.015) e CCFS (p=0.029) 

apresentaram menor progressão no grupo tratado com lítio durante as 48 semanas. 

Conclusão: Os resultados destes estudos ajudam no entendimento da depressão e 

alterações nutricionais da DMJ/SCA3 e apontam a IGFBP-1 como biomarcador e a 

sensibilidade periférica insulínica como modificador do fenótipo. Houve efetividade 

do tratamento com carbonato de lítio nos desfechos secundários do ECR, sendo 

necessária confirmação por ensaios clínicos multicêntricos.  

 

PALAVRAS-CHAVE  

Doença de Machado Joseph; Ataxia Espinocerebelar tipo 3; poliglutaminopatias; 

depressão; aspectos nutricionais; índice de massa corporal; biomarcador; fator 

modificador; escalas de ataxia; escores de ataxia; tratamento; ensaio clínico; 

carbonato de lítio. 

  



7 
 

Abstract  

Background: Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 

(SCA3) is caused by a CAG repeat expansion at ATXN3 gene, leading to 

progressive degeneration of multiple neurological systems. MJD/SCA3 is an 

invariably progressive disorder, with no current treatment. 

Objectives: To describe new disease biomarkers, non-motor aspects and to define 

the clinical SCA scales to be utilized as main outcomes in future randomized 

controlled trials (RCT) on MJD/SCA3. And further assess safety and effectiveness of 

lithium carbonate in reducing the progression of this condition. 

Methods: We performed a case-control study to evaluate: 1) the relation of 

MJD/SCA3 depressive symptoms, through Beck depression Inventory (BDI), with 

other clinical and molecular findings; 2) the Body Mass Index (BMI) of MJD/SCA3 

patients and the correlation with other clinical, molecular and neuroimaging findings; 

and 3) the Insulin/IGF-1 system (IIS) in MJD/SCA3 and the possible biomarker 

properties of its components. We further performed a systematic review on the 

psychometric properties of the described SCAs scales in order to initiate the double-

blind, parallel, placebo-controlled phase 2/3 clinical trial. 62 independently 

ambulatory MJD/SCA3 patients with ? 10 years of disease duration were randomly 

assigned in the RCT (1:1) to lithium (0.5-0.8mEq/L) or placebo. 

Results: BDI scores were higher in MJD/SCA3 patients (p= 0.012), with significant 

correlations only with the scales SARA (R=0.359, p=0.01) and NESSCA (R=0.412, 

p=0.003). MJD/SCA3 patients (N=46) presented lower BMI (24.4 ± 4.1) than control 

individuals (N=42, 27.1± 4.5, p=0.01). BMI correlated inversely with the length of the 

expanded CAG repeat (CAGn). We found higher peripheral sensitivity to insulin 

(HOMA2-%S, p=0.003, corrected for BMI) and serum levels of the IGF-1 binding 

protein, IGFBP-1 (p=0.001) in MJD/SCA3. IGFBP-1 correlated with CAGn (R=0.452; 

p = 0.006) and insulin sensitivity with the age of disease onset (R=-0.444; P = 0.003). 

In the systematic review we concluded that the semiquantitative SCA scales SARA 

and NESSCA and the quantitative instruments SCAFI and CCFS would be the most 

appropriate outcomes for the RCT.  After 24 weeks, there were no differences in the 

number of adverse events in lithium (50.3%) and placebo (40.7%) groups (p=1.00) in 

the RCT. The placebo group presented a non-significant faster progression on 

NESSCA (0.35 points, 95% CI -1.0 to 1.7, p=0.612, primary effectiveness outcome) 



8 
 

and SARA (0.96 points, 95% CI -0.46 to 2.38, p=0.186), after 48 weeks of treatment. 

Gait ataxia severity (p=0.008), the quantitative performance tasks: PATA rate 

(p=0.002) and Click Test ND (p=0.023), and the composite scores SCAFI (p=0.015) 

and CCFS (p=0.029) presented a slower progression under lithium therapy in the 

overall 48 weeks period.  

  

Conclusion: These studies added to the understanding of depressive and nutritional 

manifestations of MJD/SCA3 and points IGFBP-1 as a biomarker and peripheral 

insulin sensitivity as a disease phenotype modifier. The effectiveness of lithium 

carbonate treatment shown in secondary outcomes of the RCT opened a perspective 

for an effective therapy for this untreatable disorder that must be confirmed by large 

multicentric clinical trials.   

 

KEYWORDS  

Machado-Joseph Disease, Spinocerebellar ataxia type 3, polyglutamine disorders; 

depression; nutrition; body mass index; biomarker; disease modifier; ataxia scales; 

ataxia scores; treatment; clinical trial; lithium carbonate.   

  



9 
 

Lista de Figuras 
 

Figura nº 1 – Mapa de frequência da DMJ/SCA3 no RS ..........................................20 

Figura nº 2 - Agregados intranucleares neuronais ....................................................23 

Figura nº 3 - Domínios funcionais da Ataxina-3.........................................................24 

  



10 
 

Lista de Abreviaturas  

 

 
SIGLA Significado 

8MW 8m Walking-time 

9HPT 9-Hole Pegboard Test 

ARN ácido ribonucleico 

ATXN1 gene associado à SCA1 

ATXN2 gene associado à SCA2 

ATXN3 gene associado à DMJ/SCA3 

ATXN3 proteína ataxina-3 

CAG glutamina 

CCFS Composite Cerebellar Functional Score 

DH doença de Huntington 

DHL2 doença de Huntington-like tipo 2 

DMJ doença de Machado-Joseph 

DRPLA atrofia dentato-rubro-palido-luisiana 

ECR ensaio clínico randomizado 

ELA esclerose lateral amiotrófica 

HAT acetiltransferases de histonas 

HDAC desacetilases de histonas 

HSP proteínas heat shock 

ICARS International Cooperative Ataxia Rating Scale 

IGF-1 Fator de Crescimento Semelhante à Insulina Tipo 1 



11 
 

IMC índice de massa corporal 

IIS Sistema Insulina / IGF-1 

NESSCA Neurological Examination Score for the Assessment of 

Spinocerebellar Ataxia 

NI neuroinclusões ou agregados intranucleares neuronais 

poliQ poliglutaminopatias 

PoliQ poliglutaminas expandidas 

REM fase do sono em que ocorrem movimentos oculares rápidos 

ROS espécies reativas de oxigênio 

SARA Scale for the Assessment and Rating of Ataxia 

SBMA atrofia muscular espinhal e bulbar 

SCA ataxia espinocerebelar 

SCAFI SCA Functional Index 

SNC sistema nervoso central 

SNP sistema nervoso periférico 

UIM motivos de interação com a ubiquitina 

UPS sistema ubiquitina-proteassoma 

UMSARS Unified Multiple System Atrophy Rating Scale 

 



12 
 

Sumário 

Resumo ..................................................................................................................... 5 

Abstract ..................................................................................................................... 7 

1. Introdução ......................................................................................................... 14 

2. Revisão da Literatura ......................................................................................... 17 

2.1 Aspectos Históricos ............................................................................................ 17 

2.2 Aspectos Epidemiológicos .............................................................................. 19 

2.3 Aspectos Genéticos ......................................................................................... 21 

2.4 Fisiopatologia ................................................................................................... 23 

2.4.1 Agregados Intracelulares e proteotoxicidade ................................................... 23 

2.4.2 Funções da ATXN3 ......................................................................................... 24 

2.4.3. Haploinsuficiência como principal mecanismo de doença? ............................ 26 

2.4.4 Efeitos diretos da PoliQ e da sua tendência à agregação ............................... 27 

2.5 Aspectos Clínicos e Patológicos ....................................................................... 27 

2.5.1 Manifestações Clínicas Motoras ...................................................................... 28 

2.5.1.1 Manifestações Cerebelares .......................................................................... 28 

2.5.1.2 Manifestações Oculares ............................................................................... 29 

2.5.1.3 Achados Piramidais ...................................................................................... 29 

2.5.1.4 Achados Extrapiramidais .............................................................................. 29 

2.5.1.5 Achados relacionados ao SNP ..................................................................... 30 

2.5.2 Manifestações Clínicas Não Motoras .............................................................. 30 

2.5.2.1. Distúrbios do Sono e Olfativos..................................................................... 31 

2.5.2.2. Alterações Cognitivas e Transtornos Psiquiátricos ...................................... 31 

2.5.2.3. Outras Manifestações Não Motoras ............................................................ 32 

2.5.3 Achados Anatomopatológicos ......................................................................... 32 

2.6 Diagnóstico ......................................................................................................... 33 

2.7 História Natural ................................................................................................... 34 

2.8 Biomarcadores.................................................................................................... 34 

2.9 Tratamento .......................................................................................................... 35 

3 Objetivos................................................................................................................ 37 

3.1 Objetivo principal ............................................................................................... 37 

3.2 Objetivos secundários................................................................................... 37 

4 Referências bibliográficas da revisão ................................................................. 39 



13 
 
5 ARTIGOS EM INGLÊS ........................................................................................... 54 

5.1 Capítulo 1 - Depressive Mood is Associated with Ataxic and Non-Ataxic 

Neurological Dysfunction in SCA3 Patients……………………………………..54 

5.2 Capítulo 2 - Body Mass Index is Inversely Correlated with the Expanded 

CAG Repeat Length in SCA3/MJD Patients……………………………………62 

5.3 Capítulo 3 - Serum Insulin-Like System Alterations in Patients with 

Spinocerebellar Ataxia Type 3……………………………………………………71 

5.4 Capítulo 4 - Ataxia Rating Scales—Psychometric Profiles, Natural History 

and Their Application in Clinical Trials…………………………………………..86 

5.5 Capítulo 5 - A randomized, phase 2/3 trial of lithium carbonate in 

Machado-Joseph disease..………………………………………………………136 

6 CONSIDERAÇÕES FINAIS ................................................................................ 172 

7 APÊNDICES ......................................................................................................... 175 

7.1 Termos de consentimento livre e esclarecido ................................................... 175 

8 ANEXOS ............................................................................................................... 186 

8.1 Escalas de Ataxias ............................................................................................. 186 

 

  

 



14 
 

1. Introdução  

 

As ataxias espinocerebelares ou SCAs (do inglês, spinocerebellar ataxias), 

são um grupo de doenças heterogêneas com herança autossômica dominante e 

início na vida adulta, caracterizado por degeneração progressiva do cerebelo e de 

suas vias aferentes e eferentes. (Schöls et al, 2004; Dürr, 2010; Bettencourt e Lima, 

2012). A doença de Machado-Joseph (DMJ) ou ataxia espinocerebelar do tipo 3 

(SCA3) é a SCA mais prevalente no Brasil e em todo mundo (Schöls et al, 2004; 

Trott et al., 2006; Sequeiros, Martins e Silveira, 2012). Sua prevalência mínima no 

Estado do Rio Grande do Sul é estimada em 3,5:100.000 habitantes (Prestes et al, 

2008) representando 84% das famílias com SCAs (Trott et al., 2006). 

A DMJ/SCA3 é causada por uma expansão de sequências repetitivas CAG no 

exon 10 do gene ATXN3, localizado no cromossomo 14q32.1 (Takiyama et al, 1993, 

Kawaguchi et al, 1994). Essa mutação leva à expressão de uma cadeia 

excessivamente longa de poliglutaminas na proteína codificada, chamada ataxina-3 

(Costa e Paulson, 2012). Além da DMJ/SCA3, as SCAs 1,2,6,7,17 e DRPLA, a 

doença de Huntington (DH) e Huntington-like tipo 2 (DHL2) e a atrofia muscular 

espinhal e bulbar (SBMA) compartilham o mesmo mecanismo de mutação e muitos 

dos processo patogênicos, fazendo parte do grupo denominado de 

poliglutaminopatias (poliQ) (Dürr, 2010; Costa e Paulson, 2012).  

A DMJ/SCA3 apresenta expressão clínica heterogênea, com manifestações 

que abrangem múltiplos sistemas neurológicos (Soong e Paulson, 2007; Kieling, 

Saute e Jardim, 2007). A idade média de início dos sintomas, entre brasileiros, é de 

32 anos (Jardim et al, 2001a), sendo a ataxia cerebelar, de predomínio axial, a 

principal manifestação clínica. A ataxia pode ser acompanhada por oftalmoplegia 

externa progressiva, disartria, disfagia, sinais piramidais e extrapiramidais e 

neuropatia periférica (Dürr et al, 1996; Jardim et al, 2001a, 2010; França Jr. et al, 

2009; Costa e Paulson, 2012). Seu curso é progressivo, levando os pacientes à 

dependência funcional e ao retraimento social (Kieling et al, 2007). Sintomas 

psiquiátricos também são comuns na DMJ/SCA3 e representam um significativo 

impacto negativo na qualidade de vida dos pacientes (Schmitz-Hübsch et al., 2010).  

A progressão clínica da DMJ/SCA3 é indiscutivelmente lenta (Kieling et al, 

2007; França et al, 2009; Jardim et al, 2010). Diversos instrumentos de avaliação de 



15 
 

gravidade das manifestações cerebelares (Trouillas et al, 1997; Schmitz-Hübsch et 

al, 2006) e extracerebelares (Kieling et al, 2008; Schmitz-Hübsch et al, 2008) das 

SCAs foram desenvolvidos nos últimos anos, não havendo consenso sobre quais 

destes instrumentos parecem ser os mais adequados para utilização em ensaios 

clínicos randomizados (ECR) ou se há uma clara necessidade de desenvolvimento 

de novas escalas. A evolução lentamente progressiva medida pelas escalas de 

avaliação clínica (Jardim et al, 2010; Schmitz-Hübsch et al, 2010) pode impedir ou 

dificultar muito a detecção de efeitos terapêuticos em futuros ECRs, o que torna de 

grande importância a busca por novos biomarcadores.  

Vários fármacos já foram estudados na tentativa de retardar a progressão da 

SCAs, como buspirona (Assadi et al, 2007), fluoxetina (Monte et al,2003), 

tandospirona (Takei et al, 2004), amantadina (Botez et al., 1996), TRH (Waragai et 

al,1997), fisostigmina (Wessel et al, 1997), entre outros. Todos apresentaram 

resultados negativos ou inconclusivos, o que pode indicar uma ausência de efeito 

por não atuarem em mecanismos relevantes da doença (ainda pouco conhecidos), 

e/ou que o seguimento foi curto para uma doença de progressão lenta, e/ou ainda 

que o poder dos estudos foi insuficiente. Assim, o manejo da DMJ/SCA3 se resume 

ao aconselhamento genético, ao acompanhamento fisioterápico e de terapia 

ocupacional (Silva et al, 2010) e ao manejo sintomático para alguns de seus sinais e 

sintomas (D‘Abreu et al, 2010). 

Considerando a ausência de tratamentos farmacológicos que modifiquem o 

curso letal da DMJ/SCA3, o principal objetivo deste trabalho foi o desenvolvimento e 

realização de um ECR para avaliar a efetividade de um potencial tratamento 

neuroprotetor na DMJ/SCA3. Os estudos que serão apresentados nos capítulos 

iniciais da presente tese tornaram possível e definiram diversas das etapas para a 

realização deste ECR.  

A avaliação dos sintomas depressivos da DMJ/SCA3 e a revisão sistemática 

sobre as escalas para SCAs possibilitaram a escolha dos desfechos primários e 

secundários para o ECR. As alterações nutricionais encontradas e os achados de 

marcadores e fatores modificadores do fenótipo da DMJ/SCA3 relacionados ao IIS - 

Sistema Insulina/ Fator de Crescimento Semelhante à Insulina Tipo 1 (IGF-1) - 

serviram como base para a escolha dos biomarcadores utilizados como desfechos 

secundários no ECR. 



16 
 

Os relatos de eficácia do tratamento com Lítio através da inibição da enzima 

GSK-3? e da indução de mecanismos de limpeza celular de proteínas malformadas 

em um modelo celular de DH (Carmichael, 2002); em camundongos transgênicos 

com SCA1 (Watase et al, 2007) e esclerose lateral amiotrófica (ELA) familiar (SOD1) 

(Fornai et al, 2008); em pacientes com ELA esporádica (Fornai et al, 2008); e em  

um relato de caso de paciente com SCA2 (Hering et al, 2009), fizeram com que o 

fármaco Carbonato de Lítio, utilizado há várias décadas no tratamento de 

transtornos psiquiátricos e amplamente disponível na rede do Sistema Único de 

Saúde brasileiro, fosse escolhido como potencial terapia a ser avaliado no maior e 

mais longo Ensaio Clínico Randomizado realizado nas SCAs até o presente 

momento.  

  



17 
 

2. Revisão da Literatura 

 

Doença de Machado Joseph / Ataxia espinocerebelar 

tipo 3: aspectos históricos, clínicos e moleculares. 

 

2.1 Aspectos Históricos 

Em 1971, Nakano, Dawson e Spence, neurologistas do Peter Bent Brigham 

Hospital de Boston, Massachusetts, Estados Unidos (EUA), observaram uma grande 

família de imigrantes açorianos (descendentes de William Machado, nativo da Ilha 

de São Miguel, nos Açores) com quadro clínico de ataxia cerebelar e neuropatia 

periférica com início após os 40 anos que era herdada de modo autossômico 

dominante. Os autores relataram que os 51 indivíduos afetados na família Machado 

manifestavam a mesma doença e que, devido ao comprometimento do cerebelo e 

tronco cerebral, apresentavam formas clínicas variadas, causando diferentes 

síndromes neurológicas em diferentes momentos da vida dos indivíduos. Esta 

doença foi nomeada em artigo publicado em 1972 (Nakano, Dawson e Spence, 

1972) como Doença de Machado.  

No mesmo ano da publicação do artigo da Doença de Machado, Woods e 

Schaumburg descreveram a degeneração nigroespinodenteada com oftalmoplegia 

nuclear, presente em outra grande família que vivia no sudoeste de Massachusetts 

(família Thomas) descendente de um emigrante da ilha de Flores nos Açores 

(Woods e Schaumburg, 1972). Em 1976, Rosenberg e colaboradores descreveram 

mais uma família, não relacionada às anteriores, também de origem açoriana que 

vivia no Estado da Califórnia, EUA, de sobrenome Joseph. A doença, denominada 

de degeneração estriatonigral autossômica dominante, manifestava-se entre os 17 e 

os 42 anos por ataxia de marcha, ?rigidez parkinsoniana?, espasticidade, disartria e 

oftalmoplegia, sem haver alterações intelectuais (Rosenberg et al, 1976). Em 1978 

passa a ser chamada de Doença de Joseph (Rosenberg et al, 1978) 

Devido às diferenças fenotípicas relacionadas à heterogeneidade dos 

sintomas clínicos, acreditava-se que estas três famílias apresentassem doenças 

distintas. As descrições vindas dos EUA de doenças neurológicas hereditárias em 



18 
 

descendentes açorianos e o relato da existência nos Açores de várias famílias com 

doenças degenerativas do sistema nervoso central (SNC) levaram os pesquisadores 

portugueses Coutinho e Andrade a visitar os Açores em 1976. O resultado foi a 

descrição de 40 doentes, pertencentes a 15 grandes famílias, com início dos 

sintomas entre 30 e 50 anos de idade, mostrando grande variabilidade de 

apresentação clínica (Coutinho e Andrade, 1978). Estes autores sistematizaram os 

fenótipos da doença em 3 tipos clínicos principais. Sinais cerebelares e 

oftalmoplegia externa progressiva eram achados em quase todos os pacientes, 

associados a sinais piramidais em graus variados. Os tipos clínicos poderiam ser 

distinguidos com base na presença/ausência de sinais extrapiramidais e 

relacionados ao sistema nervoso periférico (SNP) e idade de início da apresentação 

(Coutinho e Andrade, 1978).  

A descrição de outras famílias de descendência açoriana nos EUA com 

características clínicas semelhantes e que reuniam a sintomatologia presente nas 

três famílias anteriores (Romanul et al., 1977) e a descrição das famílias nos Açores 

(Coutinho e Andrade, 1978) levou a conclusão de que se tratava da mesma doença, 

porém com expressividade clínica variável, sendo denominada de ?doença açoriana? 

(Romanul et al., 1977). Lima e Coutinho identificaram em 1980 a primeira família não 

relacionada à Ilha dos Açores ou à América do Norte na qual alguns indivíduos 

apresentavam os sintomas da ?doença açoriana? e propuseram a denominação de 

doença de Machado-Joseph (DMJ) (Lima e Coutinho, 1980). Essa denominação 

justificava-se pelo fato de a família Machado ter sido a primeira a ser descrita e a 

família Joseph por ser a maior e mais bem conhecida família com DMJ. 

Apesar do enfoque dado para as famílias de descendência açoriana como 

sendo os primeiros relatos da DMJ, na verdade, a família Drew, originária de 

Walworth, uma localidade na região nordeste da Inglaterra, foi a família mais antiga 

a ser descrita com DMJ (Fergunson  e Critchley, 1929). A primeira avaliação de um 

paciente da família Drew ocorreu no ano de 1895, no National Hospital (hoje The 

National Hospital for Neurology and Neurosurgery, Queen Square, Londres, Reino 

Unido), e foi realizada pelo eminente neurologista Sir William Gowers. O paciente 

era William Drew, com 40 anos de idade na época, apresentava-se com quadro 

clínico compatível com parkinsonismo e recebeu o diagnóstico final de Paralisia 

Agitans, conforme demonstrou a ficha clínica assinada por Gowers (Teive e Arruda, 

2004). Em 1995, Giunti, Sweeney e Harding publicaram estudo com análise 



19 
 

molecular para DMJ em uma série de famílias com SCAs, incluindo a família Drew 

de Walworth, concluindo que esta família segregava a DMJ.  

 Em 1993 estudos de ligação mapearam o gene da DMJ no braço longo do 

cromossomo 14 (Takiyama et al, 1993). Em 1994, expansões CAG em um novo 

gene localizado no cromossomo 14q32.1 foram descritas como associadas à DMJ 

(Kawaguchi et al, 1994). No mesmo ano, a mesma região no cromossomo 14q24.3-

q32.2 foi associado a famílias com SCA ainda sem diagnóstico molecular por um 

grupo de pesquisadores franceses, que acreditaram encontrar uma nova condição e 

a denominaram de SCA3 (Stevanin et al, 1994-1). Nos meses seguintes os mesmos 

autores concluíram que as assim chamadas SCA3 e DMJ eram causadas por 

anormalidades no mesmo gene (Stevanin et al, 1994-2), sendo finalmente aceitas 

como a mesma doença três anos depois (Haberhausen et al, 1995). Atualmente 

ambas a denominações, SCA3 ou DMJ, são utilizadas e amplamente aceitas. Na 

presente revisão esta doença será referida como DMJ/SCA3.   

Cabe ainda ressaltar que a hipótese de uma origem portuguesa/açoriana 

proposta nas descrições iniciais da DMJ/SCA3 tem sido contestada por estudos 

multicontinentais recentes, que sugerem uma origem Asiática ou aborígene 

australiana para a linhagem mais prevalente da doença (haplótipo ACA), permitindo 

datar a mutação original em mais de 7 mil anos (Martins et al 2007, Martins et al, 

2012). Uma introdução mais recente desta linhagem teria sucessivamente ocorrido 

na América do Norte, Alemanha, França, Portugal e Brasil.  

2.2 Aspectos Epidemiológicos 

 A prevalência das SCAs varia significativamente entre as diferentes 

populações. Nas SCAs causadas por expansão de repetições de trinucleotídeos os 

fatores que podem estar envolvidos nesta variação incluem a frequência de alelos 

normais grandes (instáveis) e de haplótipos que tenham maior tendência à expansão 

em cada população. Mecanismos de deriva gênica, como o efeito fundador, podem 

ser importantes fatores na distribuição geográfica de alguns subtipos de SCAs 

(Sequeiros, Martins e Silveira, 2012). Isso ocorreu, por exemplo, com a SCA2 em 

Cuba e com a DMJ/SCA3 nas Ilhas dos Açores e no sul do Brasil (Jardim et al, 

2001b; Schols, et al, 2004; Velázquez-Pérez et al, 2011, Camargo, 2011). 



20 
 

 Em Portugal, em estudo de base populacional conduzido por mais de 12 

anos, a prevalência geral de ataxias hereditárias foi de 7,9:100.000 (Silva et al, 

1997). Contudo, há grande variação na frequência das SCAs entre os países e estes 

frequentemente também apresentam diferenças regionais.  Independente desta 

variação de frequências, a DMJ/SCA3 é considerada a SCA mais comum 

mundialmente (Schols, et al., 2004; Sequeiros, Martins e Silveira, 2012), sendo de 

longe a mais frequente no Brasil (Lopes-Cendes et al, 1997; Trott et al, 2006), 

Portugal (Silveira et al., 2002), China (Jiang et al., 2005) e Taiwan (Soong,et al., 

2001). 

No Brasil, a prevalência de DMJ/SCA3 é especialmente elevada no Estado do 

Rio Grande do Sul (RS), onde é estimada em pelo menos 3,5:100.000 habitantes 

(Prestes et al, 2008) e onde representa 84% das famílias com SCAs (Trott et al, 

2006). Um efeito fundador açoriano, ocorrido a partir de 1748 quando foi iniciada a 

emigração de açorianos para o Sul do Brasil, é considerado como a principal razão 

para o elevado número de casos nesta região. Esta explicação histórica foi 

recentemente reforçada pela descrição de elevadas frequências regionais, 

compatíveis com um efeito fundador, por Camargo e colaboradores. Neste trabalho 

a prevalência de DMJ/SCA3 foi estimada nos diferentes munícipios do RS. Algumas 

localidades apresentaram alta prevalência de DMJ/SCA3, como as cidades de 

General Câmara (106:100.000), Palmitinho (86,7:100.000), São Jerônimo 

(49,8:100.000) e São Pedro do Sul (42,7:100.000) (Camargo, 2011). A figura nº 1 

mostra a distribuição destas frequências nos municípios do RS. As prevalências 

descritas nestas localidades estão bem acima das encontradas em Portugal e ilhas 

(3,1:100.000), Ilha de São Miguel nos Açores (27,1:100.000) e Portugal continental 

(1:100.000) (Camargo, 2011). Somente a Ilha de Flores, com prevalência de 

418:100.000, continua como a região de maior prevalência mundial de DMJ/SCA3 

(Bettencourt e Lima, 2011). 

 

  



21 
 
Figura nº 1 – Mapa de frequência da DMJ/SCA3 no RS. 

 

Mapa do Rio Grande do Sul com as localidades com maior prevalência de 

DMJ/SCA3 e suas respectivas frequências. FONTE: Camargo, 2011. 

2.3 Aspectos Genéticos 

A DMJ/SCA3 é causada por uma expansão de sequências repetitivas CAG na 

terminação 5‘ do exon 10 do gene ATXN3, localizado no cromossomo 14q32.1 

(Takiyama et al, 1993; Kawaguchi et al, 1994). O alelo normal contém entre 12 e 44 

repetições, enquanto o mutante contém entre 61 e 86 repetições (Maciel et al, 1995; 

Sequeiros, Martins e Silveira, 2012) e leva a uma expansão de poliglutaminas 

(PoliQ) na proteína correspondente, chamada ataxina-3 ou ATXN3. Nesta tese, 

denominaremos a proteína de ATXN3, em contraste com a denominação do gene, 

ATXN3 (em itálico). Alelos de tamanhos intermediários (45-56 repetições) foram 

poucas vezes descritos. O seu exato papel na penetrância da doença, bem como na 

geração de expansões de novo de penetrância completa não está claro. Cabe 



22 
 

ressaltar que mutações de novo não foram descritas para a DMJ/SCA3, sendo 

sugerido por estudos de haplótipos intragênicos a existência de dois eventos 

mutagênicos independentes ocorridos há cerca de mil e quatrocentos e sete mil 

anos (Sequeiros, Martins e Silveira, 2012). 

A herança é autossômica dominante, ou seja, cada filho de um genitor 

afetado tem um risco a priori de 50% de ser portador da mutação, com a 

probabilidade de receber ou transmitir a mutação igual entre os sexos. A penetrância 

da DMJ/SCA3 é próxima de 100%, considerada para fins de aconselhamento 

genético como completa. Existe também uma clara tendência à idade de início ser 

menor em cada geração sucessiva (Maciel et al, 1995), no fenômeno conhecido 

como antecipação 

Além da DMJ/SCA3 e SCAs 1,2,6,7,17 e DRPLA; as doenças de Huntington 

(DH), a atrofia muscular espinhal e bulbar (SBMA) e, mais recentemente, a doença 

Huntington-like tipo 2 (DHL2) compartilham o mesmo mecanismo de mutação e 

muitos dos processo patogênicos, fazendo parte do grupo denominado de doenças 

das PoliQs ou poliglutaminopatias (Dürr, 2010; Costa e Paulson, 2012). Cabe 

ressaltar que para a expressão clínica da DMJ/SCA3 são necessários tratos de 

repetições CAG mais longos do que nas demais SCAs causadas por este mesmo 

mecanismo de mutação (Riley e Orr, 2006). 

Há uma tendência à instabilidade no número de repetições de glutaminas 

quando estas atravessam divisões celulares, sejam elas mitóticas ou meióticas. 

Essa instabilidade, que tende a favorecer as expansões especialmente ao 

atravessar espermatogêneses, resulta na variação do número de repetições em 

cada geração dentro das famílias afetadas. Isso, por sua vez, explica em grande 

parte o fenômeno da antecipação (Maciel et al, 1995). Existe uma forte relação 

inversa entre número de repetições CAG e a idade de início dos sintomas (Maciel et 

al, 1995), que explica de 50 a 75% da variação na idade de aparecimento dos 

primeiros achados clínicos (Bettencourt e Lima, 2011).  

Além da antecipação per se, a instabilidade do tamanho da repetição 

expandida explica uma boa parte da variabilidade nas manifestações clínicas da 

DMJ/SCA3 (ver abaixo). 



23 
 

2.4 Fisiopatologia 

2.4.1 Agregados Intracelulares e proteotoxicidade 

Um dos marcos patológicos na DMJ/SCA3 é a formação de neuroinclusões 

(NI) ou agregados intranucleares (Figura nº 2), em que um possível efeito tóxico 

direto tem sido intensamente debatido (Costa e Paulson, 2012). As 

poliglutaminopatias são causadas por proteínas com estrutura terciária anômala e 

com propensão à agregação (Paulson, 1999). Essas proteínas misfolded, 

denominadas de ataxinas por estarem relacionadas às ataxias espinocerebelares, 

acumulam-se nas NIs junto com ubiquitinas e com chaperonas. Além de terem em 

comum uma PoliQ, há também marcante sobreposição de sintomas entre essas 

afecções, com neurodegeneração predominante do cerebelo e de núcleos do tronco 

cerebral (Paulson, 1999). 

Há NI em todas as regiões afetadas pela doença (descritas adiante) e 

também em estruturas nas quais não há clara perda neuronal. A presença de NI 

antecede os sintomas clínicos, havendo um maior número nos pacientes com 

expansões CAG mais longas. A composição das NI da DMJ/SCA3 inclui ubiquitina, 

ATXN3, tratos de PoliQ e vários fatores de transcrição (Paulson, 1999). Além das NI, 

os neurônios afetados possuem grânulos citoplasmáticos imunomarcados com 1C2 

(um anticorpo monoclonal contra PoliQ) que correspondem a um subgrupo de 

lisossomos, sugerindo que as vias de autofagocitose para a degradação proteica 

também têm relação com a ATXN3 mutada (Yamada, Tsuji e Takahashi, 2002; 

Yamada et al, 2008).  

Como as NI não se correlacionam diretamente com a neurodegeneração elas 

têm sido consideradas atualmente como biomarcadores da falência celular no 

processo de limpeza da ATXN3 mutada (Costa e Paulson, 2012). 

 



24 
 

Figura nº 2 - Agregados intranucleares neuronais 

 

Inclusão intranuclear com imunorreatividade para ATXN3 em um neurônio do núcleo 

intersticial de Cajal de uma paciente com DMJ/SCA3. FONTE: Riess et al, 2008 

Semelhante às demais condições relacionadas à PoliQ, a ATXN3 selvagem 

se colocaliza com a expandida, nas NIs  (Uchihara et al, 2001; Haacke et al, 2006). 

Desta forma, a patogênese da DMJ/SCA3 além de ser devida às características da 

proteína mutante (ganho de função tóxica), também pode ter relação com algum 

grau de perda de função da proteína selvagem, ?sequestrada? nas NI. Assim, o 

conhecimento sobre a função da ATXN3 passou a ser de grande relevância 

2.4.2 Funções da ATXN3 

A ATXN3 (Figura nº 3) é um peptídeo que se localiza tanto no citoplasma 

como no núcleo de todas as células dos animais superiores. Sua principal função 

parece ser no controle de qualidade proteica celular e ocorre fora do núcleo, 

participando do sistema ubiquitina-proteassoma (UPS). A ATXN3 contém motivos de 

interação com a ubiquitina (UIMs) em sua estrutura (Burnett e Pittman, 2003; Costa 

e Paulson, 2012), age como uma protease ubiquitina-específica (Nicastro et al, 

2005), está envolvida no reconhecimento de substratos proteolíticos pelo 

proteassoma (Doss-Pepe et al, 2003), regula a formação de agressomas (Burnett 

and Pittman, 2005) e também, por via relacionada ao UPS, suprime a toxicidade 

induzida por PoliQ (Warrick et al, 2005).  

 



25 
 
Figura nº 3 - Domínios funcionais da Ataxina-3 

 

Domínios funcionais da ATXN3: A região N-terminal contém um domínio DUB 

catalítico (Domínio Joseph, JD), dois sítios ligantes de ubiquitina e dois sinais de 

exportação nuclear (NES). A região C-terminal da ATXN3 contém 2 ou 3 UIMs, 

sinais de localização nuclear (NLS) e o trato de PoliQ. A figura também mostra os 

sítios de fosforilação da proteína.  FONTE: Costa e Paulson, 2012.  

A ATXN3 também se localiza no núcleo (Tait et al, 1998) onde tem papel na 

regulação da transcrição de outros genes (Li et al, 2002). A ATXN3 interage com 

fatores de transcrição geralmente resultando em ação repressora sobre a 

transcrição. A repressão da transcrição relacionada à ATXN3 se dá via inibição de 

acetiltransferases de histonas (HAT) (Li et al, 2002) e via recrutamento de 

desacetilases de histonas (HDAC) (Evert et al, 2006). Coativadores transcricionais 

com atividade HAT o fazem ao promover a acetilação das histonas (Torchia et al, 

1997). Ao contrário, a desacetilação das histonas via HDAC torna os promotores 

gênicos inacessíveis aos seus fatores reguladores (Nagy et al., 1997). O equilíbrio 

entre acetilação e desacetilação de histonas pode ser um processo chave na 

patogênese das poliglutaminopatias em geral.  

Estudos mais recentes mostram que a ATXN3 mutada leva tanto a infra 

quanto a supra-regulação de alguns genes (Costa e Paulson, 2012). De modo geral 

há supressão de transcrição de genes envolvidos na neurotransmissão 

glutamatérgica, sinalização do cálcio intracelular, proteínas heat shock (HSP), e 

fatores reguladores da sobrevivência e diferenciação neuronal (Chou et al, 2008) e 

supra-regulação de genes relacionados com morte celular e inflamação (Chou et al., 

2008; Evert et al., 2001, 2003). 



26 
 

Há vários exemplos de alterações de transcrição de outros genes nas demais 

poliglutaminopatias. Na DH a proteína envolvida, chamada huntingtina, interage com 

complexos nucleares envolvidos com repressão da transcrição e no processamento 

dos ácidos ribonucleicos (ARN) (Steffan et al, 2000; Kegel et al, 2002); na SCA7,  a 

ataxina-7 pode atuar também como repressora da transcrição ao inibir a atividade de 

acetilação de complexos reguladoras da transcrição (Strom et al, 2005); e na SCA1,   

a ataxina-1 inibe a  transcrição geral, também através da interação com o co-

repressores da transcrição (Tsai et al., 2004).  

É possível que alguns dos eventos relacionados à função da ATXN3 sejam 

protagonistas na fisiopatologia da condição. Fenômenos tão comuns à DMJ/SCA3 

como às demais poliglutaminopatias, como antecipação e a importante associação 

entre gravidade e idade de início, são mais logicamente relacionados ao trato PoliQ, 

independente das proteínas selvagens. Eles, no entanto, não excluem um potencial 

impacto direto da perda de função da ATXN3 nos mecanismos celulares da doença, 

Cabe destacar que o conceito de ?perda de função? a ser utilizado deve estar 

vinculado à presença de uma PoliQ na proteína. Uma vez que a perda de função 

?literal?, demonstrada pelos estudos knock-out, não se associou a fenótipos 

relevantes (Schmitt et al, 2007; Huynh et al, 2009) – como veremos a seguir.  

2.4.3. Haploinsuficiência como principal mecanismo de doença? 

Perdas de função são também chamadas de haploinsuficiência; e 

haploinsuficiências têm sido descritas algumas vezes em condições dominantes, 

especialmente quando o gene transcreve proteínas estruturais. Nos casos de perda 

de função, entretanto, costuma-se registrar efeitos relacionados à dosagem gênica. 

Por exemplo, nos indivíduos com perda dos dois alelos, a condição clínica é ainda 

mais grave do que a dos heterozigotos. Infelizmente, o número de homozigotos 

descritos para expansões CAG no gene ATXN3 é bastante pequeno. Há pelo menos 

8 casos de homozigotos que iniciaram após os 25 anos de idade, em que não houve 

associação clara com uma piora da gravidade das manifestações (Lysenko et al, 

2010). Embora em uma criança com DMJ/SCA3 homozigota (67/72 repetições) a 

doença tenha iniciado aos 4 anos (Carvalho et al, 2008). 

Modelos de camundongos knockout foram desenvolvidos para os genes 

ATXN1, ATXN2 e ATXN3. Todos surpreendentemente geraram animais viáveis, 



27 
 

férteis e sem doença histológica ou comportamental. Portanto, a supressão das 

proteínas envolvidas nas doenças de PoliQ não traz consequências maiores às 

funções neurológicas, o que é um forte argumento contra a hipótese da perda de 

função como causa destas condições (Matilla et al, 1998; Kiehl et al, 2006; Schmitt 

et al, 2007; Huynh et al, 2009). 

2.4.4 Efeitos diretos da PoliQ e da sua tendência à agregação 

A expansão de sequências CAG codifica repetições puras do aminoácido 

glutamina. Supõe-se que esta expansão leve a uma alteração na conformação do 

peptídeo produzido e que isso traga uma maior tendência à agregação. Não se sabe 

ao certo qual o papel tóxico da agregação das PoliQ, porém existem evidências de 

que ocorra alteração dos mecanismos de controle de qualidade proteica intracelular 

(Soong e Paulson, 2007).  

Vários mecanismos de controle celular devem regular os níveis de proteínas 

propensas à agregação. Chaperonas moleculares estão entre esses mecanismos, 

incluindo as chaperonas da família das proteínas heat shock HSP40/HSP70. A 

superexpressão da HSP70 e da HSP40 reduziu a agregação e a morte celular em 

modelos celulares da doença de Huntington (Carmichael et al, 2002). A HSP27, 

também suprimiu a morte celular relacionada às PoliQ ao reduzir os níveis de 

espécies reativas de oxigênio (ROS), mas neste caso sem suprimir a agregação 

(Wyttenbach et al, 2002). A família de chaperonas HSP40, também chamada de 

DNAJB, tem ação supressora sobre a agregação de poliglutaminas expandidas que 

é superior a das demais chaperonas (Hageman et al, 2010). A expressão de 

DNAJB1 em fibroblastos de pacientes com DMJ/SCA3 foi menor do que nos 

indivíduos controles, havendo correlação inversa de sua expressão com a idade de 

início dos sintomas, independente do tamanho da expansão CAG (Zijlstra et al, 

2010). Em verdade, o rearranjo e a limpeza da ATXN3 mutada parece ser realizado 

tanto pelas chaperonas moleculares, quanto pelo UPS e autofagia (Costa e Paulson, 

2012).  

2.5 Aspectos Clínicos e Patológicos 

A DMJ/SCA3 apresenta expressão clínica heterogênea, com manifestações 

que abrangem múltiplos sistemas neurológicos, sendo a ataxia cerebelar, de 



28 
 

predomínio axial, a principal manifestação clínica (Soong e Paulson, 2007; Kieling, 

Saute e Jardim, 2007). Seu curso é invariavelmente progressivo, levando os 

pacientes à dependência funcional e ao retraimento social (Kieling et al, 2007).  

A idade de início dos sintomas em brasileiros é em média de 32-36 anos 

(Jardim et al, 2001a; Trott et al, 2006) e o tempo de sobrevida após o inicio dos 

sintomas, de 21 anos em média (Kieling et al, 2007). Idades de início precoce e 

expansões CAG mais longas são preditores de menor sobrevida (Kieling et al, 

2007). 

Atualmente há descrição de 5 tipos clínicos distintos, sendo os mais 

frequentes o tipo clínico 1 (?tipo Joseph?), caracterizado por início precoce (média de 

24.3 anos) e progressão rápida dos sintomas, com sinais piramidais e 

extrapiramidais (principalmente distonia) marcados; o tipo 2 (?tipo Thomas?), com 

idade de início intermediária, próximo dos 40 anos, ataxia cerebelar e oftalmoplegia 

externa progressiva com ou sem sinais piramidais; e o tipo 3 (?tipo Machado?), de 

início mais tardio (média de 46.8 anos) e associado a alterações proeminentes do 

SNP (Bettencourt e Lima, 2011). Como já mencionamos, existe uma importante 

correlação genótipo-fenótipo, envolvendo a relação inversa entre número de 

repetições CAG e a idade de início dos sintomas (Maciel et al, 1995, Jardim et al, 

2001).  Daí também haver associação entre o número das repetições CAG e os três 

subtipos clínicos mais clássicos. 

2.5.1 Manifestações Clínicas Motoras 

2.5.1.1 Manifestações Cerebelares 

 A maior parte dos pacientes nota os primeiros sinais de alterações no 

movimento na quarta década de vida com o surgimento de ataxia cerebelar, a qual 

terá um curso inexoravelmente progressivo a partir deste momento. A ataxia de 

marcha geralmente predomina como manifestação clínica, mas os sinais de 

incoordenação dos movimentos apendiculares também são vistos comumente no 

exame neurológico destes indivíduos (Jardim et al, 2001a). Fala escandida, disfagia 

e ataxia de tronco também são achados típicos da DMJ/SCA3, mas não costumam 

estar presentes no início do quadro clínico.   



29 
 

2.5.1.2 Manifestações Oculares 

 Anormalidades oculomotoras, como a oftalmoplegia externa progressiva, são 

os segundos achados mais frequentes na DMJ/SCA3 (Jardim et al, 2001a; 

Bettencourt e Lima, 2011). Alguns raros pacientes têm na diplopia sua primeira 

manifestação. As anormalidades oculomotoras podem ser muito sugestivas de 

DMJ/SCA3 em contraste com as demais SCAs. As queixas mais comuns são de 

diplopia e em alguns casos de oscilopsia (Dürr et al, 1996). No exame destes 

pacientes pode ser observado nistagmo horizontal na mirada lateral, anormalidades 

no movimento sacádico e no acompanhamento visual e paralisia supranuclear 

vertical. O movimento sacádico vertical para cima e a convergência são os primeiros 

a serem acometidos, seguidos pelos movimentos laterais e por último pelos 

movimentos sacádicos verticais para baixo (Gordon et al, 2003). Outro achado 

relativamente comum e característico da DMJ/SCA3 é o chamado ?bulging eyes 

appearance? que ocorre pela combinação de retração palpebral e redução no 

piscamento (Jardim et al, 2001; Gordon et al, 2003), ambos aparentemente de 

natureza extrapiramidal.   

2.5.1.3 Achados Piramidais 

 Alterações piramidais como hiperreflexia generalizada, espasticidade e a 

presença do sinal de Babinski podem estar presentes na DMJ/SCA3, sendo os 

indivíduos com início precoce e expansões de repetições CAG mais longas os mais 

afetados (Coutinho e Andrade, 1978; Jardim et al, 2001a). Os membros inferiores 

são muito mais acometidos do que os superiores, onde a espasticidade, sem 

fraqueza muscular evidente, predomina (Teive et al, 2001). Há inclusive relatos de 

caso de indivíduos com paraparesia espástica como manifestação inicial ou isolada 

(Sakai e Kawakami, 1996; Teive et al, 2001), sendo este considerado um tipo clínico 

distinto dos 3 anteriores, denominado de tipo clínico 5.  

2.5.1.4 Achados Extrapiramidais 

Dois outros distúrbios do movimento são característicos da DMJ/SCA3: a 

distonia e o parkinsonismo (Rosenberg et al, 1976; Jardim et al, 2001a). A distonia 

está geralmente presente em indivíduos com início precoce dos sintomas e, na 

maioria dos casos, é de distribuição segmentar ou focal, acometendo dedos, pés e 



30 
 

ocasionalmente a região cervical. Entretanto, pacientes com distonia generalizada 

grave e formas responsivas a levodopa têm sido descritos (Münchau et al, 1999; 

Wilder-Smith et al, 2003). O parkinsonismo simétrico, manifestado por rigidez, 

bradicinesia e geralmente com resposta a levodopa, também pode ocorrer (Gwinn-

Hardy et al, 2001; Jardim et al, 2001a). Quando a manifestação clínica predominante 

é parkinsoniana, este fenótipo tem sido denominado de tipo clínico 4 (Bettencourt e 

Lima, 2011). Recentemente mutações no gene da glicocerebrosidase (GBA), que 

em heterozigose têm sido associadas com o desenvolvimento de Doença de 

Parkinson (Sidransky et al, 2009), foram estudas na DMJ/SCA3. Mutações neste 

gene foram encontradas em 33% dos pacientes com fenótipo parkinsoniano e em 

0% dos pacientes sem parkinsonismo, sendo consideradas como um fator 

modificador do fenótipo da DMJ/SCA3 (Siebert et al, 2012).  

2.5.1.5 Achados relacionados ao SNP 

 Os nervos periféricos estão acometidos em cerca de 60% dos pacientes com 

DMJ/SCA3 (Klockgether et al, 1999; Jardim et al, 2001a). Diferentemente da distonia 

e espasticidade, a neuropatia periférica é determinada principalmente pela idade do 

indivíduo, não dependendo do tamanho da expansão CAG, da idade de início ou da 

duração dos sintomas da doença (Klockgether et al, 1999). As fibras sensitivas são 

mais comumente afetadas; ocorrendo áreas disseminadas de hipoestesia tátil e 

proprioceptiva. O dano causado às fibras motoras pode ocasionar atrofia muscular e 

fraqueza de padrão distal (Klockgether et al, 1999). Anormalidades da excitabilidade 

muscular como a presença de cãibras e fasciculações são encontradas em mais de 

50% dos pacientes (França Jr. et al, 2008). Manifestações autonômicas também são 

comuns; especialmente as relacionadas ao sistema genitourinário e sudomotor, 

sendo mais frequentes em pacientes com fenótipo predominante de polineuropatia 

ou parkinsonismo (França Jr. et al, 2010).  

2.5.2 Manifestações Clínicas Não Motoras 

 Os achados motores da DMJ/SCA3 são amplamente discutidos e relatados 

na literatura desde as primeiras descrições da doença, entretanto estudos mais 

recentes também têm destacado a relevância de seus aspectos não motores. Estes 

achados são frequentemente pouco reconhecidos e valorizados, apesar de seu 

grande impacto negativo na qualidade de vida.  As principais manifestações não 



31 
 

motoras relatadas e que serão discutidas brevemente a seguir são: distúrbios do 

sono, anormalidades olfativas e transtornos cognitivos e psiquiátricos.   

2.5.2.1. Distúrbios do Sono e Olfativos 

 Distúrbios do sono como sonolência diurna excessiva, insônia, síndrome das 

pernas inquietas e distúrbio comportamental do sono REM são achados frequentes 

na DMJ/SCA3 (D‘Abreu et al, 2009; Pedroso et al, 2011). A disfunção olfatória 

(hiposmia), um achado comum e precoce de diferentes doenças 

neurodegenerativas, também foi descrita em pacientes com DMJ/SCA3 (Braga-Neto 

et al,2012a).  

2.5.2.2. Alterações Cognitivas e Transtornos Psiquiátricos  

Apesar de as funções intelectuais dos indivíduos com DMJ/SCA3 terem sido 

consideradas preservadas nas suas primeiras descrições (Rosenberg et al, 1976), 

estudos mais recentes têm demonstrado que de fato ocorre prejuízo cognitivo, mas 

sem haver um quadro francamente demencial. Os pacientes podem apresentar 

disfunção executiva, alteração no processamento de informações visuais e déficits 

em memória verbal e visual (Braga-Neto et al, 2012b).  

Os sintomas psiquiátricos são comuns na DMJ/SCA3 e representam um 

impacto negativo significativo na qualidade de vida dos pacientes que é comparável 

ou superior ao que é causado pelos sintomas motores desta doença (Schmitz-

Hübsch et al, 2010). Os sintomas depressivos são os mais estudados, seguidos 

pelos transtornos de ansiedade que também são frequentes (Kawai et al, 2004; 

Braga-Neto et al, 2012c). Os sintomas psiquiátricos não parecem ser manifestações 

prodrômicas da doença, já que indivíduos portadores da mutação no gene ATXN3 

pré-sintomáticos apresentam escores em escalas de depressão e ansiedades 

similares aos de seus familiares não portadores da mutação (Cecchin et al, 2007; 

Rodrigues et al, 2012).  

O cerebelo tem conexões com áreas corticais e subcorticais não motoras 

associadas com processamento emocional, sendo sugerido um papel na 

personalidade e afeto (Wolf, Rapoport e Schweizer, 2009). A disfunção cognitiva na 

DMJ/SCA3 foi sugerida como associada à neurodegeneração induzida pela doença, 

onde, em uma síndrome afetiva cognitiva cerebelar, o componente afetivo seria 



32 
 

relacionado a dano neural (Wolf, Rapoport e Schweizer, 2009; Braga-Neto et al, 

2012b). Contudo até o momento os estudos que avaliaram a relação entre a 

disfunção cognitiva e transtornos do humor na DMJ/SCA3 tiveram resultados 

negativos (Kawai et al, 2004; Schmitz-Hübsch et al 2011).  

2.5.2.3. Outras Manifestações Não Motoras 

 Dor crônica (França Jr. et al, 2007) e fadiga (Friedman e Amick, 2008) 

também são achados frequentes na DMJ/SCA3 e que levam a prejuízo na qualidade 

de vida. Alterações nutricionais são descritas em algumas poliglutaminopatias, como 

na DH, em que há perda de peso em estágios inicias e mesmo em indivíduos pré-

sintomáticos (Marder et al, 2009). Em camundongos transgênicos para DMJ/SCA3 

há perda de peso progressiva durante o curso da doença que é prevenida com o 

bloqueio da expressão do transgene da ataxina-3 mutada (Boy et al, 2009). Apesar 

disso, as alterações nutricionais, assim como outras alterações periféricas, sem 

relação direta com o SNC ou SNP, não foram ainda avaliadas de forma sistemática 

na DMJ/SCA3.   

2.5.3 Achados Anatomopatológicos 

 A avaliação macroscópica de cérebros de pacientes com DMJ/SCA3 em 

estágios avançados demonstra despigmentação da substantia nigra, atrofia 

significativa do cerebelo, ponte e bulbo cerebral, assim como atrofia dos nervos 

cranianos III ao XII (Riess et al, 2008). Contudo, diversos estudos recentes com 

técnicas não convencionais têm demonstrado que a degeneração é muito mais 

ampla, com dano disseminado em cerebelo, tálamo, mesencéfalo, ponte, bulbo e 

medula espinhal (Riess et al, 2008; Rüb et 2008). Estes achados excedem o 

chamado padrão olivopontocerebelar de neurodegeneração e dão suporte a uma 

série de achados clínicos que eram menos compreendidos.  

As seguintes vias e núcleos de substância cinzenta podem estar entre os 

alvos do processo degenerativo: núcleos das vias cerebelo-tálamo-cortical e 

gânglios da base-tálamo-cortical, substantia nigra, núcleos não motores talâmicos, 

componentes subcorticais do sistema somato-sensitivo, núcleos vestibulares e 

oculomotores, e núcleos do tronco cerebral relacionados à ingestão alimentar (Riess 

et al, 2008; Rüb et 2008). Cabe ressaltar a preservação dos componentes corticais e 



33 
 

subcorticais do sistema límbico na DMJ/SCA3, diferentemente do que é visto em 

outras SCAs (Riess et al, 2008). Há também degeneração da substância branca 

central e periférica na DMJ/SCA3, incluindo: nervos periféricos, pedúnculos 

cerebelares, tratos vestibuloespinhal e espinocerebelar, assim como os fascículos 

longitudinal medial, grácil e cuneiforme (Riess et al, 2008).  

A progressão temporal dos achados patológicos na DMJ/SCA3 não é bem 

conhecida, sendo sugerido que o núcleo denteado cerebelar, núcleos vestibulares e 

oculomotores, e substantia nigra seriam as estruturas encefálicas primeiramente 

envolvidas, enquanto tálamo, núcleos do tronco cerebral relacionados à ingestão 

alimentar e os demais nervos cranianos seriam afetados mais tardiamente (Riess et 

al, 2008). 

2.6 Diagnóstico 

 O diagnostico é suspeito com base em sinais e sintomas clínicos e história 

familiar detalhada, e é realizado pelo exame molecular. Cabe ressaltar que nem 

sempre a história familiar é aparente, como nos casos de morte prematura do 

genitor afetado (antes do início dos sintomas), de marcado fenômeno de 

antecipação, ou de ilegitimidade (Subramony, 2012). Apesar de algumas 

manifestações clínicas serem altamente sugestivas do diagnóstico de DMJ/SCA3, 

não há achado clínico ou neurorradiológico patognomônico. Naqueles indivíduos em 

que a ataxia cerebelar não é acompanhada de herança familiar definida, outros 

exames serão mandatórios para descartar causas tratáveis sistêmicas ou 

neurológicas. 

Em indivíduos com síndrome atáxica progressiva e diagnóstico molecular 

confirmado de DMJ/SCA3 em sua família, a testagem específica para mutação no 

gene ATXN3 é apropriada e deve confirmar o diagnóstico. O teste molecular para 

DMJ/SCA3 é disponível na prática clínica com sensibilidade e especificidade 

próximas a 100%. A abordagem diagnóstica para os indivíduos com SCA sem 

diagnóstico molecular definido na família é geralmente realizada através de painéis 

diagnósticos construídos com base epidemiológica (Saute e Jardim, 2008). 

Programas baseados em diretrizes internacionais de testes pré-sintomáticos estão 

disponíveis em alguns centros, podendo ser oferecido aos familiares em risco 

(Rodrigues et al, 2012; Rolim et al, 2006). 



34 
 

2.7 História Natural 

A progressão clínica da DMJ/SCA3 é bastante lenta (Kieling et al, 2007; 

França et al, 2009; Jardim et al, 2010). Diversos instrumentos de avaliação da 

gravidade das manifestações cerebelares (Trouillas et al, 1997; Schmitz-Hübsch et 

al, 2006) e extracerebelares (Kieling et al, 2008; Schmitz-Hübsch et al, 2008-1) das 

SCAs foram desenvolvidos nos últimos anos, assim como escores funcionais com 

medidas quantitativas (Schmitz-Hübsch et al, 2008-2; du Montcel et al, 2008). Tanto 

nos escores de avaliação de ataxia, ICARS e SARA (D‘Abreu et al, 2007; Schmitz-

Hübsch et al, 2010), quanto nos de disfunção de múltiplos sistemas neurológicos, 

NESSCA e UMSARS (D‘Abreu et al, 2007; Jardim et al, 2010), a progressão das 

SCAs estudadas foi lenta, mostrando pequena sensibilidade à mudança. Fatores 

como o tamanho da expansão CAG mutada e a idade de início parecem influenciar a 

velocidade de progressão, sendo maior em pacientes com expansões mais longas e 

idades mais precoces de início dos sintomas (Jardim et al, 2010, Jacobi et al, 2011). 

O conhecimento da história natural da DMJ/SCA3 e demais SCAs é de 

fundamental importância para o desenvolvimento de futuros ensaios clínicos. 

Contudo, a evolução lentamente progressiva medida pelas escalas de avaliação 

clínica até o momento mostra a dificuldade da detecção de efeitos terapêuticos, o 

que torna de grande importância a busca por outros biomarcadores que possam ser 

utilizados como desfechos substitutos. 

2.8 Biomarcadores  

A descrição de biomarcadores pode auxiliar no entendimento fisiopatológico 

da DMJ/SCA3, dar informações de relevância clínica que possam auxiliar na decisão 

de fármacos com potencial terapêutico a serem testados em ECR ou mesmo 

encurtar o tempo de seguimento e aumentar o poder estatístico dos estudos quando 

utilizados como desfechos substitutos. Os diversos candidatos a biomarcadores já 

relatados para a DMJ/SCA3 serão descritos a seguir. 

Os achados de neuroimagem parecem ter sido os mais estudados até o 

momento. O grau de atrofia cerebelar e do tronco cerebral por ressonância 

magnética nuclear (RMN) apresenta correlação com a idade do paciente e com o 

tamanho da expansão CAG (Abe et al 1998; Onodera et al 1998, Schulz et al, 2009). 

A atrofia do tronco cerebral também se correlaciona com a escala de ataxia SARA 



35 
 

(Schulz et al, 2009). A técnica de avaliação da morfometria encefálica por RMN foi 

muito aprimorada nos últimos anos (D‘Abreu et al, 2012), contudo sua aplicabilidade 

e utilidade nos ECRs ainda parece ser complicada. Os achados de neuroimagem 

não são precoces na doença e provavelmente terão uma baixa sensibilidade a 

mudanças, tanto terapêuticas como de história natural. 

Achados neurofisiológicos também foram estudados como potenciais 

biomarcadores da DMJ/SCA3. Entre eles, recordamos os achados relacionados ao 

SNP como a redução da amplitude do potencial de ação sensitivo do nervo sural 

(França Jr. et al, 2009). Ocorre progressão significativa desta alteração em 12 

meses, a qual é maior em indivíduos com expansões mais longas. Além disso, 

também parece haver disfunção em filtros sensoriais, como o filtro sensorial auditivo 

P50 (Guisolfi et al, 2004). No entanto, a dúvida sobre a aplicabilidade do uso da 

neurofisiologia no acompanhamento de um ECR reside novamente na suspeita de 

que as alterações terão baixa sensibilidade a mudanças, tanto terapêuticas como de 

história natural. 

Marcadores bioquímicos de rotas relacionadas ao processo patogênico, 

avaliados em sangue periférico ou líquido cérebro espinhal, apresentam um 

potencial de biomarcador com maior responsividade a mudança. Entre eles, 

encontramos na literatura apenas a enolase neurônio-específica (NSE) sérica, que 

foi inicialmente associada à DMJ/SCA3 pelo nosso grupo (Tort et al, 2005). Este 

resultado foi confirmado recentemente por um estudo realizado na China (Zhou et al, 

2011). Contudo, sua aplicabilidade e utilidade em estudos de história natural e em 

ECRs, assim como para os demais biomarcadores citados não está estabelecida.  

2.9 Tratamento 

Vários fármacos já foram estudados como tratamentos sintomáticos para 

ataxia ou na tentativa de retardar a progressão da SCAs, como foi o caso de 

amantadina (Botez et al., 1996), TRH (Waragai et al.,1997), fisostigmina (Wessel et 

al., 1997), fluoxetina (Monte et al.,2003), tandospirona (Takei et al., 2004), buspirona 

(Assadi et al., 2007) e IGF-1 (Arpa et al, 2012). Dois estudos recentes merecem 

maior detalhamento. Um deles foi um ECR com objetivo de avaliar o efeito do 

riluzole como tratamento sintomático para ataxias. O grupo tratado com riluzole 

apresentou com maior frequência melhora de 5 pontos na escala de ataxia ICARS 



36 
 

após 4 e 8 semanas de tratamento. Este estudo avaliou 40 pacientes com diferentes 

tipos de ataxias hereditárias e esporádicas, nenhum deles com DMJ/SCA3 (Ristoria 

et al, 2010). Outro ECR recente com o agonista parcial do receptor nicotínico de 

acetilcolina ?4?2, vareniclina, tratou por 8 semanas 20 pacientes (10 vareniclina, 10 

placebo) com DMJ/SCA3 (Zesiewicz et al, 2012). Os resultados foram controversos 

e apresentaram eficácia em alguns desfechos de análises exploratórias da escala 

SARA. O número pequeno de pacientes avaliados, as diferenças nas características 

basais entre os grupos e os resultados controversos não dão suporte ao uso da 

vareniclina como uma opção terapêutica estabelecida.  

Desta forma, continuamos sem dispor de tratamentos farmacológicos que 

modifiquem a evolução da DMJ/SCA3 e demais SCAs. O atendimento desses 

pacientes baseia-se no aconselhamento genético, acompanhamento fisioterápico e 

de terapia ocupacional (Silva et al, 2010), bem como manejo sintomático para alguns 

de seus sinais e sintomas (D‘Abreu et al, 2010). 

O uso de inibidores de HDAC (Chou et al, 2011), de fármacos que atuem 

melhorando os sistemas de controle celular de qualidade proteica (Fornai et al, 

2008; Yamamoto, Cremona Rothman, 2006) e em outros mecanismos de 

modificação pós transcricionais das ataxinas expandidas (Paulson, 2003; Vig et al, 

2006); e as técnicas de silenciamento e degradação do ARN que levaria a 

expressão da proteína mutada através de ARNs de interferência (Alves et al, 2008) e 

olinucleotídeos antisense (Kordasiewicz  et al, 2012) são algumas das estratégias 

terapêuticas a serem melhor estudadas, especialmente à luz do atual entendimento 

da fisiopatologia da DMJ/SCA3. Essas abordagens provavelmente trabalhariam com 

terapêuticas candidatas a se tornarem específicas da DMJ/SCA3.  

Um ECR sobre segurança e eficácia de um inibidor da HDAC foi planejado 

pelo nosso grupo. No entanto, razões regulatórias impediram a realização do ensaio 

no Brasil. As demais abordagens, embora pareçam muito promissoras por atuarem 

proximalmente na cadeia de eventos causais da doença, ainda dependem de vários 

estudos de segurança pré-clínicos. Por isso, torna-se imperioso o estudo de 

substâncias neuroprotetoras, embora talvez menos específicas e possivelmente 

mais distais na cadeia de causalidade celular.  Evidências qualificadas, similares às 

demonstrados nos modelos pré-clínicos, são necessárias, para que neuroprotetores 

possam ser aplicáveis aos pacientes contemporâneos.  



37 
 

3 Objetivos 

3.1 Objetivos Gerais  

1) Descrever as seguintes manifestações clínicas não motoras da DMJ/SCA3: 

sintomas depressivos  e alterações nutricionais; 

2) Caracterizar novos biomarcadores e fatores modificadores do fenótipo da 

DMJ/SCA3. 

3) Revisar os instrumentos de avaliação clínica de SCAs já descritos na literatura, na 

tentativa de identificar quais são os mais indicados como desfechos principais nos 

futuros ECR. 

4) Avaliar a segurança e efetividade do tratamento com Carbonato de Lítio sobre os 

sintomas motores atáxicos e não-atáxicos da DMJ/SCA3;  

3.2 Objetivos Específicos 

1) Sintomas não motores: 

- sintomas depressivos e sua relação com os aspectos atáxicos e não-atáxicos 

avaliado pelas escalas SARA e NESSCA, bem como sua correlação com outros 

aspectos clínicos e moleculares; 

- achados nutricionais: através da comparação do índice de massa corporal (IMC) de 

pacientes com DMJ/SCA3 com indivíduos controles de características sócio-

demográficas semelhantes e da correlação destes achados com os demais aspectos 

clínicos, moleculares e de neuroimagem.  

2) Novos biomarcadores na DMJ/SCA3: 

- caracterização do Sistema Insulina/ IGF-1 na DMJ/SCA3 e o potencial de 

biomarcador e modificador da doença de seus componentes.  

3) Analisar os instrumentos clínicos de avaliação das SCAs descritos até o momento 

em seus aspectos de validação, estudos de história natural e aplicação em ECRs. 

Será realizada revisão sistemática da literatura, na tentativa de identificar quais 



38 
 

desfechos são os mais indicados para utilização nos futuros ECRs e se há uma clara 

necessidade de desenvolvimento de novos escores clínicos.  

4) Avaliar a segurança e efetividade do tratamento com Carbonato de Lítio sobre os 

sintomas motores atáxicos e não-atáxicos da DMJ/SCA3 em um ensaio clínico 

randomizado, duplo-cego, paralelo, placebo controlado de fase 2/3. 



39 
 

4 Referências bibliográficas da revisão  

 

1.  Abe Y, Tanaka F, Matsumoto M, Doyu M, Hirayama M, Kachi T, et al. CAG 

repeat number correlates with the rate of brainstem and cerebellar atrophy in 

Machado-Joseph disease. Neurology. 1998 Sep;51(3):882–4.  

2. Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, et 

al. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in 

a rat model of Machado-Joseph disease. PLoS ONE. 2008;3(10):e3341.  

3. Arpa J, Sanz-Gallego I, Medina-Báez J, Portela LV, Jardim LB, Torres-Aleman 

I, Saute JA. Subcutaneous Insulin-Like Growth Factor-1 Treatment in 

Spinocerebellar Ataxias: An Open Label Clinical Trial. Mov Disord. 2011; 26 

(2):358 59.  

 
4.  Assadi M, Campellone JV, Janson CG, Veloski JJ, Schwartzman RJ, Leone P. 

Treatment of spinocerebellar ataxia with buspirone. J. Neurol. Sci. 2007 Sep 

15;260(1-2):143–6.  

5.  Bettencourt C, Lima M. Machado-Joseph Disease: from first descriptions to 

new perspectives. Orphanet J Rare Dis. 2011;6:35.  

6.  Botez MI, Botez-Marquard T, Elie R, Pedraza OL, Goyette K, Lalonde R. 

Amantadine hydrochloride treatment in heredodegenerative ataxias: a double 

blind study. J. Neurol. Neurosurg. Psychiatr. 1996 Sep;61(3):259–64.  

7.  Boy J, Schmidt T, Wolburg H, Mack A, Nuber S, Böttcher M, et al. Reversibility 

of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. 

Hum. Mol. Genet. 2009 Nov 15;18(22):4282–95.  

8.  Braga-Neto P, Dutra LA, Pedroso JL, Felício AC, Alessi H, Santos-Galduroz 

RF, et al. Cognitive deficits in machado-joseph disease correlate with 

hypoperfusion of visual system areas. Cerebellum. 2012a Dec;11(4):1037–44.  

9.  Braga-Neto P, Felicio AC, Hoexter MQ, Pedroso JL, Dutra LA, Alessi H, et al. 

Cognitive and olfactory deficits in Machado-Joseph disease: a dopamine 

transporter study. Parkinsonism Relat. Disord. 2012b Aug;18(7):854–8.  



40 
 

10.  Braga-Neto P, Pedroso JL, Alessi H, Dutra LA, Felício AC, Minett T, et al. 

Cerebellar cognitive affective syndrome in Machado Joseph disease: core 

clinical features. Cerebellum. 2012c Jun;11(2):549–56.  

11.  Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein 

ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. 

Hum. Mol. Genet. 2003 Dec 1;12(23):3195–205.  

12.  Burnett BG, Pittman RN. The polyglutamine neurodegenerative protein ataxin 3 

regulates aggresome formation. Proc. Natl. Acad. Sci. U.S.A. 2005 Mar 

22;102(12):4330–5.  

13. Camargo, G. Mutação do gene ATNX3 da Doença de Machado-Joseph no Rio 

Grande do Sul: aspectos epidemiológicos e de comportamento meiótico. 2011. 

60f. Dissertação de Mestrado. Programa de Pós-Graduação em Genética e 

Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre. 

2011.  

14.  Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-

3beta inhibitors prevent cellular polyglutamine toxicity caused by the 

Huntington‘s disease mutation. J. Biol. Chem. 2002 Sep 13;277(37):33791–8.  

15.  Carvalho DR, La Rocque-Ferreira A, Rizzo IM, Imamura EU, Speck-Martins 

CE. Homozygosity enhances severity in spinocerebellar ataxia type 3. Pediatr. 

Neurol. 2008 Apr;38(4):296–9.  

16.  Cecchin CR, Pires AP, Rieder CR, Monte TL, Silveira I, Carvalho T, et al. 

Depressive symptoms in Machado-Joseph disease (SCA3) patients and their 

relatives. Community Genet. 2007;10(1):19–26.  

17.  Chou A-H, Chen S-Y, Yeh T-H, Weng Y-H, Wang H-L. HDAC inhibitor sodium 

butyrate reverses transcriptional downregulation and ameliorates ataxic 

symptoms in a transgenic mouse model of SCA3. Neurobiol. Dis. 2011 

Feb;41(2):481–8.  

18.  Chou A-H, Yeh T-H, Ouyang P, Chen Y-L, Chen S-Y, Wang H-L. 

Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 

transgenic mice by inducing transcriptional dysregulation. Neurobiol. Dis. 2008 



41 
 

Jul;31(1):89–101.  

19.  Costa M do C, Paulson HL. Toward understanding Machado-Joseph disease. 

Prog. Neurobiol. 2012 May;97(2):239–57.  

20.  Coutinho P, Andrade C. Autosomal dominant system degeneration in 

Portuguese families of the Azores Islands. A new genetic disorder involving 

cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. 

Neurology. 1978 Jul;28(7):703–9.  

21.  D‘Abreu A, França M Jr, Conz L, Friedman JH, Nucci AM, Cendes F, et al. 

Sleep symptoms and their clinical correlates in Machado-Joseph disease. Acta 

Neurol. Scand. 2009 Apr;119(4):277–80.  

22.  D‘Abreu A, Franca M Jr, Lopes-Cendes I, Cendes F. The international 

cooperative ataxia rating scale in Machado-Joseph disease. Comparison with 

the unified multiple system atrophy rating scale. Mov. Disord. 2007 Oct 

15;22(13):1976–9.  

23.  D‘Abreu A, França MC Jr, Paulson HL, Lopes-Cendes I. Caring for Machado-

Joseph disease: current understanding and how to help patients. Parkinsonism 

Relat. Disord. 2010 Jan;16(1):2–7.  

24.  D‘Abreu A, França MC Jr, Yasuda CL, Campos BAG, Lopes-Cendes I, Cendes 

F. Neocortical atrophy in Machado-Joseph disease: a longitudinal 

neuroimaging study. J Neuroimaging. 2012 Jul;22(3):285–91.  

25.  Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K. Ataxin-3 interactions 

with rad23 and valosin-containing protein and its associations with ubiquitin 

chains and the proteasome are consistent with a role in ubiquitin-mediated 

proteolysis. Mol. Cell. Biol. 2003 Sep;23(18):6469–83.  

26.  Du Montcel ST, Charles P, Ribai P, Goizet C, Le Bayon A, Labauge P, et al. 

Composite cerebellar functional severity score: validation of a quantitative 

score of cerebellar impairment. Brain. 2008 May;131(Pt 5):1352–61.  

27.  Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and 

beyond. Lancet Neurol. 2010 Sep;9(9):885–94.  



42 
 

28.  Dürr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, et al. 

Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and 

neuropathological features. Ann. Neurol. 1996 Apr;39(4):490–9.  

29.  Evert BO, Vogt IR, Kindermann C, Ozimek L, De Vos RA, Brunt ER, et al. 

Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines 

and spinocerebellar ataxia type 3 brains. J. Neurosci. 2001 Aug 1;21(15):5389–

96.  

30.  Evert BO, Araujo J, Vieira-Saecker AM, De Vos RAI, Harendza S, Klockgether 

T, et al. Ataxin-3 represses transcription via chromatin binding, interaction with 

histone deacetylase 3, and histone deacetylation. J. Neurosci. 2006 Nov 

1;26(44):11474–86.  

31.  Evert BO, Vogt IR, Vieira-Saecker AM, Ozimek L, De Vos RAI, Brunt ERP, et 

al. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct 

effects of normal and mutant ataxin-3. J. Neuropathol. Exp. Neurol. 2003 

Oct;62(10):1006–18.  

32. Fergunson FR, Critchley M. A clinical study of an heredo-familial disease 

resembling disseminated sclerosis. Brain 1929 Jul;52:203-225. 

33.  Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, et al. 

Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. 

Sci. U.S.A. 2008 Feb 12;105(6):2052–7.  

34. França M Jr, D‘abreu A, Nucci A, Cendes F, Lopes-Cendes I. Prospective 

study of peripheral neuropathy in Machado-Joseph disease. Muscle Nerve. 

2009 Dec;40(6):1012–8. 

35.  França MC Jr, D‘Abreu A, Nucci A, Lopes-Cendes I. Clinical correlates of 

autonomic dysfunction in patients with Machado-Joseph disease. Acta Neurol. 

Scand. 2010 Jun;121(6):422–5.  

36.  França MC Jr, D‘Abreu A, Friedman JH, Nucci A, Lopes-Cendes I. Chronic 

pain in Machado-Joseph disease: a frequent and disabling symptom. Arch. 

Neurol. 2007 Dec;64(12):1767–70.  

37.  França MC Jr, D‘Abreu A, Nucci A, Cendes F, Lopes-Cendes I. Progression of 



43 
 

ataxia in patients with Machado-Joseph disease. Mov. Disord. 2009 Jul 

15;24(9):1387–90.  

38.  França MC Jr, D‘Abreu A, Nucci A, Lopes-Cendes I. Muscle excitability 

abnormalities in Machado-Joseph disease. Arch. Neurol. 2008 Apr;65(4):525–

9.  

39.  Friedman JH, Amick MM. Fatigue and daytime somnolence in Machado Joseph 

Disease (spinocerebellar ataxia type 3). Mov. Disord. 2008 Jul 15;23(9):1323–

4.  

40.  Gaspar C, Lopes-Cendes I, Hayes S, Goto J, Arvidsson K, Dias A, et al. 

Ancestral origins of the Machado-Joseph disease mutation: a worldwide 

haplotype study. Am. J. Hum. Genet. 2001 Feb;68(2):523–8.  

41.  Giunti P, Sweeney MG, Harding AE. Detection of the Machado-Joseph 

disease/spinocerebellar ataxia three trinucleotide repeat expansion in families 

with autosomal dominant motor disorders, including the Drew family of 

Walworth. Brain. 1995 Oct;118 ( Pt 5):1077–85.  

42.  Gordon CR, Joffe V, Vainstein G, Gadoth N. Vestibulo-ocular arreflexia in 

families with spinocerebellar ataxia type 3 (Machado-Joseph disease). J. 

Neurol. Neurosurg. Psychiatr. 2003 Oct;74(10):1403–6.  

43.  Gwinn-Hardy K, Singleton A, O‘Suilleabhain P, Boss M, Nicholl D, Adam A, et 

al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease 

in a black family. Arch. Neurol. 2001 Feb;58(2):296–9.  

44.  Haacke A, Broadley SA, Boteva R, Tzvetkov N, Hartl FU, Breuer P. Proteolytic 

cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and 

sequestration of non-expanded ataxin-3. Hum. Mol. Genet. 2006 Feb 

15;15(4):555–68.  

45.  Haberhausen G, Damian MS, Leweke F, Müller U. Spinocerebellar ataxia, type 

3 (SCA3) is genetically identical to Machado-Joseph disease (MJD). J. Neurol. 

Sci. 1995 Sep;132(1):71–5.  

46.  Hageman J, Rujano MA, Van Waarde MAWH, Kakkar V, Dirks RP, 

Govorukhina N, et al. A DNAJB chaperone subfamily with HDAC-dependent 



44 
 

activities suppresses toxic protein aggregation. Mol. Cell. 2010 Feb 

12;37(3):355–69.  

47.  Hering S, Achmüller C, Köhler A, Poewe W, Schneider R, Boesch SM. 

Phenotype variability in spinocerebellar ataxia type 2: a longitudinal family 

survey and a case featuring an unusual benign course of disease. Mov. Disord. 

2009 Apr 15;24(5):774–7.  

48.  Huynh DP, Maalouf M, Silva AJ, Schweizer FE, Pulst SM. Dissociated fear and 

spatial learning in mice with deficiency of ataxin-2. PLoS ONE. 

2009;4(7):e6235.  

49  Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The 

natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up 

study. Neurology. 2011 Sep 13;77(11):1035–41.  

50.  Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Neurologic 

findings in Machado-Joseph disease: relation with disease duration, subtypes, 

and (CAG)n. Arch. Neurol. 2001 Jun;58(6):899–904.  

51 Jardim LB, Silveira I, Pereira ML, Ferro A, Alonso I, Do Céu Moreira M, et al. A 

survey of spinocerebellar ataxia in South Brazil - 66 new cases with Machado-

Joseph disease, SCA7, SCA8, or unidentified disease-causing mutations. J. 

Neurol. 2001 Oct;248(10):870–6. 

52.  Jardim LB, Hauser L, Kieling C, Saute JAM, Xavier R, Rieder CRM, et al. 

Progression rate of neurological deficits in a 10-year cohort of SCA3 patients. 

Cerebellum. 2010 Sep;9(3):419–28.  

53.  Jiang H, Tang B, Xu B, Zhao G, Shen L, Tang J, et al. Frequency analysis of 

autosomal dominant spinocerebellar ataxias in mainland Chinese patients and 

clinical and molecular characterization of spinocerebellar ataxia type 6. Chin. 

Med. J. 2005 May 20;118(10):837–43.  

54.  Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. 

CAG expansions in a novel gene for Machado-Joseph disease at chromosome 

14q32.1. Nat. Genet. 1994 Nov;8(3):221–8.  

55.  Kawai Y, Takeda A, Abe Y, Washimi Y, Tanaka F, Sobue G. Cognitive 



45 
 

impairments in Machado-Joseph disease. Arch. Neurol. 2004 

Nov;61(11):1757–60.  

56.  Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, et al. Huntingtin is 

present in the nucleus, interacts with the transcriptional corepressor C-terminal 

binding protein, and represses transcription. J. Biol. Chem. 2002 Mar 

1;277(9):7466–76.  

57.  Kiehl T-R, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, Pulst S-M. 

Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem. 

Biophys. Res. Commun. 2006 Jan 6;339(1):17–24.  

58.  Kieling C, Prestes PR, Saraiva-Pereira ML, Jardim LB. Survival estimates for 

patients with Machado-Joseph disease (SCA3). Clin. Genet. 2007 

Dec;72(6):543–5.  

59.  Kieling C, Rieder CRM, Silva ACF, Saute JAM, Cecchin CR, Monte TL, et al. A 

neurological examination score for the assessment of spinocerebellar ataxia 3 

(SCA3). Eur. J. Neurol. 2008 Apr;15(4):371–6.  

60.  Kieling C, Morales Saute JA, Jardim LB. When ataxia is not just ataxia. Nat Clin 

Pract Neurol. 2007 May;3(5):E2.  

61.  Klockgether T, Schöls L, Abele M, Bürk K, Topka H, Andres F, et al. Age 

related axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph 

disease (SCA3/MJD). J. Neurol. Neurosurg. Psychiatr. 1999 Feb;66(2):222–4.  

62.  Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel 

KA, et al. Sustained therapeutic reversal of Huntington‘s disease by transient 

repression of huntingtin synthesis. Neuron. 2012 Jun 21;74(6):1031–44.  

63.  Li F, Macfarlan T, Pittman RN, Chakravarti D. Ataxin-3 is a histone-binding 

protein with two independent transcriptional corepressor activities. J. Biol. 

Chem. 2002 Nov 22;277(47):45004–12.  

64.  Lima L, Coutinho P. Clinical criteria for diagnosis of Machado-Joseph disease: 

report of a non-Azorena Portuguese family. Neurology. 1980 Mar;30(3):319–

22.  



46 
 

65.  Lopes-Cendes I, Teive HG, Calcagnotto ME, Da Costa JC, Cardoso F, Viana 

E, et al. Frequency of the different mutations causing spinocerebellar ataxia 

(SCA1, SCA2, MJD/SCA3 and DRPLA) in a large group of Brazilian patients. 

Arq Neuropsiquiatr. 1997 Sep;55(3B):519–29.  

66.  Lysenko L, Grewal RP, Ma W, Peddareddygari LR. Homozygous Machado 

Joseph Disease: a case report and review of literature. Can J Neurol Sci. 2010 

Jul;37(4):521–3.  

67.  Maciel P, Gaspar C, DeStefano AL, Silveira I, Coutinho P, Radvany J, et al. 

Correlation between CAG repeat length and clinical features in Machado-

Joseph disease. Am. J. Hum. Genet. 1995 Jul;57(1):54–61.  

68.  Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I. Dietary intake 

in adults at risk for Huntington disease: analysis of PHAROS research 

participants. Neurology. 2009 Aug 4;73(5):385–92.  

69.  Martins S, Calafell F, Gaspar C, Wong VCN, Silveira I, Nicholson GA, et al. 

Asian origin for the worldwide-spread mutational event in Machado-Joseph 

disease. Arch. Neurol. 2007 Oct;64(10):1502–8.  

70.  Martins S, Soong B-W, Wong VCN, Giunti P, Stevanin G, Ranum LPW, et al. 

Mutational origin of Machado-Joseph disease in the Australian Aboriginal 

communities of Groote Eylandt and Yirrkala. Arch. Neurol. 2012 Jun;69(6):746–

51.  

71.  Matilla A, Roberson ED, Banfi S, Morales J, Armstrong DL, Burright EN, et al. 

Mice lacking ataxin-1 display learning deficits and decreased hippocampal 

paired-pulse facilitation. J. Neurosci. 1998 Jul 15;18(14):5508–16.  

72.  Monte TL, Rieder CRM, Tort AB, Rockenback I, Pereira ML, Silveira I, et al. 

Use of fluoxetine for treatment of Machado-Joseph disease: an open-label 

study. Acta Neurol. Scand. 2003 Mar;107(3):207–10.  

73.  Münchau A, Dressler D, Bhatia KP, Vogel P, Zühlke C. Machado-Joseph 

disease presenting as severe generalised dystonia in a German patient. J. 

Neurol. 1999 Sep;246(9):840–2.  

74.  Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, et al. Nuclear 



47 
 

receptor repression mediated by a complex containing SMRT, mSin3A, and 

histone deacetylase. Cell. 1997 May 2;89(3):373–80.  

75.  Nakano KK, Dawson DM, Spence A. Machado disease. A hereditary ataxia in 

Portuguese emigrants to Massachusetts. Neurology. 1972 Jan;22(1):49–55.  

76.  Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ, Pastore A. The 

solution structure of the Josephin domain of ataxin-3: structural determinants 

for molecular recognition. Proc. Natl. Acad. Sci. U.S.A. 2005 Jul 

26;102(30):10493–8.  

77.  Paulson HL. Protein fate in neurodegenerative proteinopathies: polyglutamine 

diseases join the (mis)fold. Am. J. Hum. Genet. 1999 Feb;64(2):339–45.  

78.  Paulson H. Polyglutamine neurodegeneration: minding your Ps and Qs. Nat. 

Med. 2003 Jul;9(7):825–6.  

79.  Paulson H. Machado-Joseph disease/spinocerebellar ataxia type 3. Handb Clin 

Neurol. 2012;103:437–49.  

80.  Paulson HL. Dominantly inherited ataxias: lessons learned from Machado-

Joseph disease/spinocerebellar ataxia type 3. Semin Neurol. 2007 

Apr;27(2):133–42.  

81.  Pedroso JL, Braga-Neto P, Felício AC, Dutra LA, Santos WAC, Do Prado GF, 

et al. Sleep disorders in machado-joseph disease: frequency, discriminative 

thresholds, predictive values, and correlation with ataxia-related motor and 

non-motor features. Cerebellum. 2011 Jun;10(2):291–5.  

82.  Prestes PR, Saraiva-Pereira ML, Silveira I, Sequeiros J, Jardim LB. Machado-

Joseph disease enhances genetic fitness: a comparison between affected and 

unaffected women and between MJD and the general population. Ann. Hum. 

Genet. 2008 Jan;72(Pt 1):57–64.  

83.  Riess O, Rüb U, Pastore A, Bauer P, Schöls L. SCA3: neurological features, 

pathogenesis and animal models. Cerebellum. 2008;7(2):125–37.  

84.  Riley BE, Orr HT. Polyglutamine neurodegenerative diseases and regulation of 

transcription: assembling the puzzle. Genes Dev. 2006 Aug 15;20(16):2183–



48 
 

92.  

85.  Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, et al. 

Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled 

pilot trial. Neurology. 2010 Mar 9;74(10):839–45.  

86.  Rodrigues CSM, De Oliveira VZ, Camargo G, Osório CM da S, De Castilhos 

RM, Saraiva-Pereira ML, et al. Presymptomatic testing for neurogenetic 

diseases in Brazil: assessing who seeks and who follows through with testing. J 

Genet Couns. 2012 Feb;21(1):101–12.  

87.  Rolim L, Leite A, Lêdo S, Paneque M, Sequeiros J, Fleming M. Psychological 

aspects of pre-symptomatic testing for Machado-Joseph disease and familial 

amyloid polyneuropathy type I. Clin. Genet. 2006 Apr;69(4):297–305.  

88.  Romanul FC, Fowler HL, Radvany J, Feldman RG, Feingold M. Azorean 

disease of the nervous system. N. Engl. J. Med. 1977 Jun 30;296(26):1505–8.  

89.  Rosenberg RN, Nyhan WL, Bay C, Shore P. Autosomal dominant striatonigral 

degeneration. A clinical, pathologic, and biochemical study of a new genetic 

disorder. Neurology. 1976 Aug;26(8):703–14.  

90.  Rosenberg RN, Nyhan WL, Coutinho P, Bay C. Joseph‘s disease: an 

autosomal dominant neurological disease in the Portuguese of the United 

States and the Azores Islands. Adv Neurol. 1978;21:33–57.  

91.  Rüb U, Brunt ER, Deller T. New insights into the pathoanatomy of 

spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr. Opin. Neurol. 

2008 Apr;21(2):111–6.  

92.  Sakai T, Kawakami H. Machado-Joseph disease: A proposal of spastic 

paraplegic subtype. Neurology. 1996 Mar;46(3):846–7.  

93. Saute JA, Jardim LB. Ataxias hereditárias. In: Márcia L. F. Chaves; Alessandro 

Finkelsztejn; Marco Antonio Stefani. (Org.). Rotinas em Neurologia e 

Neurocirurgia. 1ed.Porto Alegre: ARTMED, 2008, v. 1, p. 363-380. 

94.  Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, Klockgether T, et al. 

Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein 



49 
 

ubiquitination. Biochem. Biophys. Res. Commun. 2007 Oct 26;362(3):734–9.  

95.  Schmitz-Hübsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. 

Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia 

symptoms. Neurology. 2008 Sep 23;71(13):982–9.  

96.  Schmitz-Hübsch T, Du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, 

et al. Scale for the assessment and rating of ataxia: development of a new 

clinical scale. Neurology. 2006 Jun 13;66(11):1717–20.  

97.  Schmitz-Hübsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, 

et al. Responsiveness of different rating instruments in spinocerebellar ataxia 

patients. Neurology. 2010 Feb 23;74(8):678–84.  

98.  Schmitz-Hübsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Saccà F, et 

al. SCA Functional Index: a useful compound performance measure for 

spinocerebellar ataxia. Neurology. 2008 Aug 12;71(7):486–92.  

99 Schulz JB, Borkert J, Wolf S, Schmitz-Hübsch T, Rakowicz M, Mariotti C, et al. 

Visualization, quantification and correlation of brain atrophy with clinical 

symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage. 2010 Jan 

1;49(1):158–68.  

100.  Sequeiros J, Martins S, Silveira I. Epidemiology and population genetics of 

degenerative ataxias. Handb Clin Neurol. 2012;103:227–51.  

101.  Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et 

al. Multicenter analysis of glucocerebrosidase mutations in Parkinson‘s 

disease. N. Engl. J. Med. 2009 Oct 22;361(17):1651–61.  

102.  Siebert M, Donis KC, Socal M, Rieder CRM, Emmel VE, Vairo F, et al. 

Glucocerebrosidase gene variants in parkinsonian patients with Machado 

Joseph/spinocerebellar ataxia 3. Parkinsonism Relat. Disord. 2012 

Feb;18(2):185–90.  

103.  Silva MC, Coutinho P, Pinheiro CD, Neves JM, Serrano P. Hereditary ataxias 

and spastic paraplegias: methodological aspects of a prevalence study in 

Portugal. J Clin Epidemiol. 1997 Dec;50(12):1377–84.  



50 
 

104  Silva RCR, Saute JAM, Silva ACF, Coutinho ACO, Saraiva-Pereira ML, Jardim 

LB. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. 

Braz. J. Med. Biol. Res. 2010 Jun;43(6):537–42.  

105.  Silveira I, Lopes-Cendes I, Kish S, Maciel P, Gaspar C, Coutinho P, et al. 

Frequency of spinocerebellar ataxia type 1, dentatorubropallidoluysian atrophy, 

and Machado-Joseph disease mutations in a large group of spinocerebellar 

ataxia patients. Neurology. 1996 Jan;46(1):214–8.  

106.  Soong B, Paulson HL. Spinocerebellar ataxias: an update. Curr. Opin. Neurol. 

2007 Aug;20(4):438–46.  

107.  Soong B W, Lu Y C, Choo K B, Lee H Y. Frequency analysis of autosomal 

dominant cerebellar ataxias in Taiwanese patients and clinical and molecular 

characterization of spinocerebellar ataxia type 6. Arch. Neurol. 2001 

Jul;58(7):1105–9.  

108.  Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, 

et al. The Huntington‘s disease protein interacts with p53 and CREB-binding 

protein and represses transcription. Proc. Natl. Acad. Sci. U.S.A. 2000 Jun 

6;97(12):6763–8.  

109.  Stevanin G, Le Guern E, Ravisé N, Chneiweiss H, Dürr A, Cancel G, et al. A 

third locus for autosomal dominant cerebellar ataxia type I maps to 

chromosome 14q24.3-qter: evidence for the existence of a fourth locus. Am. J. 

Hum. Genet. 1994 Jan;54(1):11–20.  

110.  Stevanin G, Sousa PS, Cancel G, Dürr A, Dubourg O, Nicholson GA, et al. The 

gene for Machado-Joseph disease maps to the same 3-cM interval as the 

spinal cerebellar ataxia 3 gene on chromosome 14q. Neurobiol. Dis. 1994 

Nov;1(1-2):79–82.  

111.  Ström A-L, Forsgren L, Holmberg M. A role for both wild-type and expanded 

ataxin-7 in transcriptional regulation. Neurobiol. Dis. 2005 Dec;20(3):646–55.  

112. Subramony SH. Overview of autosomal dominant ataxias. Handb Clin Neurol. 

2012;103:389–98. 

113.  Tait D, Riccio M, Sittler A, Scherzinger E, Santi S, Ognibene A, et al. Ataxin-3 



51 
 

is transported into the nucleus and associates with the nuclear matrix. Hum. 

Mol. Genet. 1998 Jun;7(6):991–7.  

114.  Takei A, Fukazawa T, Hamada T, Sohma H, Yabe I, Sasaki H, et al. Effects of 

tandospirone on ?5-HT1A receptor-associated symptoms? in patients with 

Machado-Josephe disease: an open-label study. Clin Neuropharmacol. 2004 

Feb;27(1):9–13.  

115.  Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, 

et al. The gene for Machado-Joseph disease maps to human chromosome 

14q. Nat. Genet. 1993 Jul;4(3):300–4.  

116.  Teive HA, Iwamoto FM, Camargo CH, Lopes-Cendes I, Werneck LC. 

Machado-Joseph disease versus hereditary spastic paraplegia: case report. 

Arq Neuropsiquiatr. 2001 Sep;59(3-B):809–11.  

117.  Teive HAG, Arruda WO. [The Drew family of Walworth: one century from the 

first evaluation until the final diagnosis, Machado-Joseph disease]. Arq 

Neuropsiquiatr. 2004 Mar;62(1):177–80.  

118.  Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, et al. The 

transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor 

function. Nature. 1997 Jun 12;387(6634):677–84.  

119.  Tort ABL, Portela LVC, Rockenbach IC, Monte TL, Pereira ML, Souza DO, et 

al. S100B and NSE serum concentrations in Machado Joseph disease. Clin. 

Chim. Acta. 2005 Jan;351(1-2):143–8.  

120.  Trott A, Jardim LB, Ludwig HT, Saute JAM, Artigalás O, Kieling C, et al. 

Spinocerebellar ataxias in 114 Brazilian families: clinical and molecular 

findings. Clin. Genet. 2006 Aug;70(2):173–6.  

121.  Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et 

al. International Cooperative Ataxia Rating Scale for pharmacological 

assessment of the cerebellar syndrome. The Ataxia Neuropharmacology 

Committee of the World Federation of Neurology. J. Neurol. Sci. 1997 Feb 

12;145(2):205–11.  

122.  Tsai C-C, Kao H-Y, Mitzutani A, Banayo E, Rajan H, McKeown M, et al. Ataxin 



52 
 

1, a SCA1 neurodegenerative disorder protein, is functionally linked to the 

silencing mediator of retinoid and thyroid hormone receptors. Proc. Natl. Acad. 

Sci. U.S.A. 2004 Mar 23;101(12):4047–52.  

123.  Uchihara T, Fujigasaki H, Koyano S, Nakamura A, Yagishita S, Iwabuchi K. 

Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary 

ataxias--triple-labeling immunofluorescence study. Acta Neuropathol. 2001 

Aug;102(2):149–52.  

124.  Velázquez-Pérez L, Rodríguez-Labrada R, García-Rodríguez JC, Almaguer-

Mederos LE, Cruz-Mariño T, Laffita-Mesa JM. A comprehensive review of 

spinocerebellar ataxia type 2 in Cuba. Cerebellum. 2011 Jun;10(2):184–98.  

125.  Vig PJS, Subramony SH, D‘Souza DR, Wei J, Lopez ME. Intranasal 

administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 

mice. Brain Res. Bull. 2006 May 15;69(5):573–9.  

126.  Waragai M, Ogawara K, Takaya Y, Hayashi M. [Efficacy of TRH-T for 

spinocerebellar degeneration--the relation between clinical features and effect 

of TRH therapy]. Rinsho Shinkeigaku. 1997 Jul;37(7):587–94.  

127.  Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, Paulson HL, et 

al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a 

ubiquitin-associated mechanism. Mol. Cell. 2005 Apr 1;18(1):37–48.  

128.  Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, et al. 

Lithium therapy improves neurological function and hippocampal dendritic 

arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007 

May;4(5):e182.  

129.  Wessel K, Langenberger K, Nitschke MF, Kömpf D. Double-blind crossover 

study with physostigmine in patients with degenerative cerebellar diseases. 

Arch. Neurol. 1997 Apr;54(4):397–400.  

130.  Wilder-Smith E, Tan EK, Law HY, Zhao Y, Ng I, Wong MC. Spinocerebellar 

ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a 

Chinese family. J. Neurol. Sci. 2003 Sep 15;213(1-2):25–8.  

131.  Wolf U, Rapoport MJ, Schweizer TA. Evaluating the affective component of the 



53 
 

cerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci. 

2009;21(3):245–53.  

132.  Woods BT, Schaumburg HH. Nigro-spino-dentatal degeneration with nuclear 

ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J. 

Neurol. Sci. 1972 Oct;17(2):149–66.  

133.  Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo A-P, 

Rubinsztein DC. Heat shock protein 27 prevents cellular polyglutamine toxicity 

and suppresses the increase of reactive oxygen species caused by huntingtin. 

Hum. Mol. Genet. 2002 May 1;11(9):1137–51.  

134.  Yamada M, Sato T, Tsuji S, Takahashi H. CAG repeat disorder models and 

human neuropathology: similarities and differences. Acta Neuropathol. 2008 

Jan;115(1):71–86.  

135.  Yamada M, Tsuji S, Takahashi H. Involvement of lysosomes in the 

pathogenesis of CAG repeat diseases. Ann. Neurol. 2002 Oct;52(4):498–503.  

136.  Yamamoto A, Cremona ML, Rothman JE. Autophagy-mediated clearance of 

huntingtin aggregates triggered by the insulin-signaling pathway. J. Cell Biol. 

2006 Feb 27;172(5):719–31.  

137.  Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, et al. A 

randomized trial of varenicline (Chantix) for the treatment of spinocerebellar 

ataxia type 3. Neurology. 2012 Feb 21;78(8):545–50.  

138 Zhou J, Lei L, Shi Y, Wang J, Jiang H, Shen L, et al. Serum concentrations of 

NSE and S100B in spinocerebellar ataxia type 3/Machado-Joseph disease. 

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Jun;36(6):504–10. 

139.  Zijlstra MP, Rujano MA, Van Waarde MA, Vis E, Brunt ER, Kampinga HH. 

Levels of DNAJB family members (HSP40) correlate with disease onset in 

patients with spinocerebellar ataxia type 3. Eur. J. Neurosci. 2010 

Sep;32(5):760–70.  



54 
 

Capítulo 1 - Depressive Mood is Associated with Ataxic and 

Non-Ataxic Neurological Dysfunction in SCA3 Patients 

5 ARTIGOS EM INGLÊS 

 

 

 

 

 

 

 

 

 

 

 

 

   



55 
 

Depressive mood is associated with ataxic and non-ataxic neurological 

dysfunction in SCA3 patients. 

 

Jonas Alex Morales Saute,
1,3

 Andrew Chaves Feitosa da Silva,
4
 Karina 

Carvalho Donis,
4
 Leonardo Vedolin,

5
 Maria Luiza Saraiva-Pereira,

4
 Laura Bannach 

Jardim. 
1,2,4 

 

1
 Postgraduate Program in Medical Sciences and Department of 

2
Internal 

Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; 
3
 

Neurology and 
4
Medical Genetics Services, Hospital de Clínicas de Porto Alegre 

(HCPA), Porto Alegre, RS, Brazil; 
5
Neuroradiology Service, Hospital Moinhos de 

Vento, Porto Alegre, Brazil 

 

* Corresponding author: 

 

Jonas Alex Morales Saute 

Postgraduate Program in Medical Sciences 

Neurology Service, Hospital de Clínicas de Porto Alegre (HCPA) 

Universidade Federal do Rio Grande do Sul. 

Rua Ramiro Barcelos, 2.350 

Zip Code 90035-903, Porto Alegre, Rio Grande do Sul, Brazil  

e-mail: j4ws@yahoo.com 

tel/Fax: +55 51 3359 8520/ 55 51 3359.8001 

 

Financial Disclosure: None of the authors declared a conflict of interest.  



56 
 

 

Letter to the Editor 

We read with interest the article recently published in Cerebellum by Klinke, et al., 

entitled Neuropsychological Features of Patients with Spinocerebellar Ataxia (SCA) 

Types 1, 2, 3, and 6., especially as it pertains to the depressive mood scores 

obtained in those patients [1].  SCAs are a group of autosomal dominant ataxic 

disorders affecting mainly the cerebellum and its afferent and efferent connections; 

however in most SCAs the consecutive degenerative process also involves 

extracerebellar structures [2].  

A recent survey of subjective health status performed in 526 SCA patients from the 

EUROSCA clinical group, found that 46% of those patients reported 

depression/anxiety problems, which was one of the three independent predictors of 

subjective health status together with ataxia severity and extent of noncerebellar 

involvement [3]. We previously reported that SCA3 symptomatic patients have higher 

depressive mood scores on the Beck Depression Inventory (BDI) than controls 

(caregivers), whereas their children at risk have BDI scores lower than the same 

control group. Depressive mood scores on the BDI correlated with the neurological 

disability measured by the Barthel Index of Physical Incapacitation in our study [4], 

and correlated with the dominant motor hand dysfunction in the study by Klinke et al. 

[1]. 

In order to further evaluate depressive symptoms in SCA3 patients and their 

relationship with the recently obtained ataxia scores, we performed a case control-

study in 49 molecularly confirmed SCA3 patients from the neurogenetics clinic of 

HCPA and 41 healthy, non-related individuals with similar age, gender, and 

environmental characteristics– such as spouses or neighbors of the affected 

individuals (mainly caregivers) – as the control group. The ATXN3 expanded regions 

were analyzed as previously described [5].
 
 

The Beck Depression Inventory (BDI), in its Brazilian version [6],
 
was applied to 

quantify the depressive symptoms of subjects. BDI is usually interpreted as follows: 

0–10 (absence or subtle depression), 11–18 (mild depression), 19– 29 (moderate 

depression), and 30–63 (severe depression). 



57 
 

Two clinical ataxia scales were applied: the SARA [7],
 
which evaluates ataxic signals 

and the NESSCA [8], which is a global neurological evaluation encompassing ataxic 

and non-ataxic signals. Both scores vary from 0 to 40 points, increasing with disease 

severity. Disease duration and age of onset were informed by patients and their 

relatives.  

For detailed patient characteristics see Table 1. SCA3 patients presented higher 

depressive scores on BDI (p=0.012) when compared to controls (Fig.1A). 

Considering the severity of depressive symptoms, 61% of controls versus 36.7% of 

SCA3 patients had absence of or subtle depression, 17% versus 28.5% had mild, 

22% versus 34.6% had moderate or severe scores on BDI (Fig. 1B). BDI correlated 

moderately with SARA (R= 0.359, p=0.01 - Fig 1C) and NESSCA (R= 0.412, p=0.003 

– Fig. 1D). When dividing NESSCA into two sub-scores, the first related to ataxic 

signals (maximum of 16 points) and the second to non-ataxic signals (maximum of 

24 points), both scores correlated significantly with BDI (R=0.411, p=0.003; R=0.348 

p=0.01, respectively). BDI was also correlated with disease duration, though did not 

achieve statistical significance (R=0.273 p=0.057). BDI was not associated with other 

clinical or molecular parameters of SCA3 (data not shown).   

We also performed MRI (1.5 T system) randomly in 30 (16 females) of these SCA3 

patients - whose demographic characteristics were similar to those found in the 

overall group of patients - in order to correlate the measures of normalized volumes 

of the brainstem, mesencephalus, pontine tegmentum, basis of pons, medulla 

oblongata, and cerebellum with BDI. More detailed procedures of the utilized 

technique were described elsewhere [9]. We found no significant correlations of MRI 

volumetries with BDI (data not shown). 

Our data shows a direct correlation of disease severity (measured by SARA and 

NESSCA) with depressive symptoms, and is in accordance with the results 

presented by Klinke et al [1], though perhaps with slightly stronger evidence, since 

those authors reported only a trend towards correlation of BDI with SARA [1]. Our 

significance probably relied on a larger and more homogeneous sample of patients 

(only with SCA3), with worse SARA and BDI scores.  

Considering SCA3 only, it is evident that our patients had longer disease duration 

and CAG repeat lengths than those described in that paper [1]. One could argue that 



58 
 

the higher depression scores could be related to the longer CAG expansions we saw, 

but we did not find any evidence of that. We found a correlation of BDI with disease 

duration; however this was likely to be a confounding factor relating larger disease 

durations with more severe ataxic scores. Lastly, sociocultural differences between 

Brazilians and Europeans should be borne in mind, though it is impossible to test for 

these. 

Although these factors – mutation severity, disease duration, and cultural 

characteristics - are not mutually exclusive, the absence of any association between 

BDI and molecular findings or MRI normalized volumes, in our study, suggest that 

depression in SCA3 is not primarily related to brain involvement, but rather related to 

physical incapacity [1,10].  

Depressive symptoms are very common and significantly impair the quality of life of 

ataxic patients [3,4]. At least in SCA3, patients may respond well to treatments aimed 

at improving the ways in which they deal with their disability, such as Occupational 

Therapy [11]. That our data support the view that depressive symptoms in SCA3 are 

not primarily related to the underlying pathological process could be a matter of 

debate. However – whether organic or reactive – depressive symptoms are an 

integral part of SCA3 deserving attention from the physicians who treat this disease. 

References: 

1 - Klinke I, Minnerop M, Schmitz-Hübsch T, Hendriks M, Klockgether T, Wüllner U, 

et al. Neuropsychological Features of Patients with Spinocerebellar Ataxia (SCA) 

Types 1, 2, 3, and 6. Cerebellum. 2010. [Epub ahead of print] 

2 - Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar 

ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3:291–

304. 

3 - Schmitz-Hübsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R, et al. 

Self-Rated Health Status in Spinocerebellar Ataxia—Results from a European 

Multicenter Study. Mov Disord. 2010;5: 587-95. 

4 - Cecchin CR, Pires AP, Rieder CR, Monte TL, Silveira I, Carvalho T, et al. 

Depressive Symptoms in Machado-Joseph Disease (SCA-3): Patients and Their 

Relatives. Community Genet. 2007;10:19-26. 



59 
 

5 - Bauer PO, Kotliarova SE, Matoska V, Musova Z, Hedvicakova P, Boday A, et al. 

Fluorescent multiplex PCR--fast method for autosomal dominant spinocerebellar 

ataxias screening. Genetika. 2005;41:830-7. 

6 - Gorenstein C, Andrade L. Validation of a portuguese version of the beck 

depression inventory and the state -trait anxiety inventory in Brazilian subjects. Braz 

J Med Biol Res.1996; 29: 453-7. 

7 - Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et 

al. Scale for the assessment and rating of ataxia: development of a new clinical 

scale. Neurology. 2006; 66:1717–20. 

8 - Kieling C, Rieder CR, Silva AC, Saute JA, Cecchin CR, Monte TL, Jardim LB. A 

neurological examination score for the assessment of spinocerebellar ataxia 3 

(SCA3). Eur J Neurol. 2008;15:371-6. 

9 - Vedolin L, Schwartz IV, Komlos M, Schuch A, Azevedo AC, Vieira T, et al. Brain 

MRI in mucopolysaccharidosis: effect of aging and correlation with biochemical 

findings. Neurology. 2007;69:917-24. 

10 - Rüb U, Brunt ER, Deller T. New insights into the pathoanatomy of 

spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol. 2008; 

21:111-6. 

11 – Silva RCR, Saute JA, Silva ACF, Coutinho ACO,  Saraiva-Pereira ML, Jardim 

LB. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz J 

Med Biol Res. 2010 [Epub ahead of print] 

  



60 
 
Table 1 

 

 

Figure 1: Depression scores in SCA3 (A) BDI score in SCA3 patients and controls. 

(B) Representation (%) of the severity of BDI scores between groups. (C) Correlation 



61 
 

of BDI with SARA and (D) Correlation of BDI with NESSCA. Values are given as 

means and error bars represent standard error (SEM); * p &amp;lt;0.05;** p &amp;lt;0.01. 

 

  



62 
 

Capítulo 2 - Body Mass Index is Inversely Correlated with 

the Expanded CAG Repeat Length in SCA3/MJD Patients  

 

 

 

 

 

 

 

 

 

 

  



63 
 

Body mass index is inversely correlated with the expanded CAG repeat 

number in SCA3 patients 

 

Jonas Alex Morales Saute
1,4

, Karina Carvalho Donis
5
, Gabriele Nunes Souza

5
, 

Andrew Chaves Feitosa da Silva
5
, Leonardo Vedolin

6
, Maria Luiza Saraiva-Pereira

3,5
, 

Luis Valmor Cruz Portela
3
, Laura Bannach Jardim. 

1,2,5 

 

1
Postgraduate Program in Medical Sciences and Departments of 

2
Internal Medicine 

and 
3
Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, 

Brazil; 
4
 Neurology and 

5
Medical Genetics Services, Hospital de Clínicas de Porto 

Alegre (HCPA), Porto Alegre, RS, Brazil; 
6
Neuroradiology Service, Hospital Moinhos 

de Vento, Porto Alegre, Brazil 

 

* Corresponding author: 

Jonas Alex Morales Saute 

Neurology Service, Hospital de Clínicas de Porto Alegre (HCPA) 

Universidade Federal do Rio Grande do Sul. 

Rua Ramiro Barcelos, 2.350 

Zip Code 90035-903, Porto Alegre, Rio Grande do Sul, Brazil  

e-mail: j4ws@yahoo.com 

tel/Fax: +55 51 3359 8520/ 55 51 3359.8001 

 



64 
 

 Search Terms: 

[ 298 ] Spinocerebellar ataxia, [ 98 ] Trinucleotide repeat diseases, [ 163 ] Gait 

disorders/ataxia, [ 175 ] Neuroendocrinology. 

Financial Disclosure: None of the authors declared a conflict of interest.  

Acknowledgments 

This research was supported by the Brazilian funding agencies FIPE-HCPA, 

CNPq, FINEP, INAGEMP and FAPERGS and by the Spanish institute CIBERNED.  



65 
 

Abstract 

 

Objectives: We aimed to evaluate the body mass index (BMI) of patients with SCA3 

and to assess the correlations with clinical, molecular, biochemical and neuroimaging 

findings. 

Methods: A case-control study with 46 SCA3 patients and 42 healthy, non-related 

control individuals with similar age and sex was performed. Clinical evaluation was 

done with the ataxia scales SARA and NESSCA. Serum insulin, insulin like-growth 

factor 1 (IGF-1) and magnetic resonance imaging (MRI) normalized volumetries of 

cerebellum and brain stem were also assessed. 

Results: BMI was lower in SCA3 patients when compared to controls (p=0.01). BMI 

was associated with NESSCA, expanded CAG repeat number (CAG)n and serum 

insulin levels; however in the linear regression model, (CAG)n was the only variable 

independently associated with BMI, in an inverse manner (R=-0.404, p=0.012).  

Conclusions: In this report we present evidence that low BMI is not only present in 

SCA3, but is also directly related to the size of the expanded CAG repeats, which is 

the causative mutation of the disease. This association points that weight loss might 

be a primary disturbance of SCA3, although further detailed analyses are necessary 

for a better understanding of the nutritional deficit and its role in the pathophysiology 

of SCA3. 

 

 

 



66 
 

Introduction 

Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative 

disease with no current treatment caused by a dynamic mutation involving CAG 

trinucleotide repeat expansions, being part of the so-called group of polyglutamine 

(polyQ) disorders
1
.  

In spite of clearly present in clinical practice, nutritional alterations in SCA3 patients 

were only covered by anecdotal reports in the literature. We have recently evaluated 

the role of insulin/insulin-like growth factor 1 (IGF-1) system (IIS) in SCA3 patients 

finding that SCA3 patients presented lower Body Mass Index (BMI) than controls
2
. In 

the present report, we aimed to deepen the understanding about weight loss in this 

disease, looking for correlations with clinical, molecular, biochemical and 

neuroimaging findings, in a case-control study. 

Methods 

We recruited 46 SCA3 patients from the neurogenetics clinic of HCPA and 42 

healthy, non-related individuals, with similar age, gender, and environmental 

characteristics – mainly caregivers – as the control group. The clinical evaluation was 

performed with the Scale for the Assessment and Rating of Ataxia (SARA)
3
 and the 

Neurological Examination Score for Spinocerebellar Ataxia (NESSCA)
4
. Both scores 

vary from 0–40 points, increasing with disease severity. Weight and height were 

measured always in the same devices and BMI was calculated with the formula 

[weight / (height)²]. Disease duration and age of onset were informed by patients and 

their relatives.  

We also performed brain magnetic resonance imaging (MRI - 1.5 T system) 

randomly in 26 (14 females) of these SCA3 patients - whose demographic 

characteristics were similar to those found in the overall group of patients - in order to 

correlate the measures of normalized volumes of the brainstem, mesencephalus, 

pontine tegmentum, basis of pons, medulla oblongata, and cerebellum with BMI. 

More detailed procedures of the utilized technique were described elsewhere
5
.  

A blood sample was collected in the same day of the clinical evaluation in order to 

measure serum lipid profile, glucose, insulin (Electrochemiluminescence - Roche 

Diagnostics, Germany) and IGF-1 levels (ELISA - DuoSet R&amp;amp;D System, USA). All 



67 
 

samples were obtained between 10 AM and 4 PM and all subjects were under fasting 

conditions. The study was approved by the local Ethics Committee and all subjects 

gave their informed written consent. 

All variables in the study showed a normal distribution on Kolmogorov-Smirnov test. 

Continuous variables comparison between cases and controls were performed with 

two-tailed unpaired Student‘s t-test. One-Way ANOVA was performed to compare 

the BMI within the different degrees of dysphagia. Gender was analyzed with ?
2
 test 

and all correlations with Pearson correlation test followed by multiple linear 

regression model. Statistical significance was defined as p &amp;lt;0.05.  

Results 

For detailed clinical characteristics of enrolled subjects see Table 1.  

BMI was found to be lower in SCA3 patients when compared to controls (p=0.01 – 

corrected for age – Fig 1A), correlating inversely with CAG expanded repeats – 

CAG(n) - (R=-0.484, R
2
=0.234, p=0.001 – Fig 1B) and NESSCA (R=-0.351, 

R
2
=0.123, p=0.02); and directly with age at onset (R=-0.496, R

2
=0.246, p=0.001) and 

age (R=0.396, R
2
=0.157, p=0.008).   

Former results from this case control study showed that SCA3 patients presented 

lower serum insulin and normal IGF-1 levels
2
. In the present study, we found that 

serum insulin levels were directly associated with BMI (R=0.428, R
2
=0.183 p=0.006), 

while IGF-1 levels were not (R=-0.088, p=0.473). However, in the multiple linear 

regression model constructed with insulin levels, NESSCA, age and CAG(n) or age 

at onset, the only studied factor that was independently associated with BMI was the 

number of expanded CAG repeats (R=-0.404, p=0.012), with only a trend for insulin 

levels (R=0.293, p=0.074). 

Dysphagia might also be an important cause of weight loss, and since one item of 

NESSCA evaluates dysphagia, we divided SCA3 patients in accordance to it – as 

having no, mild or severe dysphagia. No significant differences in BMI were found 

among these subgroups (p=0.228).  

Finally, we found no significant correlation between BMI and brainstem MRI 

volumetries after correction for age (data not shown). 



68 
 

 

Discussion 

In this report we present evidence that low BMI is not only present in SCA3, but is 

also directly related to the severity of SCA3 causal mutation – the expanded CAG 

repeats size. 

A few previous studies evaluated weight loss in polyQ disorders. In a SCA3 

transgenic model, mice presented a progressive loss of body weight during disease 

course that was prevented by blocking ataxin-3 transgene expression
6
.  In transgenic 

Huntington Disease (HD) mice, higher CAG repeats were related to a faster rate of 

weight loss
7
. Similar results were found in clinical studies of HD, where a significant 

underweight state was found in early stages and even in asymptomatic carriers,
8
 HD 

patients with higher CAG repeats also showed a faster rate of weight loss
7
, which is 

in agreement with our present findings in SCA3. 

We were not able to relate BMI to the degree of dysphagia, in the present study, 

although this association needs to be better evaluated. It is also worth to remind that 

we did not find an association between BMI and disease duration and that BMI 

inverse correlation with NESSCA was not independent from the CAG expanded 

repeat size. In other words, there was no clear association between clinically severe 

disease depicted by specific ataxia scores or longer disease duration with lower BMI. 

Alterations in the insulin/IGF-1 system have been involved in weight loss of 

transgenic animal models and of patients with HD
9
. We have formerly described that 

SCA3 patients present reduced insulin levels, and that insulin levels were related to 

age at onset of symptoms
2
. Now, we found that, although insulin levels were directly 

associated with BMI, the CAG expanded repeat length was the only variable 

independently related to weight loss.  

Since the most important determinant of the BMI seems to be the CAG expanded 

repeat, weight loss may be a primary disturbance of SCA3 and therefore further 

detailed analyses are necessary for a better understanding of the nutritional deficit 

and its role in the pathophysiology of SCA3. 

 



69 
 

References 

1 - Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and 

beyond. Lancet Neurol. 2010;9:885-894. 

2 – Saute JA, da Silva ACF, Muller AP, et al. Serum Insulin-Like System Alterations 

in Patients with Spinocerebellar Ataxia Type 3. Mov Disord. 2010; In Press. 

3 - Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and 

rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717–1720. 

4 - Kieling C, Rieder CR, Silva AC, et al. A neurological examination score for the 

assessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 2008;15:371–376. 

5 - Vedolin L, Schwartz IV, Komlos M, et al. Brain MRI in mucopolysaccharidosis: 

effect of aging and correlation with biochemical findings. Neurology 2007;69:917-24. 

6 - Boy J, Schmidt T, Wolburg H, et al. Reversibility of symptoms in a condicional 

mouse model of spinocerebellar ataxia type 3. Hum Mol Genetics 2009; 18:4282-

4295. 

7 - Aziz N A, van der Burg M M, Landwehrmeyer GB, et al. Weight loss in Huntington 

disease increases with higher CAG repeat number. Neurology 2008;71:1506-1513. 

8 - Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I; Huntington Study 

Group. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS 

research participants. Neurology 2009;73:385-392. 

9 - Andreassen O A, Dedeoglu A, Stanojevic V et al. Huntington‘s Disease of the 

Endocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin 

Gene Expression. Neurobiology of Disease 2002;11:410–424. 



70 
 

 
Figure 1 – BMI of SCA3 patients and its correlation with (CAG)n.  

(A) BMI comparison of patients with SCA3 and controls corrected for age - values are 

given as means and error bars represent SEM. (B) CAG expanded repeat (CAG)n 

simple correlation with BMI.** p &amp;lt;0.01; ***p &amp;lt;0.001 

Table 1 – Demographic characteristics of the enrolled individuals 

 Controls SCA3 Patients p 

 Mean (SD) Mean (SD)  

N 42 46 NA 

Age (years) 45.5 (12) 44.5(11) 0.683 

Gender (M/F) 16/26 22/24 0.357 

BMI (kg/m
2
) 27.1 (4.5) 24.4 (4.1) 0.01**

 a
 

Disease Duration (years) NA 9.97 (6.6) NA 

Age at onset (years) NA 34.5 (10) NA 

CAG(n) NA 73.3 (3) NA 

NESSCA NA 17.5 (6.3) NA 

SARA NA 14.4 (7.6) NA 

a
 – Corrected for age 

NA – not applicable 

** p&lt;0.01 

 



71 
 

Capítulo 3 - Serum Insulin-Like System Alterations in 

Patients with Spinocerebellar Ataxia Type 3 

 

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  



72 
 

Serum Insulin-like system alterations in patients with spinocerebellar ataxia 

type 3 (SCA3)  

Jonas Alex Morales Saute,
1,3,5

 Andrew Chaves Feitosa da Silva,
4
 Alexandre Pastoris 

Muller,
1
 Gisele Hansel,

1
 Alexandre Silva de Mello,

4
 Fábio Maeda,

3,6
 Leonardo 

Vedolin,
6
 Maria Luiza Saraiva-Pereira,

1,4
 Diogo Onofre Souza,

1
 Ignacio Torres-

Aleman,
7,8

 Luis Valmor Cruz Portela,
1
* Laura Bannach Jardim 

2,3,4
 

1
Departments of Biochemistry and of 

2
Internal Medicine, and 

3
Post-Graduate 

Program in Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto 

Alegre, RS, Brazil; 
4
Medical Genetics and 

5
Neurology Services, Hospital de Clínicas 

de Porto Alegre (HCPA), Porto Alegre, RS, Brazil; 
6
Neuroradiology Service, Hospital 

Moinhos de Vento, Porto Alegre, Brazil
 7

Laboratory of Cellular and Molecular 

Neuroendocrinology, Instituto Cajal, Consejo Superior de Investigaciones Cientificas 

(CSIC) and 
8
CIBERNED, Madrid, Spain;  

 

* Corresponding author: 

Luis Valmor Cruz Portela 

Department of Biochemistry, Instituto de Ciências Básicas da Saúde 

Universidade Federal do Rio Grande do Sul 

Rua Ramiro Barcelos 2600 Anexo  

CEP 90.035-003, Porto Alegre, Rio Grande do Sul, Brazil  

e-mail: roskaportela@gmail.com 

tel/Fax: +55 51 3316 5540. 



73 
 

Search terms:  

Spinocerebellar ataxia, polyglutamine disorders, IGF-1, Insulin, IGFBP, Machado-

Joseph Disease 

Finantial Disclosure: None of the authors declared a conflict of interest.  

Running Title: Insulin-like system in SCA3 



74 
 

Abstract 

Background: Spinocerebellar ataxias (SCAs) constitute a group of autosomal 

dominant neurodegenerative disorders without treatment. The Insulin/IGF-1 system 

(IIS) has been shown to play a role in the neurological dysfunction of SCAs and other 

polyglutamine disorders. We aimed to study the biomarker profile of serum IIS 

components in SCA3. 

Methods: We performed a case-control study with 46 SCA3 patients and 42 healthy 

individuals evaluating the peripheral IIS profile (Insulin, IGF-1, IGFBP1 and 3) and 

the correlation with clinical, molecular and neuroimaging findings 

Results: SCA3 patients presented lower insulin and IGFBP3 levels and higher insulin 

sensitivity (HOMA2), free IGF-I, and IGFBP1 levels when compared to controls. 

IGFBP-1 levels were directly associated with CAG expanded repeat length; IGF-1 

was associated with specific brain-stem regions volumetries on MRI. Insulin levels 

and sensitivity were related to age at onset of symptoms.   

Conclusions: Our findings indicate an involvement of IIS components in SCA3 

neurobiology and IGFBP-1 as a potential biomarker of the disease. 

Abbreviations: SCA=Spinocerebellar ataxia; IGF-1 = insulin-like growth factor I; 

IGFBP=  insulin-like growth factor binding protein 



75 
 

Introduction 

Spinocerebellar ataxias (SCAs) constitute a group of autosomal dominant 

neurodegenerative disorders with no current treatment.
1,2

 The most prevalent SCAs 

are those caused by CAG trinucleotide repeat expansions,
1
  being part of the so-

called group of polyglutamine (polyQ) disorders.
2
  

The insulin/insulin-like growth factor 1 (IGF-1) system (IIS) – encompassing Insulin, 

IGF-1, and IGFBPs - plays important neuromodulatory functions in the central 

nervous system (CNS).
3,4,5

 Abnormalities in the IIS signaling pathway were thought to 

play a part in the physiopathological processes of various neurodegenerative 

disorders, including Alzheimer´s disease, SCAs and Huntington Disease (HD) 

through different mechanisms.
3,4,6,7,8

 

Chronic treatment with IGF-1 improved neurological deficits in neurotoxic and 

transgenic animal models of ataxia.
9,10

 In transgenic animal models of other polyQ 

disorders, there was also evidence of involvement of signaling components of the IIS 

in the modulation of mutant proteins and disease phenotype.
11,12

 On clinical grounds, 

altered serum levels of IGF-1 and IGF-1 binding proteins (IGFBPs) have been 

reported in patients with late onset cerebellar ataxia (LOCA).
13 

Bearing in mind these evidences pointing that IIS might be altered in PolyQ 

disorders, we aimed to investigate the biomarker profile of serum IIS components in 

SCA3, considering their relation with clinical, molecular and neuroimaging findings.   

Methods 

Design and Subjects  

A case-control study was performed between May and October of 2007 with 46 

molecularly confirmed SCA3 patients from the neurogenetics clinic of HCPA and 42 

healthy, community, non-related individuals with similar age, gender, and 

environmental characteristics. Nutritional and mood evaluation were done to control 

confounding factors. The ATXN3 expanded regions were analyzed as previously 

described.
14 

Subjects diagnosed with other neurological, endocrine, renal or hepatic 

disorders were excluded. The study was approved by the local Ethics Committee and 

all subjects gave their informed written consent. 



76 
 

Clinical Evaluation 

Two clinical ataxia scales were applied: the SARA
15 

and NESSCA scores.
16

 Disease 

duration and age of onset were informed by patients and their relatives. All subjects 

completed Beck Depression Inventory (BDI).
17

 

Magnetic Resonance Imaging   

MRI was done using 1.5 T system. Sagital T1 weighted images (TR=2000 ms and 

TE=3.45 ms) - slice thickness of 1mm, pixel size of 0.49mm - were performed. The 

normalized volumes of the brainstem, mesencephalus, pontine tegmentum, basis of 

pons, medulla oblongata, and cerebellum of SCA3 patients were measured on fluid-

attenuated inversion recovery (FLAIR), using semi-automated segmentation 

techniques and voxel count volumetry using the software ImageJ. More detailed 

procedures of this technique were described elsewere.
18 

 

Samples and Assays 

Serum was obtained by blood centrifugation at 6000 x g for 5 min, frozen 

immediately and stored at -70 ºC until analyses. All samples were obtained between 

10 a.m. and 4 p.m. and all subjects were under fasting conditions. Serum IGF-1 

(DuoSet R&amp;amp;D System, USA), IGFBP-1 (Medix Biochemica, Finland) and IGFBP-3 

(Mediagnost, Germany) were measured in duplicate by ELISA. Serum Insulin (Roche 

Diagnostics, Germany) was determined by electrochemiluminescence. We utilized 

the HOMA Calculator v2.2.2 to determine HOMA2 parameters. 

Statistical Analysis 

All variables in the study showed a normal distribution on One-Sample Kolmogorov-

Smirnov test, but HOMA2-%S - which was log transformed. Comparisons of IIS 

components levels between cases and controls were done by two-tailed unpaired 

Student‘s t-test. Univariate General Linear Model was utilized to control for 

confounding factors that were significantly correlated with the outcomes. Gender was 

analyzed with Chi-Square test and all correlations with Pearson correlation test 

followed by linear regression model. Statistical significance was defined as p &amp;lt;0.05.  

  



77 
 
Results  

Demographic data of cases and controls are shown in Table 1. MRI was obtained 

randomly in 26 (14 females) of these SCA3 patients, whose demographic 

characteristics were similar to those found in the overall group of patients.  

Insulin/IGF-1 System (IIS) 

Differences regarding serum concentrations of IGF-1, IGFBP-1, IGFBP-3, IGF-

1:IGFBP-3 molar ratio, Insulin and HOMA analysis between cases and controls are 

shown in Table 2.  

Total IGF-1 serum levels did not differ between groups (p=0.550 – corrected for age) 

nor correlated with clinical or molecular variables. IGF-1 was inversely correlated with 

medulla oblongata (R=-0.489 p=0.011) and basis of pons volumetry (R=-0.439 

p=0.025) on MRI (Supp. Fig 1 and 2) 

IGFBP-1 serum levels were higher in patients with SCA3 than in controls (p=0.001 - 

corrected for BMI). IGFBP-1 levels were correlated significantly with CAG expanded 

repeats (R=0.451 p=0.003 – Fig 1) – which was the only factor independently 

associated in the linear regression model (R=0.452 p=0.006). IGFBP-1 did not 

correlate with MRI volumetries. 

IGFBP-3 levels were lower (p=0.001) and the IGF-1:IGFBP-3 molar ratio (an indirect 

form of measuring free IGF-1) was higher (p=0.039 – corrected for age and gender) 

in SCA3 patients than in controls. Neither IGFBP-3 nor IGF-1:IGFBP-3 molar ratio 

independently correlated significantly with any clinical, molecular or MRI volumetries 

variables. 

Insulin levels were lower in cases than in controls (p=0.027, after correction for BMI). 

Age of onset correlated directly with insulin levels (R=0.510 p=0.0001) and was the 

only factor independently associated in the linear regression model with insulin 

(R=0.365 p=0.026 – Fig 2). When we considered age of onset as a dependent factor, 

both Insulin (R=0.404 p=0.012) and CAG expanded repeat (R=-0.738 p=0.0001) 

influenced the variable independently. Insulin levels did not correlate with MRI 

volumetries. 



78 
 

HOMA analysis was perfomed in order to examine the steady state ?-cell function 

(HOMA2-%B), peripheral insulin sensitivity (HOMA2-%S) and resistance (HOMA2-IR 

Index). HOMA2-%B (?-cell function) was similar between groups (p=0.637), whereas 

the Log (HOMA2-%S) (insulin sensitivity) was higher (p=0.003 – corrected for BMI) 

and HOMA2-IR Index (insulin resistance) was lower (p=0.022 – corrected for BMI) in 

patients with SCA3 than in control participants.  Log (HOMA2-%S) and HOMA2-IR 

Index correlated with age of onset (R=-0.444 p=0.003 and R=0.492 p=0.001, 

respectively – Fig 2), which was the only factor independently associated with these 

variables in the linear regression model. (R=-0.408 p=0.014 and R=0.378 p=0.021, 

respectively). When age of onset was considered as the dependent factor HOMA2-

%S (R=-0.408 p=0.014) or HOMA2-IR Index (R=0.378 p=0.021) and CAG expanded 

repeat (R=-0.703 p=0.0001) influenced the variable independently. None of the 

HOMA parameters correlated with MRI volumetries.  

Discussion 

The present results indicated significant changes in various constituents of the IIS in 

SCA3 patients, pointing IGFBP-1 as a disease biomarker and a possible disease 

modifier effect related to insulin sensitivity. 

We found no differences in serum IGF-1 levels in SCA3 patients, however we 

observed that IGF-1 serum levels were inversely correlated with the volume of 

medulla oblongata and basis pontis, two brain structures that are primarily affected in 

SCA3.  

IGFBP-3 levels – which binds more than 80% of peripheral IGF-1 and increases its 

half-life -
19 

were lower, while an indirect measure of free IGF-1 levels, the IGF-

1:IGFBP-3 molar ratio, was higher in SCA3 patients than in controls. Higher levels of 

free IGF-1 may have opposite consequences: the peptide might either be early 

metabolized, being in insufficient levels for an adequate transport to the CNS; or 

might be coupled to the higher expressed IGFBP-1 increasing its transport to target 

brain areas, once this binding protein is known to participate in tissue allocation of 

circulating IGF-1.
20

 

IGFBP-1 levels were higher in SCA3 patients than in controls and were 

independently related only to CAG expanded repeats, with more severe mutations 

leading to higher levels of IGFBP-1. These results point IGFBP-1 as a possible 



79 
 

biomarker of the disease, therefore the actual link between this biomarker and 

neuropathology should be put in perspective. Mutated ataxin-3 could interfere with 

IGFBP-1 synthesis or metabolism due to its ubiquitin related properties and to its 

disruptive effects on gene transcription.
2
 Since ataxin-3 is also associated with 

endoplasmic reticulum (ER) stress and ER stress is in turn related to increased 

IGFBP-1 production in liver,
21

 Thus, higher IGFBP-1 levels may constitute a marker 

of ER stress due the mutated ataxin-3.  

We found lower serum levels of insulin in SCA-3 patients when compared to controls, 

even when corrected for BMI. These findings are in agreement with those previously 

described in patients with LOCA.
13 

According to our data, insulin levels were 

independently and directly associated with age at onset, but interestingly were not 

correlated with CAG expanded repeats. Because we found different levels of insulin, 

but no changes in glucose levels, we studied the peripheral insulin sensitivity. SCA3 

patients had higher insulin sensitivity and lower resistance index than the control 

group, with a normal steady state ?-cell function. This higher sensitivity to insulin 

was, again, inversely associated only with age at onset. According to these data, 

SCA3 patients seemed to show an increased peripheral sensitivity to insulin, and in 

consequence, a reduction in serum levels of insulin. Higher sensitivity to insulin and 

lower insulin levels were both related to earlier disease onset.   

In polyQ disorders the strongest determinant of age of onset is the number of CAG 

expanded repeats of the mutated protein.
22

. As our cross-sectional study was 

performed years after the clinical onset of SCA3, we were not able to determine 

whether insulin sensitivity was indeed influencing age of onset or whether the 

opposite occurred.  

Conclusions 

Since SCAs are rare and slow progressive disorders, the identification of biomarkers 

with clinical relevance could help to shorten trials and reduce the number of patients 

needed. In the present study we found a potential role of IGFBP-1 as a serum 

biomarker and a possible disease modifying mechanism related to insulin sensitivity 

in SCA3 which deserves future investigations.  

 



80 
 

Acknowledgments 

This research was supported by the Brazilian funding agencies FIPE-HCPA, CNPq, 

FINEP, INAGEMP and FAPERGS and by the Spanish institute CIBERNED.  

Author Roles 

1.       Research project: A. Conception, B. Organization, C. Execution; 

2.       Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 

3.       Manuscript: A. Writing of the first draft, B. Review and Critique; 

Saute: 1A, 1B, 1C, 2A, 2B, 2C, 3A. da Silva: 1B, 1C. Muller: 1B, 1C, 3B. Hansel: 1B, 

1C. de Mello: 1C. Maeda: 1C. Vedolin: 1B, 1C. Saraiva-Pereira: 1C. Souza: 1A,3B. 

Torres-Aleman: 1A, 1B, 3B. Portela: 1A, 1B, 2C, 3B. Jardim: 1A,1B, 2C, 3B.  

References 

1 - Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar 

ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004;3:291–

304. 

2 – Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding 

revisited. Trends Neurosci 2008;31:521-528. 

3 - Schulingkamp R, Pagano T, Hung D, Raffa R. Insulin receptors and insulin action 

in the brain: review and clinical implications. Neurosci Biobehav Rev 2000;24:855–

872. 

4 – Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific 

mechanisms. Lancet Neurol 2004;3:169-178. 

5 - Aberg ND, Brywe KG, Isgaard J. Aspects of Growth Hormone and Insuline-Like 

Growth Factor-I Related to Neuroprotection, Regeneration, and Functional Plasticity 

in the Adult Brain. ScientificWorldJournal 2006;6:53-80. 

6 - Cohen E, Paulsson JF, Blinder P, et al. Reduced IGF-1 signaling 

delays age-associated proteotoxicity in mice. Cell 2009;139:1157-69. 



81 
 

7 - Cohen E, Dillin A. The insulin paradox: aging, proteotoxicity and 

neurodegeneration. Nat Rev Neurosci 2008; 9: 759–767. 

8 - Emamian ES, Kaytor MD, Duvick LA, et al. Serine 776 of ataxin-1 is critical for 

polyglutamine-induced disease in SCA1 transgenic mice. 

Neuron 2003;38:375-387. 

9 - Fernandez AM, de la Vega AG, Torres-Aleman I. Insulin-like growth factor I 

restores motor coordination in a rat model of cerebellar ataxia. Proc Natl Acad Sci U 

S A 1998; 95:1253-1258. 

10 - Vig PJ, Subramony SH, D'Souza DR, Wei J, Lopez ME. Intranasal 

administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. 

Brain Res Bull 2006;69:573-9. 

11 - Colin E, Regulier E, Perrin V, et al. Akt is altered in an animal model of 

Huntington's disease and in patients. Eur J Neurosci 2005;21:1478-1488. 

12 - Palazzolo I, Burnett BG, Young JE, et al. Akt blocks ligand binding and protects 

against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet 

2007;16:1593-1603. 

13 - Torres-Aleman I, Barrios V, Lledo A, Berciano J. The insulin-like growth factor I 

system in cerebellar degeneration. Ann Neurol 1996;39:335-342. 

14 - Bauer PO, Kotliarova SE, Matoska V et al. Fluorescent multiplex PCR--fast 

method for autosomal dominant spinocerebellar ataxias screening. Genetika 

2005;41:830-837 

15 - Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and 

rating of ataxia: development of a new clinical scale. Neurology 2006; 66:1717–1720. 

16 - Kieling C, Rieder CR, Silva AC, Saute JA, Cecchin CR, Monte TL, Jardim LB. A 

neurological examination score for the assessment of spinocerebellar ataxia 3 

(SCA3). Eur J Neurol 2008;15:371-376. 

17 - Gorenstein C, Andrade L. Validation of a portuguese version of the beck 

depression inventory and the state -trait anxiety inventory in Brazilian subjects. Braz 

J Med Biol Res 1996; 29: 453-457. 



82 
 

18 - Vedolin L, Schwartz IV, Komlos M, et al. Brain MRI in mucopolysaccharidosis: 

effect of aging and correlation with biochemical findings. Neurology 2007;69:917-924. 

19 - Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM. Increased 

circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimer 

Dis 2007;12:285-90. 

20 - Berg U, Gustafsson T, Sundberg CJ, Kaijser L, Carlsson-Skwirut C, Bang P. 

Interstitial IGF-I in exercising skeletal muscle in women. Eur J Endocrinol 

2007;157:427-435. 

21 - Marchand A, Tomkiewicz C, Magne L, Barouki R, Garlatti M. Endoplasmic 

reticulum stress induction of insulin-like growth factor-binding protein-1 involves 

ATF4. J Biol Chem 2006;281:19124-19133. 

22 - Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic 

and environmental factors modulate Huntington's disease age of onset. Proc Natl 

Acad Sci U S A 2004;101:3498-3503. 

Table 1 

 



83 
 

Table 2 

 

Figure 1: IGFBP-1 as a biomarker of SCA3 (A) Analysis of IGFBP-1 serum levels in 

SCA3 patients and controls corrected for BMI. (B) CAG expanded repeat (CAG)n 

simple correlation with IGFBP-1 serum levels. Values are given as means and error 

bars represent standard error (SEM); ** p &amp;lt;0.01; ***p &amp;lt;0.001. 

 



84 
 

Figure 2: Correlation between Insulin homeostasis parameters with SCA3 age of 

onset. Age of Onset simple correlation with Insulin serum levels (A), sensitivity (B) - 

Log (HOMA2-%S) - and resistance (HOMA2-IR) index (C).** p &amp;lt;0.01; ***p &amp;lt;0.001 

 

 

Supplementary Figure 1: The inverse correlation between IGF-1 serum levels and 

Basis Pons and Medulla Oblongata volumetries on MRI. Two patients with similar 

ages, disease duration and CAG expanded repeats were chosen as an example. (A) 

and (C) represent a fifty two year old man, with nine years of disease duration and 72 

CAG repeats on MJD gene. (B) and (D) represent a fifty one year old woman, with 

thirteen years of disease duration and 71 CAG repeats on MJD gene. Bars indicate 

percent difference between the individual and the mean study population values of 

IGF-1 serum levels and MRI brain stem volumes. 



85 
 

 

 Supplementary Figure 2: Total IGF-1 correlations with brain stem volumetries. IGF-

1 serum levels simple correlation with (A) medulla oblongata and (B) basis of pons 

MRI volumetries.* p&lt;0.05 

  



86 
 

Capítulo 4 - Ataxia Rating Scales - Psychometric Profiles,  

Natural History and Their Application in Clinical Trials.  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

  



87 
 

Ataxia rating scales – psychometric profiles, natural history and their 

application in clinical trials 

Jonas Alex Morales Saute
1,2

, Karina Carvalho Donis
3
, Carmen Serrano-Munuera

4
, 

David Genis
5
, Luís Torres Ramirez

6
, Pilar Mazzetti

6
,  Luis Velázquez Pérez

7
, Pilar 

Latorre
8
,  Antoni Matilla-Dueñas

8,9
, Jorge Sequeiros

10
, Laura Bannach Jardim

1,2,3,11
*, 

on behalf of the Iberoamerican multidisciplinary network for the study of movement 

disorders (RIBERMOV) study group. 

1 - Neurology Service, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 

2350, 90.035-903 Porto Alegre, Brazil; 2 - Postgraduate Program in Medical 

Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; 3 - 

Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Rua Ramiro 

Barcelos 2350, 90.035-903 Porto Alegre, Brazil; 4 – Department of Internal Medicine, 

Hospital Sant Joan de Déu de Martorell, Barcelona, Spain; 5 - Neurodegenerative 

Disease Unit, Dr Josep Trueta University Hospital, Girona, Spain; 6 – National 

Institute for the Neurological Sciences Julio Oscar Trelles Montes, Lima, Peru; 7 - 

Center for Research and Rehabilitation of Hereditary Ataxias ?Carlos Juan Finlay? 

(CIRAH), Holguín, Cuba; 8 - Department of Neurosciences and Neurology Service, 

Health Sciences Research Institute and Hospital Germans Trias I Pujol, Universitat 

Autònoma de Barcelona, Badalona, Spain; 9 – Basic, Translational and Molecular 

Neurogenetics Research Unit, Health Sciences Research Institute Germans Trias i 

Pujol (IGTP), Universitat Autònoma de Barcelona, Ctra. de Can Ruti, Camí de les 

escoles s/n, 08916 Badalona, Barcelona, Spain; 10 - IBMC - Institute for Molecular 

and Cell Biology, and ICBAS; Universidade do Porto, Porto, Portugal; 11 - 

Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto 

Alegre, Brazil 



88 
 

 

* Corresponding author: 

Laura Bannach Jardim 

Medical Genetics Service, Hospital de Clínicas de Porto Alegre, 

Rua Ramiro Barcelos 2350, 

90.035-903 Porto Alegre, Brazil 

e-mail: ljardim@hcpa.ufrgs.br  

 

Conflict of Interest: All authors declare no conflicts of interest.  



89 
 

Abstract 

We aimed to perform a comprehensive systematic review of the existing ataxia 

scales. We described the disorders for which the instruments have been validated 

and used, the time spent in its application, its validated psychometric properties, and 

their use in studies of natural history and clinical trials. Methods: a search from 1997 

onwards was performed in the MEDLINE, LILACS and Cochrane databases. The 

websites ClinicalTrials.gov and Orpha.net were also used to identify the endpoints 

used in ongoing randomized clinical trials. Results: we identified and described the 

semi-quantitative ataxia scales (ICARS, SARA, MICARS, BARS); semi-quantitative 

ataxia and non-ataxia scales (UMSARS, FARS, NESSCA); a semi-quantitative non-

ataxia scale (INAS); quantitative ataxia scales (CATSYS 2000, AFCS, CCFS and 

CCFSw, and SCAFI); and the self-performed ataxia scale FAIS. Discussion: SARA 

and ICARS were the best studied and validated so far, and their reliability sustain 

their use. Ataxia and non-ataxia scores will probably provide a better view of the 

overall disability in long-term trials and studies of natural history. Up to now, no clear 

advantage has been disclosed for any of them; however, we recommend the use of 

specific measurements of gait, since gait ataxia is the first significant manifestation in 

the majority of ataxia disorders and comment on the best scales to be used in 

specific ataxia forms. Quantitative ataxia scales will be needed to speed up evidence 

from phase-II clinical trials, from trials focused on the early phase of diseases, and 

for secondary endpoints in phase-III trials. Finally, it is worth remembering that 

estimation of the actual minimal clinically relevant difference is still lacking;  this, 

together with changes in quality of life, will probably be the main endpoints to 

measure in future therapeutic studies. 

 



90 
 

Keywords: ataxia scales, ICARS, SARA, MICARS, BARS, UMSARS, FARS, 

NESSCA, INAS, CATSYS, ACFS, CCFS, SCAFI, FAIS, hereditary ataxias.



91 
 

1. INTRODUCTION 

Originally a Greek word, meaning ?confusion? or ?absence of order?, ataxia signifies 

motor incoordination. Ataxias are a very heterogeneous group of diseases with 

different etiology, including genetic and non-genetic forms [1].
 
Since the 19th century, 

when Pierre Marie suggested a clinical differentiation between Friedreich and other 

forms of hereditary ataxia, it has been clear that they affect multiple neurological 

subsystems, presenting also non-ataxia features such as pyramidal and 

extrapyramidal signs and peripheral findings, among others [2].
 
 

There are many reasons for the lack of treatment for cerebellar ataxia, one of them 

being its relatively low population frequency; others include: the still recent discovery 

of some causal mutations; our incomplete knowledge about its pathogenic 

mechanisms; and the relatively new development of standardized, well-validated 

scales to understand better its natural history and evaluate properly drug efficacy in 

clinical trials. Therefore, most ataxic disorders (sporadic or inherited) still have no 

current effective pharmacological treatment, and patients endure the inevitable 

degenerative course of their disease. 

We performed a comprehensive, systematic review of classical and more recently 

developed ataxia scales. Topics such as the disorders for which each instrument was 

validated and used, time spent in its application, and the validated psychometric 

properties are discussed. The use of these scales, in particular for natural history 

studies and clinical trials, is described. This review also aims at standardizing the 

tools used in studies of natural history, biomarkers, disease modifiers and clinical 

trials, and will be further developed within the Iberoamerican multidisciplinary network 

for the study of movement disorders (RIBERMOV; www.ribermov.org). 



92 
 

2. METHODS 

Criteria for including studies in this review 

We intended to include all studies describing and validating ataxia-rating scales or 

scores for inherited or sporadic cerebellar ataxia (excluding multiple sclerosis); 

studies evaluating the natural history of an ataxic disorder with one of these scales; 

and randomized, placebo-controlled clinical trials using these ataxia scales to 

measure its clinical endpoints. 

Search methods 

Two investigators (JAMS, KCD) independently performed a search in the MEDLINE, 

LILACS and Cochrane databases, and checked also the list of references in relevant 

papers, without restriction to language or publication status. The search terms were 

?ataxia score? or ?ataxia scale?. After finding an ataxia scale, we searched again 

those databases with its name. In order to determine which scales were used to 

measure endpoints in randomized clinical trials for ataxias, we also searched for the 

terms ?treatment? and ?spinocerebellar ataxia? (also ?SCA?) or autosomal dominant 

cerebellar ataxia? (ADCA) or ?Friedreich ataxia? (?FRDA?), or ?Multiple System 

Atrophy? (?MSA?) or ?Fragile X-associated tremor/ataxia syndrome? (?FXTAS?). We 

limited the research to 1997 onwards, as this was the year of publication of the first 

scale in use, ICARS. We also searched the website ClinicalTrials.gov 

(http://clinicaltrials.gov/) and the clinical trials section of the website Orphanet 

(http://www.orpha.net) with the term ?ataxia treatment?, in order to find the scores 

being utilized in ongoing clinical trials. The most recent search was performed during 

July 2011. 

Study organization 



93 
 

Scales were ordered and organized according to their purpose and characteristics, 

into the following groups: (1) semi-quantitative ataxia scales; (2) semi-quantitative 

ataxia and non-ataxia scales; (3) semi-quantitative non-ataxia scales; (4) quantitative 

ataxia scales; and (5) self-performed ataxia scales. For each of these groups, scales 

were described according to the year of publication.   

Sensitivity to change 

In order to standardize the indices of sensitivity to change in the scores, when 

available, we provided the Cohen‘s Effect Size (ES) or the Standardized Response 

Mean (SRM). Values of 0.20, 0.50, and 0.80 were considered to represent a small, 

moderate, and large change, respectively, for both indices. When not explicit, but 

data were available, we applied the following formulas: (1) mean score change / 

standard deviation (SD) of score at baseline (for ES); and (2) mean score change / 

SD of score change (for SRM). 

3. RESULTS 

Table 1 summarizes the information regarding validation, time needed for application, 

studies of natural history, sensitivity to change and clinical trials performed with each 

ataxia scale. If studies of natural history or clinical trials using a given scale are 

lacking, this information was also pointed out in Table 1. Details are presented below.  

3.1 Semi-quantitative ataxia scales 

ICARS – International Cooperative Ataxia Rating Scale [3] 

a) Scale description 

The ICARS is a semi-quantitative 100-point scale, consisting of 19 items, divided into 

four unequally weighted sub-scores: posture and gait disturbance (7 items; 34 



94 
 

points); limb kinetic function (7 items; 52 points); speech disorder (2 items; 8 points); 

and oculomotor disorder (3 items; 6 points). The higher the score, the worse is the 

patient‘s performance [3]. 

b) Validation 

Internal consistency of the ICARS‘ items was first studied in MSA with a high 

Cronbach‘s ? of 0.93 [4]. In 2004, a study evaluating patients with SCA (SCA1 and 

SCA2) and Friedreich ataxia found that the inter-rater correlation for the total ICARS 

score (Kendall´s ?) was 0.99, being the lowest in the speech subscale 0.79 and the 

highest 0.99 for the posture/gait subscales [5]. 

Spinocerebellar ataxias. In a large European multicentric study, 156 SCA patients 

(SCA1, SCA2, SCA3/MJD - Machado-Joseph disease, SCA6, SCA7 and SCA14) 

were evaluated with ICARS [6]. High inter-rater reliability with an intraclass 

correlation coefficient (ICC) of 0.95 and high test-retest reliability (ICC of 0.97) were 

depicted. The authors found that some items of posture and gait disturbances were 

overlapping and interdependent. If the patient scores between 4 and 8 points i n item 

1(gait), he/she would automatically score the maximum in item 2 (gait speed). Items 

3 (standing capacities, ranging 0 to 6), 4 (spread of feet, 0 to 4), 5 (body sway with 

eyes open, 0 to 4) and 6 (body sway with eyes closed, 0 to 4) were also clearly 

interdependent (e.g., oscillating with eyes open, determined oscillating also with eyes 

closed). Factorial analysis showed that four factors determine 70% of the total 

variance. These factors, however, were not coincident with the ICARS subscales, 

except for the oculomotor one. Significant correlations of ICARS with the Barthel 

index (r=-0.70) and disease duration (r=0.43) were also identified. In another study, 

52 SCA3/MJD patients were evaluated by ICARS. Internal consistency for the total 



95 
 

score showed a Cronbach‘s ? of 0.94. The ICARS correlated with both disease 

duration (r=0.54) and the number of CAGs in the expanded allele (r=0.35) [7].  

Friedreich ataxia (FRDA).  For FRDA, 96 patients were assessed with ICARS, FARS 

and SARA [8]. The internal consistency of ICARS measured by Cronbach‘s ? was 

0.69, when considering all four subscales, and 0.95, when considering the scale‘s 

single items. There was a strong direct correlation among all three scales, and all 

significantly correlated with disease duration (r=0.695, for ICARS) and activities of 

daily living (ADL) (r=0.924, for ICARS). The principal component analysis yielded four 

factors explaining the rates of ICARS. Only one factor loaded for a single subscale 

(oculomotor function), whereas all other factors were not correlated with any specific 

subscale. Another study assessed 76 patients with FRDA with both ICARS and 

FARS, finding a significant correlation between both scales, as well as with functional 

index and disease duration [9]. 

c) Natural history 

Spinocerebellar ataxias. Thirty-four SCA3/MJD patients were followed for an average 

of 13.3 months, depicting a mean deterioration of 5.1/100 points in ICARS, varying 

from 37.6 ±19.2 to 42.7 ±18.6. There was no correlation of variation in ICARS with 

age of onset , (CAG)n or disease duration [10]. No index of sensitivity to change was 

reported, but an ES of 0.26 could be estimated for the study period with the data 

presented. There was no reference for Minimally Important Difference (MID) for 

ICARS in SCAs. 

Friedreich ataxia. A study evaluated 43 FRDA patients with both ICARS and FARS, 

in a 12-month period; the mean worsening in ICARS was 5/100 (SD 6.8); ES was 

0.26. Using the data reported we could also calculate an SRM of 0.73. There was no 



96 
 

attempt in this study to define MID for ICARS, and the authors stated that ?even a 

small benefit from a therapeutic intervention is likely to be clinically relevant? [9]. 

Considering the placebo groups of clinical trials, there was either no worsening [11], 

or even an improvement of 1.3/100 points [12], after 6 months of observation (both 

studies evaluated idebenone efficacy in FRDA). A change from a baseline of 2.5 and 

5 points on ICARS, in 6 and 12 months, respectively, was considered clinically 

meaningful in this trial [12]. 

d) Clinical trials 

At least 13 trials used ICARS, as the neurological endpoint. Among them, there were 

two studies on miscellaneous cerebellar disorders: a double--blinded, randomized 

clinical trial, designed to evaluate the efficacy of riluzole in different sporadic (MSA, 

multiple sclerosis, paraneoplastic) and inherited ataxias (SCA1, SCA2, SCA28, 

FRDA, FXATS ) [13]; and a trial on ondansetron in patients with cerebellar cortical 

atrophy, MSA, familial cerebellar degeneration and miscellaneous cerebellar 

disorders [14].  

Spinocerebellar ataxias. Four randomized clinical trials utilized ICARS as the 

neurological endpoint in patients with SCAs: a crossover trial for the treatment with 

branched-chain amino acids, including patients with SCA6 and SCA7 [15]; and two 

trials evaluating buspirone, in patients with ?olivopontocerebellar atrophy? [16] and in 

patients with other SCAs and FRDA [17]. None of them showed significant 

differences from placebo. On ClinicalTrials.gov one study evaluating lithium in SCA1 

(NCT00683943) also used ICARS to measure outcome. 

Friedreich ataxia. Five randomized clinical trials testing antioxidants used ICARS as 

the neurological endpoint [11,12,18,19,20]. In one, in a pre-specified analysis, there 



97 
 

was a significant improvement on ICARS, but no difference in FARS, after 6 months 

of idebenone [11]. On ClinicalTrials.gov, two trials are using ICARS in FRDA: one 

tests epoetin alfa (NCT00631202) and another study evaluates pioglitazone 

(NCT00811681).  

SARA – Scale for the Assessment and Rating of Ataxia [21] 

a) Scale description 

SARA has eight items, yielding a total score of 0 (no ataxia) to 40 (most severe 

ataxia) [21]:  gait (score 0 to 8), stance (0 to 6), sitting (0 to 4), speech disturbance (0 

to 6), finger chase (0 to 4), nose-finger test (0 to 4), fast alternating hand movements 

(0 to 4) and heel-shin slide (0 to 4). Limb kinetic functions (items 5 to 8) are rated 

independently for both body sides, and its arithmetic mean is included in the total 

score. 

b) Validation 

Spinocerebellar ataxia. SARA internal consistency was first studied in patients with 

several SCAs, within a European multicentric collaborative study [21]. The inter-rater 

reliability was very high, with an ICC of 0.98. All single items had good inter-rater 

reliability, with ICC &gt;0.80 with the exception of left hand nose-finger test (ICC=0.76) 

and left Heel-shin slide (ICC=0.74) Test-retest reliability had an ICC of 0.90. Internal 

consistency was also high, with a Cronbach‘s ? of 0.94. SARA score increased with 

disease stage (p&amp;lt;0.001) and was closely correlated with the Barthel index (r=0.80) 

and part IV (functional assessment) of the Unified Huntington‘s Disease Rating Scale 

(UHDRS-IV) (r=0.89), whereas it had only a weak correlation with disease duration 

(r=0.34). Linearity of SARA was assessed through a regression analysis, with a 



98 
 

global assessment visual analogue scale (VAS). SARA ratings fitted a linear model 

(r
2
=0.98, p&lt;0.0001). 

Friedreich ataxia. A study of 96 patients with FRDA showed an ICC of 0.99 [8]. The 

internal consistency for the eight items was 0.89. All SARA items showed high 

construct validity. SARA was correlated with ICARS (r=0.953) and FARS (r=0.938) 

total scores. SARA‘s total score correlated with disease duration (r=0.712) and with 

the activities of daily living (r=0.929). The principal component analysis yielded one 

single factor for SARA results.  

As RIBERMOV is an Iberoamerican initiative, it is worth mentioning that SARA was 

translated and validated into Brazilian Portuguese [22]. It was applied to 30 patients 

with SCA2, SCA3/MJD, SCA6, Friedreich ataxia and ataxia with unknown etiology, 

with a Cronbach‘s ? of 0.94. There was no significant correlation between SARA and 

ICARS score in that sample (r=0.33; p&lt;0.07).  

Sporadic ataxias. A study tested SARA reliability and validity in 64 patients with 

different sporadic ataxia disorders or non-progressing cerebellar lesions. Inter and 

intra-rater reliability had an ICC of 0.98 and 0.99 [23]. Most single items had a good 

inter-rater and test-retest reliability, with ICCs above 0.80. Internal consistency was 

also high, with a Cronbach‘s ? of 0.97. Score increased with disease stage, and was 

closely correlated with Barthel index (r=0.63) and UHDRS-IV (r=0.62), but only 

weakly with disease duration (r=0.44). 

c) Natural history  

Spinocerebellar ataxias. For one year, 171 patients with SCAs (SCA1, SCA2, 

SCA3/MJD, SCA6), were followed ; the mean annual score change was 1.38/40, with 

a standard deviation of 2.8 [24]. The authors considered SRM to be more adequate 



99 
 

to their sample than ES, with an overall SRM of 0.5. When progression of the 

disease according to patient‘s global impression (PGI) was considered, there was an 

annual score change of 1.69/40 ± 2.9 points (1.17 to 2.20), if PGI was worse (n=120), 

with an SRM of 0.59; and 0.43/40 ± 2.1 points (-0.21 to 1.07), if PGI was stable 

(n=43), with an SRM of 0.21. SARA was also able to correctly classify cases with 

subjectively relevant worsening, based on PGI, therefore showing responsiveness. 

Another recent study evaluated 133 patients with different SCAs, and found that 

SARA worsened 1/40 ± 2.4 points, after 12 months [25]. The authors described an 

ES of less than 0.2 and a SRM of 0.41. Although discussed, none of the studies tried 

to define the MID of SARA in SCAs. 

d) Clinical trials 

A single-blinded, placebo-controlled, pilot study compared the efficacy of pregabalin 

on cerebellar signs caused by cortical cerebellar atrophy, evaluating the cerebellar 

function with the SARA [26]. On Clinicaltrials.gov, eight trials are underway using 

SARA, for the evaluation of lithium carbonate in SCA1 (NCT00683943), SCA2 

(NCT00998634) and SCA3/MJD (NCT01096082); sodium phenylbutyrate 

(NCT01096095) in SCA3/MJD; varenicline (NCT00992771) in SCA3/MJD; 

carbamylated erythropoietin in FRDA (NCT01016366), riluzole in hereditary ataxias 

(NCT01104649) and KPS-0373 (mimetic of TRH action) in spinocerebellar 

degeneration (NCT01384435). 

MICARS – Modified International Cooperative Ataxia Rating Scale [27] 

a) Scale description 



100 
 

The 120-point MICARS was developed by adding seven additional tests to the 

ICARS: in kinetic function (decomposition of leg movement,; decomposition of leg 

tapping; rebound of the arms; and overshoot of the arms; each 0 to 2 points, and 

scored for both left and right); speech disorders (dysarthria alternating syllable, 0 to 2 

points); and oculomotor function (abnormal eye movements at rest, 0 or 1 point). The 

higher the score, the worse is the ataxic syndrome [27]. 

b) Validation 

MICARS was applied to 91 patients with different sporadic and inherited cerebellar 

disorders. There was a strong correlation of MICARS with ICARS; the Cronbach´s ? 

of MICARS varied from 0.80 to 0.86. The inter-rater reliability of MICARS was 0.93 

[27]. 

BARS ? Brief Ataxia Rating Scale [27] 

a) Scale description 

BARS is a shorter modified form of ICARS (MICARS) [27], consisting of five subsets 

that evaluate walking capacity (0 to 8 points), heel-to-shin test for decomposition of 

movement (0 to 4, scored left and right), finger-to-nose test for decomposition and 

dysmetria (0 to 4 points scored left and right), dysarthria (0 to 4), and anomalies of 

ocular pursuit (0 to 2), with a total score of 30 points (most severe ataxia).  

b) Validation 

This scale was constructed and applied together with MICARS  [27]. Cronbach‘s ? for 

BARS was 0.90 and inter-rater reliability (intraclass correlation coefficient) was 0.91. 

3.2 Semi-quantitative ataxia and non-ataxia scales 



101 
 

UMSARS ? Unified Multiple System Atrophy Rating Scale [28] 

a) Scale description 

UMSARS is a semi-quantitative multidimensional rating scale developed for patients 

with MSA. It was based on well-established scales utilized in Parkinson disease, the 

Hoehn and Yahr Scale (H&amp;amp;Y) and the Schwab and England Scales [29], on the 

ICARS and on the Composite Autonomic Symptom Scale (COMPASS) [28]. 

UMSARS comprises four parts, including a historical review of disease-related 

impairments (Part I, 12 items), motor examination (Part II, 14 items), autonomic 

examination (Part III), and global disability scale (Part IV). A single score, from 0 (no 

impairment) to 4 (severe impairment), was generated for each item. The maximum 

(worst) scores are 48 for UMSARS-I, 56 for UMSARS-II, and 5 for UMSARS-IV. 

UMSARS-III is mainly descriptive. 

b) Validation 

UMSARS was first validated in patients with cerebellar and Parkinsonian MSA 

subtypes [28]. The Cronbach‘s ? coefficient of UMSARS-I and UMSARS- II was 0.84 

and 0.90, respectively. The overall inter-rater reliability (k) was at least substantial 

(0.6–0.8) or excellent (&gt;0.8) for all UMSARS-I items, except for orthostatic 

hypotension. The overall analysis showed substantial or excellent inter-rater 

agreement for the majority of UMSARS-II items; however ocular motor dysfunction, 

increased tone, rapid alternating movements of hands and fingertapping showed only 

moderate inter-rater agreement. There was a strong and significant correlation of 

UMSARS with H&amp;amp;Y, Schwab and England Scale, and ICARS. UMSARS also 

correlated moderately with timed-walking tests. Items of UMSARS-III related to 



102 
 

autonomic examination did not correlate with UMSARS I, II and IV, nor with other 

measures of global disability.  

Spinocerebellar ataxia. UMSARS was evaluated in 52 SCA3/MJD patients showing a 

high internal consistency (Cronbach´s ? of 0.91 for UMSARS I and 0.93 for UMSARS 

II). There was strong correlation between the ICARS and UMSARS-II [7]. 

c) Natural history 

Multiple system atrophy. In 2005, the EMSA study group published the first natural 

history study on MSA, using UMSARS, and showed a significant worsening of 4.2/48, 

6.6/56, and 0.4/5 points in UMSARS I, II and IV, respectively, after a mean follow-up 

of 6.4 months [30]. The study continuation reported a mean worsening of 6.7/48 

(+35.6%), 9.6/56 (+57.3%) and 0.8/5 points (+33.3% relative to baseline) in UMSARS 

I, II and IV, respectively, after a mean of 12.3 months [31]. These values were 

considered as a parameter of sensitivity to change; however, none of the classical 

standardized parameters were reported. From the data provided we could calculate 

an ES of 0.79, 1.12 and 0.72 for UMSARS I, II and IV. Patients without pyramidal 

signs showed a faster progression in UMSARS I and II, while patients with cerebellar 

signs showed a faster progression in UMSARS II. Fast progression of UMSARS II 

scores was also associated to mild baseline disability, according to UMSARS II, as 

well as to short disease duration. Another study showed a mean worsening of 3.1/48 

(UMSARS I) and 4.5/56 (UMSARS II), after 1 year [32]. The ES (estimated with the 

published study data) was 0.43 and 0.64 for UMSARS I and II. None of the studies 

tried to define the MID of UMSARS for MSA. 

Spinocerebellar ataxias. After a mean follow-up of 13.3 months, the mean UMSARS-

II score worsened 2.7/56 points in 32 SCA3/MJD patients, with no significant 

differences in UMSARS-I and IV during that period [7]. Neither an index of sensitivity 



103 
 

to change nor any attempt to define MID were described; however, with the data 

provided, we calculated an ES of 0.23 for UMSARS-II in SCA3/MJD patients during 

this period. 

d) Clinical trials 

Two randomized clinical trials on MSA, one evaluating minocycline [33], and the 

other evaluating r-hGH [34], used UMSARS or UMSARS-II scores as neurological 

endpoints. 

FARS – Friedreich Ataxia Rating Scale [35] 

a) Scale description 

The Friedreich Ataxia Rating Score (FARS) was developed in 2005, from a larger 

scale devised by the Cooperative Ataxia Group, to evaluate functional and 

neurological deficits, with a greater weight given to gait and stance [35]. The scale is 

ascending in severity (0 meaning normal examination), and has four domains: I - 

functional staging (0 to 6, overall mobility); II - ADL (0 to 36); III - neurological 

assessment of bulbar, upper and lower limbs, peripheral nerve, and upright 

stability/gait functions (maximum scores of 11, 36, 16, 26, and 28; total  of 117); and 

IV - quantitative timed activities: PATA rate, 9-hole pegboard (9-HPT) and timed 25-

foot walk (T25FW), which will be detailed in the quantitative scales section.  

b) Validation 

The first study evaluating the psychometric properties of FARS assessed only 14 

FRDA patients. ICC was 0.95 for the total neurological score; ICC was also high for 

all partial scores, except for the bulbar (0.29) and the peripheral nerves items (0.74) 



104 
 

[35]. A larger study, published the following year, evaluated 155 FRDA patients and 

found a significant correlation between the functional and ADL component of FARS 

with disease duration; the FARS score was predicted by (GAA)n length [36]. They 

also found a significant correlation of FARS to the Physical Component Summary 

(PCS) of the quality of life questionnaire SF-36. In another study, ninety-six FRDA 

patients were assessed with FARS (Part III), ICARS and SARA [8]. Cronbach‘s ? 

was 0.86 for the five subscales and 0.97 for raw data. There was a strong direct 

correlation among the three scales, and all significantly correlated with disease 

duration (r=0.695) and ADL (r=0.918). Principal component analysis yielded five 

different factors, of which only factor 4 loaded for a specific subscale (bulbar 

function). Another study assessed 76 patients with FRDA with ICARS and FARS and 

found a significant correlation between them, as well as with functional indexes and 

disease duration [9]. 

c) Natural history 

A study evaluated 43 FRDA patients with ICARS and FARS, during a 12-month 

period, finding a mean worsening of 9.5/159 points (SD 9.1), with an effect size of 

0.34 [9]. Using the data provided, we could calculate an SRM of 1.04. Any significant 

differences were considered as the MID by the authors. Another group reported 

progression in the scores of 168 patients, after 12 and 24 months [37]. Mean change 

in FARS and E-FARS (sum of the FARS I, II and III scores) was 3.55/125 

(SRM=0.53) and 5.5/167 (SRM=0.63), after one year, and 6.16/125 (SRM=0.84) and 

8.93/167 (SRM=1.00), after two years. In this study, women (SRM=1.02) progressed 

significantly faster than men (SRM=0.62), after two years. Finally, in placebo groups 

of randomized clinical trials, a non-significant deterioration of about 0.6/117 points 

[12], or no change at all [11], were reported after 6 months. 

d) Clinical trials 



105 
 

Two randomized-controlled clinical trials (idebenone) used FARS [11,12]. None 

found a significant change with the intervention. On ClinicalTrials.gov one trial 

evaluating varenicline utilized FARS as the primary efficacy outcome but was early 

terminated (NCT00803868). A study evaluating carbamylated erythropoietin 

(NCT01016366) and another evaluating alpha-tocopherolquinone (A0001) 

(NCT01035671) also used FARS to measure the endpoint.  

NESSCA – Neurological Examination Score for the Assessment of 

Spinocerebellar Ataxia [38] 

a) Scale description 

NESSCA was developed in 2001 and published in 2008. It is a semi-quantitative 40-

point scale, covering 18 different items, higher scores indicating worse performance 

[38,39]; 14items correspond to parts of a standard neurological examination (gait 

ataxia, limb ataxia, presence and characteristics of nystagmus, oculomotor deficit, 

pyramidal findings, dysarthria, distal amyotrophy, fasciculations, sensory loss, 

dystonia, rigidity, bradykinesia, eyelid retraction and blepharospasm); and four items 

rely on patient information (dysphagia, sphincter function, cramps and vertigo). 

Principal components analysis showed the 18 items loaded four distinct factors that 

accounted together for 52% of total variance (cerebellar and peripheral 24,56%; 

extrapyramidal 11,14%; pyramidal, speech and dysphagia 9,37%; vertigo, cramps 

and nystagmus 5,9%). 

b) Validation 

NESSCA was validated only in SCA3/MJD [38]. Cronbach‘s ? was 0.77 and inter-

rater reliability (k) was 0.97. In a multidimensional scale like this one, internal 

consistency is considered adequate when the Cronbach‘s ? varies from 0.7 to 0.9 [2]. 



106 
 

The scale significantly correlated with the following external variables: disease stage, 

disease duration, number of CAGs, SARA and Barthel index. 

c) Natural history 

The largest published cohort of SCA patients using a validated ataxia score was 

performed with NESSCA: 105 SCA3/MJD patients were followed during a mean 

follow-up of five years [39]. NESSCA scores produced a general growth curve that 

covered at least 18 years of disease duration, with a mean 12-month deterioration of 

1.26/40 points. The number of CAG repeats and the age-at-onset of symptoms both 

modify significantly progression of the disease by this scale. A one-year increase in 

the age-of-onset produced a reduction in the growth curve slope of 0.03 points, 

showing improvement in the prognosis, whereas an increase in one CAG repeat was 

related to an increase by 0.15 points , indicating a poorer prognosis. In other words, 

the larger the (CAG)n and the earlier the disease onset, the faster the disease 

progressed [39]. We could calculate an ES of 0.22 per 12 months. There was no 

definition of MID in this study. 

d) Clinical trials 

No published trial used this scale. On ClinicalTrials.gov, two trials, evaluating lithium 

carbonate (NCT01096082) and sodium phenylbutyrate (NCT01096095), in 

SCA3/MJD patients are underway using NESSCA to measure outcome. 

3.3 Semi-quantitative non-ataxia scales 

INAS ? Inventory of Non-Ataxia Symptoms [40] 

a) Scale description 



107 
 

The Inventory of Non-Ataxia Symptoms (INAS) was developed for the extracerebellar 

features of ataxias and consists of 30 items, each related to one of 16 

symptoms/syndromes: areflexia, hyperreflexia, extensor plantar response, spasticity, 

paresis, amyotrophy, fasciculations, myoclonus, rigidity, chorea, dystonia, resting 

tremor, sensory symptoms, brainstem oculomotor signs (horizontal and vertical 

ophthalmoparesis, slowing of saccades), urinary dysfunction, and cognitive 

impairment [40]. INAS count thus ranges 0 to 16.  

b) Validation 

A study evaluating 526 patients with SCA1, SCA2, SCA3/MJD and SCA6 found that 

INAS count correlated with disease duration in all SCAs, and with SARA in SCA1, 

SCA2 and SCA3/MJD [40]. In SCA2 and SCA3/MJD, the INAS count increased with 

repeat length and decreased with age at onset. Retest reliability in a study in patients 

with stable disease found a moderate ICC of 0.79 [24].  

c) Natural history  

The follow up for one year of 171 patients with SCA showed a mean annual change 

of 0.37/16 in INAS (SRM=0.26). Considering only patients who reported worsening, 

according to PGI, the annual score change was 0.46/16 ± 1.4 (SRM=0.33), when PGI 

was worse, and 0.26/16 ± 1.5 (SRM=0.17), when the PGI was stable [24]. 

3.4 Quantitative performance ataxia scales 

These scales are intended to reliably detect small clinical changes over short periods 

of time. Measures of performance give rise to continuous variables, which will 

theoretically provide better sensitivity and responsiveness o the scale. Another 

advantage is that results of the overall or composite scales have been presented as 

Z-scores, what allows an easier comparison across tests. Z-scores are a way of 



108 
 

standardizing results, indicating how many standard deviations an observation is 

above or below the mean. They result in a dimensionless quantity, which is derived 

by subtracting the observed mean from an individual raw score and then dividing the 

difference by the standard deviation.  

CATSYS 2000 ? Coordination Ability and Tremor System [41] 

a) Scale description 

Development of CATSYS started in 1986, when searching for a new method to 

assess quickly brain damage caused by exposure to organic solvents. During the 

nineties, the CATSYS 7 became available for neurotoxicology and occupational 

medicine, and in 2000 was replaced by Windows-based software, the CATSYS 2000. 

It is a portable device, recording four measures of neuromotor control: tremor, 

reaction time, hand coordination and postural sway. Hand coordination is measured 

with pronation-supination and finger-tapping movements, executed at constant and 

accelerated rhythms, in a recording drum, with the right and left hand, under standard 

conditions: (1) hand pronation-supination at a constant slow (1 Hz) and a constant 

fast (2.5 Hz) metronome beat; (2) hand pronation-supination at an accelerating 

rhythm (from 1.6 Hz to 7.5 Hz); (3) finger tapping at a constant slow (1 Hz) and a 

constant fast (2.5 Hz) beat; and (4) finger tapping at an accelerating rhythm (from 1.6 

Hz to 8.1 Hz). Reaction time is assessed in both hands, using a handheld switch 

activated by the thumb to a sound stimulus. Postural tremor is quantified in both 

hands over 24.6 sec., by asking the subjects to hold a light pen (Tremor® Pen), 

which contains a biaxial accelerometer, horizontally at 10cm in front of their navel, 

and free of body contact or any obstacles. Postural sway is tested by asking the 

subject to stand on a force platform, feet 1cm apart and arms at their sides for 75 

sec. Subjects are instructed to look at a picture placed around 2m in front of them, or 



109 
 

to keep their eyes closed. These tasks were performed with or without a pad of 

polystyrene foam (2cm thick) under their feet.  Four conditions are thus measured: 

(1) eyes open; (2) eyes closed; (3) eyes open standing on a foam pad; and (4) eyes 

closed standing on a foam pad. 

b) Validation 

CATSYS was validated in normal individuals free of neurological deficits evaluating 

the effect of age and gender on the different tasks [41]. 

Fragile X-associated tremor and ataxia syndrome (FXTAS). A study of 16 patients 

with FXTAS, 16 premutation carriers and 14 healthy controls was performed with 

CATSYS, together with an adapted intention tremor score performed with the 

Tremor® Pen [42]. A 30sec postural sway test with eyes open and closed showed 

differences between those with FXTAS and both controls and premutation carriers 

(p=0.0004 - discriminant validity). Up to six FXTAS subjects could not complete the 

various sway tasks. The manual coordination measures (pronation-supination, hand-

tapping and index finger-tapping) and the reaction time measure were not different 

among groups. Within the intention tremor measure, FXTAS patients exhibited a 

significant difference in the non-dominant (p=0.02) and dominant hand (p=0.0008) 

when compared to both controls. The authors established statistical criteria to define 

ataxia in the postural sway test and postural tremor with the Tremor® Pen. There 

was 70% concordance of self-reported ataxia and 80% for tremor with CATSYS; 

however, 30% and 23% who did not report ataxia or tremor, respectively, were 

?positive‘ with the CATSYS criteria [43]. Another recent study using this scale, to 

screen for FXTAS symptoms, found that almost all subjects had tremor and/or ataxia 

according to CATSYS (45/47), but only about 2/3 were aware of symptoms. The 

neurological exam performed by a movement disorders specialist detected tremor 



110 
 

and/or ataxia in all but one of the ?CATSYS-positive‘ subjects, thus showing the high 

sensitivity of this scale [44]. 

No study evaluated CATSYS 2000 in SCAs, MSA or FRDA. 

FARS part IV, Z2 and Z3 ? Friedreich Ataxia Rating Scale [35, 36] 

a) Scale description 

Part IV of FARS is composed by quantitative timed activities: the PATA rate, which is 

the number of repetitions of the word ?PATA? in a 10sec interval, using a tape 

recorder; the 9-hole Pegboard (9HPT), to test motor coordination; and gait 

assessment, using a timed walk of 50 - 25ft one way, turn and walk back, with or 

without a device (T25FW). In FARS, the 9HPT time was measured for completion 

and removal of all pegs for each hand separately. 

Two composite scores were derived from FARS-IV: the Z2, which is the sum of Z-

scores of 9HPT
?1

 and the reciprocal of the timed 25 feet walk (T25FW
?1

); and the Z3, 

which adds Z2 to the Z-score of the low-contrast letter acuity vision test (LCLA). 

LCLA is calculated as the number of correct letters read, using both eyes, for three 

charts: 100% contrast from a distance of 3.2m, and 1.25% and 2.5% contrast from a 

distance of 2m. Each chart had a maximum score of 70 letters, with an overall total of 

210 letters [36, 37]. 

b) Validation 

The psychometric properties of FARS-IV were first evaluated in 14 FRDA patients. 

Timed activities tested had high inter-rater reliability: ICC of 0.92 for PATA, 0.93 for 

9-HPT and T25FW. The correlation of individual timed measures with ADLs was 

moderate (r varying from 0.50 to 0.66) [35]. A further study evaluating 155 FRDA 



111 
 

patients found an ICC for the different tasks between trials from 0.93 to 0.99. In this 

study, 136/154 patients were able to perform the 9HPT and only 73/152 were able to 

perform the T25FW [36]. Both Z2 and Z3 scores correlated with ADL (r=-0.83, for 

both), functional disability (r=-0.93 and r=-0.89,) and disease duration (r=-0.55 for 

both), as well as with the Physical Component Summary of SF-36 scores (r=-0.41 

and r=-0.36, respectively). 

c) Natural history 

A study evaluating disease progression in 168 FRDA patients found that the 9HPT
?1

 

mean- change after one year was of 0.00087±0.002 (SRM=0.43) and 

?0.0016±0.0024 (SRM=0.66), after two years; T25FW
?1 

change -0.0094±0.036 

(SRM=0.26) after one year and -0.015 ± 0.036 (SRM=0.41), after two years; LCLA 

change 2.29±11.9 (SRM=0.19), after one year; and 5.99±16.2 (SRM=0.37), after two 

years. PATA rate showed no change over time. Z2 change was -0.17±0.45 

(SRM=0.37), after one year and -0.32±0.47 (SRM=0.68) after two years. Z3 change 

was -0.23±0.58 (SRM=0.39), after one year; and -0.48±0.66 (SRM=0.72), after two 

years. Changes in 9HPT
?1

 appeared linear over time, as shown by proportional 

alterations in the mean at baseline and at years one and two. The same did not 

happen with T25W
?1

, LCLA and PATA, suggesting either floor or ceiling effects [37]. 

In the placebo group of a clinical trial there was no significant change of Z2 and Z3, 

after 6 months of treatment [12].  

d) Clinical Trials 

A clinical trial evaluating idebenone in FRDA used Z2 and Z3 scores as endpoints 

[12] 



112 
 

ACFS ? Ataxia Functional Composite Scale [45] 

a) Scale description 

The Ataxia Functional Composite Scale (ACFS) [45] is very similar to the composite 

score Z3, being the sum of the Z-scores for 9HPT, Low Contrast Visual Acuity 

(LCVA) and T25W, divided by 3. LCVA, very similar to LCLA (Figure 2), is the 

number of correct letters read from four charts, with gray letters of progressively 

smaller size, on a white background; each chart in the set corresponds to a different 

level of contrast, with a maximum score of 60 for each contrast level (100%, 5%, 

1.25% and 0.6%) [45]. 

b) Validation 

The ACFS was evaluated in a clinical trial with 20 patients with hereditary ataxias (4 

each with SCA2 and FRDA; 2 with SCA3; and one each with DRPLA, SCA6, and 

SCA17; 6 with idiopathic SCA; and one with expanded CAG repeat tracts both for in 

the SCA1 and SCA2 genes), finding a strong correlation with ICARS. 

c) Natural history 

A clinical trial evaluating buspirone in the same population of the score validation, 

over 12 weeks, found no significant difference in ACFS from baseline to the final 

score in the placebo group [17]. 

d) Clinical trials 

One clinical trial evaluating buspirone used ACFS [17]. 

CCFS and CCFSw – Composite Cerebellar Functional Score [25, 46] 

a) Scale description 



113 
 

The CCFS was intended as an objective quantitative test of general coordination, but 

ended up to be a scale for upper limb ataxia [46]. Although the first version included 

a walking distance measurement, the final, established CCSF consists of two tests 

on the dominant side: the 9HPT and the click test (Figure 1). In CCFS, the 9HPT, 

measured in seconds, from the time first peg is placed in a hole to when the last peg 

is placed. The Click test uses a homemade device composed of two mechanical 

counters fixed on a wooden board, 39 cm apart, where finger-pointing coordination is 

measured. Patients use their index finger to press the buttons on alternate counters, 

for 10 times. The performance of controls on all tests was measured and a linear 

model fitted for differences between the dominant and non-dominant hands, and 

values were adjusted for age [46]. The Z-score was obtained by subtracting the 

expected time (obtained in controls) from the time observed in the patient. Linear 

regression analysis showed that these two independent tests, the 9HPT and the click 

test on the dominant side, accounted for the severity of the cerebellar syndrome, as 

reflected by the SARA scores. 

Final CCFS is calculated as: 

10

Z pegboard dominant hand Z click dominant hand
CCFS log 7 4

10 10

? ?
? ? ? ?? ?

? ? , 

where Zpegboard D  equals Pegboard D - (13.4 - 0.16 x age + 0.002 x age
2
) and Zclick D = 

click D – (8 + 0.05 x age). 

As mentioned above, all values were adjusted for age and expressed as logs of Z-

scores, the differences between the observed time and the expected time due to age. 

Z-scores of each test varied around 0 in the control group, and around 16-17 in the 

SCA group.  



114 
 

Recently, in order to improve CCFS responsiveness, the CCFSw score was created, 

which also includes the dominant hand-writing test. The patient is asked to write a 

standard sentence (?maître corbeau sur un arbre perché‘) (or Master Crow is perched 

on a tree), with his dominant hand, as fast as possible, but legibly. CCFSw showed 

an estimated lower sample size for trials than CCFS in the standardized response 

mean (SRM) of the scores [25]. It is important to emphasize that in the description 

study of the CCFS score [46], the writing test was excluded from the score, because 

the dominant hand 9HPT and click tests alone, independently accounted for the 

severity of the cerebellar syndrome reflected by the SARA score. 

CCFSw is calculated as:  

10

Zpegboard D Zclick D writing D
CCFS log 7 4

10 10 10

Z? ?
? ? ? ? ?? ?

? ? , 

where ZwritingD = writing D – (8.5 + 0.05 x age).  

b) Validation 

The CCFS was studied in 141 patients with SCAs (SCA1, SCA2, SCA3/MJD, SCA6, 

SCA7, SCA14, SCA25, SCA28 and unknown SCA) and 53 patients with autosomal 

dominant spastic paraplegia (SPG4, SPG3, and unknown SPG) [46]; 31 patients 

were not able to perform all the upper limb tests - 26 could not write, 11 could not use 

the pegboard, seven could not perform the click test. All these were excluded from 

the analysis. The CCFS was higher in SCAs than in dominant spastic paraplegias, 

and correlated with a visual analogue scale of the quality of life questionnaire EQ-5D, 

with disease duration and with SARA. CCFS scores were lower in SCA3/MJD 

patients than in SCA1 and SCA2. Another study evaluated CCFS test-retest reliability 

in 14 healthy individuals, and found an ICC of 0.73 [25]. 



115 
 

c) Natural history  

The 12-month natural history of CCFS was evaluated in 133 patients with different 

SCAs (SCA1, SCA2, SCA3/MJD, SCA5, SCA6, SCA7, SCA14, SCA21, SCA25, 

SCA28). During this period the score significantly worsened by 0.0197±0.0614 points 

(ES&lt;0.2, SRM=0.32), and the CCFSw score worsened by 0.0236±0.0585 points 

(ES&lt;0.2, SRM=0.40). Sample size estimates were best when only SCA1, 2 and 3 

patients were considered [25]. MID was defined taken SARA as the standard, looking 

for the minimal number of Z-scores of CCFS that would account for the severity of 

the disease measured by SARA [46]. 

d) Clinical trials 

No published trial used this scale. On ClinicalTrials.gov a study evaluating lithium 

carbonate (NCT01096082) in SCA3/MJD patients is underway using CCFS to 

measure outcome. 

SCAFI ? SCA Functional Index [47] 

a) Scale description 

SCAFI is composed of the 8m walking time (8MW) at maximum speed, the 9HPT 

performed as in FARS IV and the PATA repetition rate [47]. The 8MW was defined 

as the time needed to walk 8m with any device, but without assistance by another 

person or the walls; 8MW was measured from a standing start with feet behind the 

start line (although the walking aid, if used, was allowed in front of that line). Stop 

criteria were 180sec for 8MW and 300sec for 9HPT. All tests were perfomed twice 

resulting in a mean value   After appropriate transformation of the absolute values 

into Z-scores, a functional composite (FC) is formed as the arithmetic mean of all 



116 
 

three Z-scores. Values are expressed as the arithmetic mean of all three Z-scores. 

SCAFI has no fixed range variation, but rather indicates how many standard 

deviations an observation is above or below the mean. 

b) Validation 

SCAFI was applied in 412 clinically symptomatic patients with SCA; 63  subjects 

were unable to perform one or more tests [47] and were excluded from the analysis. 

Internal consistency was indicated by a Cronbach‘s ? of 0.82 for all three tests, and 

of 0.72 when compared PATA*8MW and 0.80 to 8MW*9HPT. This showed a strong 

negative linear correlation of SCAFI (r=-0.872) and the individual tests with SARA 

(PATA Z-score, r=-0.663; 9HPT Z-score, r=-0.817; and 8MW Z-score, r=-0.783). 

Correlations with UHDRS-IV were similarly high and positive higher functional 

independence was associated with better performance for all three functional 

measures (PATA Z-score. r=0.607; 9HPT Z-score, r=0.708; 8MW Z-score, r= 0.789; 

and SCAFI, r=0.814). 

c) Natural history  

A one-year follow-up of 171 patients with SCAs [24] showed a mean change of Z-

scores of -0.159±0.33 in SCAFI (SRM=-0.48), -0.084±0.59 in 8MW (SRM=-0.14), -

0.0232±0.35 in 9HPT (SRM=-0.67), and -0.160±0.68 in PATA (SRM=-0.24). When 

cases with deterioration according to PGI were considered, the annual score change 

was -0.172±0.30 (-0.12 to -0.23) in SCAFI (SRM=-0.57), -0.115±0.48 (-0.03 to -0.20) 

in 8MW (SRM=-0.24), -0.261±0.35 (-0.20 to -0.32) in 9HPT (SRM=-0.74), and -

0.140±0.73 (-0.02 to -0.26) in PATA (SRM=-0.22), when PGI was towards worsening 

(n=120); and -0.193±0.38 (-0.08 to -0.31) in SCAFI (SRM=-0.51), -0.114±0.74 (-0.34 

to 0.11) in 8MW (SRM=-0.15), -0.198±0,35 (-0.09 to -0.30) in 9HPT (SRM=-0.57), 



117 
 

and -0.268±0.79 (-0.03 to -0.51) in PATA (SRM=-0.34), when the PGI was for 

stability (n=43). The sample size estimation by the standardized response mean 

(SRM) for a clinical trial was the lowest for 9HPT, followed by SARA and SCAFI, with 

only a small SRM for PATA and a non-significant change for the 8MW. Although 

discussed, MID was not defined for SCAFI.  

d) Clinical trials 

No published trial used this scale. On ClinicalTrials.gov a study evaluating lithium 

carbonate (NCT01096082) in SCA3/MJD patients is underway using SCAFI to 

measure outcome. 

3.5 Self-performed ataxia scales 

FAIS – Friedreich´s Ataxia Impact Scale [48] 

a) Scale description 

FAIS is a patient-reported questionnaire [48], with eight subscales representing three 

clinical areas: symptoms (speech, body movement); physical functioning (upper limb, 

lower limb, complex tasks); and psychological and social impact (mood, self-

perception, isolation); with a total of 126 items in its larger version. Three shorter 

subscales were constructed: a 65-item version, for observational studies (??FAIS-

OBS‘‘); a 63-item version, for studies of more disabled patients (??FAIS-MORE‘‘); and 

a 63-item version for persons with less disability (??FAIS-LESS‘‘). The higher the 

score, the worse the patient‘s symptoms [48] 

b) Validation 

FAIS was validated on a postal survey in 307 patients with FRDA. There is no study 

correlating FAIS or its subscales with any of the other ataxia rating scales [48]. 



118 
 

4. DISCUSSION 

Desirable properties of a clinical scale for the ataxias 

Ataxia scales were mainly developed to express the burden of a known disease in a 

given patient, allowing for comparison with other patients with the same disorder. 

Like any other clinical scales, several properties, such as validity, reliability and 

sensitivity to change are essential, other desirable properties being linearity and 

brevity. In addition, particularly in the case of multidimensional scales, division into 

reasonable sub-scales should be supported by factor analysis [49].  

Categorical versus numerical scales  

One of the first issues to be discussed is whether any scale should be categorical or 

numerical. The coexistence of both qualitative and quantitative classifications has 

good reasons. Of course, the more finely we can measure something, the better; 

rating an attribute on a scale in which each point is equally spaced is vastly superior 

to dividing it into rougher categories. Functional ataxia scores do fulfill these 

characteristics; however, they cover only some signals of cerebellar dysfunction; and, 

frequently, patients are unable to perform some of the tasks. By contrast, many of the 

ataxia scales are categorical or semi-quantitative: their advantage is that they are 

based on specific tests and maneuvers included in any proper neurological 

examination. One way to overcome inconveniences of such scales is to avoid simple 

dichotomization (present/absent), as e.g. in the INAS count, as this will reduce all 

positive responses (strong, moderate or mild) to a single value, resulting in a loss of 

information and reliability, as well as sensitivity to change.  

Weighting items and partial scores (subscales) 



119 
 

Since most ataxia scores are categorical and composed of items of different clinical 

and individual relevance, another question is how to weight correctly different items 

in the whole scale. For example, should mild dysarthria with preserved intelligibility 

be equated to mild gait ataxia? This has been little discussed. Most scales seemed to 

adopt a theoretical approach, based on expert opinion, and none presents empirical 

data to estimate weighting of single items in the final score. As most ataxia scales 

show high internal consistency among their various items, it is probable that an 

empirical approach for differential weighting would just add complexity for the scorer, 

while contributing little to improve scale properties [49]. 

Face and content validity 

Whereas face and content validity of semi-quantitative scales are generally good and 

reliable, for quantitative scales, these criteria are more difficult to prove, since most of 

them are timed tasks. For instance, a delay in the 9HPT or 8MW performance may 

also be explained by bradykinesia or dystonic movements, and do not necessarily 

represent upper limb or gait ataxia. For theses scores, we may only demonstrate 

validity of each criterion, when correlating them to classical semi-quantitative ataxia 

scales. 

Brevity and linearity 

Achieving all desirable properties in a single scale may be very difficult and not all of 

these do necessarily need to be present. For instance, brevity may or may not be 

desirable, since length can reduce errors of measurements, improving reliability. 

Linearity, i.e., if the trait severity is reliably represented by simple summing of the 

scores of individual items, should be demonstrated, in order to allow adequate 

interpretation in future trials. This demands longitudinal observations, or may be 



120 
 

inferred from cross-sectional studies through a strong correlation with a well-known 

linear score, as is the case for SARA with a global assessment visual analogue scale 

[21]. In transversal observations performed during the construction of a scale, floor 

and ceiling effects, or skewness, are hints of non-linearity. Sometimes, linearity is just 

a matter of interpretation of the results. For instance, in the application of NESSCA to 

the natural history of SCA3/MJD, when each patient‘s follow-up was used to obtain a 

growth curve, a linear progression was obtained [39]. Different rates of change are 

sometimes related to the disease stage and may eliminate linearity from a given 

scale; however, if we can identify those individuals destined to have a faster 

progression, we may help decreasing the sample size needed for therapeutic trials. 

For example, FARS and its composite scores are most sensitive to change in FRDA 

patients under age 30 years [36]. 

Reliability, validity, internal consistency and responsiveness 

Reliability, validity and internal consistency are easier to validate, when constructing 

a scale, than other properties. But, the biggest challenge is possibly to demonstrate 

sensitivity to significant changes.  

Assessing disease progression is a topic of considerable divergence in literature [49]. 

In order to allow comparing changes in different scores over time, we used ES or 

SRM. Of course, most scores were intended to have high sensitivity to changes in 

disease status, in order to detect clinical minimally important difference (MID) in trials 

and natural history studies. MID is not the same as sensitivity to change, or as true 

responsiveness (clinically important changes) and has seldom been demonstrated 

[49], particularly for neurodegenerative disorders [50]. Some authors consider any 

small significant difference as clinically relevant for ataxias [9]. Ideally, MID should 

include other, mainly subjective changes, such as psychological well-being and 



121 
 

quality of life, which also have validation properties that may be different for different 

disorders. These dimensions, however, were not covered in this review.  

Choosing the adequate scale for the right ataxia 

The ideal ataxia scale should be simple to apply, requiring little training, not much 

time-consuming, well acceptable to the patient and the rater; and, at the same time, 

be valid, reliable, sensitive to disease progression, while little insensitive to small 

fluctuations, and provide results that can be easily analyzed and interpreted. 

Nevertheless, depending on the type of study and the specific form of ataxia, 

compromises may have to be made.  

When designing a study of natural history or a clinical trial, authors should choose 

between disease-specific versus generic ataxia scales. If disease-specific scales, like 

UMSARS (for MSA-C) or NESSCA (for MJD/SCA3) were chosen, a greater 

specificity will probably reduce its capacity of generalization. In a generic scale, like 

SARA, the opposite might happen. Comparisons between different diseases may or 

may not be the major aim, and the questions under study will be the main factors for 

that choice. The advantages and disadvantages of including functional measures in a 

composite scale (e.g., FARS), versus using separate scales for deficits, disability and 

handicap, are mainly related to the statistical analysis. If a composite scale is used, 

the study will have only one clinical variable; if separate scales are used, several 

variables will be included, what will imply multiple-testing corrections. 

 Measuring the ataxia component: ICARS versus SARA 

Among the scales that intend to measure incoordination only, ICARS was the most 

widely used scale for all ataxias, with good reliability and responsiveness. Although 



122 
 

still largely used, however, ICARS is being replaced by other tools in more recent 

studies. Its main drawback is the interdependency or redundancy of some of its 

items. Redundancy lessens the validity of a scale, since it may under or overestimate 

the effects of a potential treatment. Redundancy may also raise doubts as to the 

effect size of disease duration (the average worsening of 5/100 points per year, in 

FRDA [ES=0.26, SRM=0.73] and in SCA3/MJD [ES=0.26]) [9,10]. The use of SARA, 

a very reliable and less time-consuming tool, has been growing. It is more 

parsimonious (with probably no redundancy), easier to apply than ICARS, and has 

shown reasonable sensitivity to change. The responsiveness of SARA on disease 

duration was similar to that of ICARS (SARA showed a mean worsening of 1.38/40 

[SRM=0.5] points per year in various SCAs [24]). Notwithstanding, its variability is 

high, and a large sample size is required for small differences. Finally, further 

validation and natural history studies will probably define if MICARS and BARS may 

become useful ataxia scales. 

The impact of extra-cerebellar manifestations 

Other recent scales for the SCAs include also items on extra-cerebellar 

manifestations, which allow a better assessment of disease impact [2, 51]: this is the 

case with UMSARS, FARS, NESSCA and INAS.  

UMSARS and FARS may be described as disease-severity scoring systems (DS3), 

since they measure both impairment and disability. UMSARS is the most used and 

well-validated for MSA. This might be partly explained by the sensitivity of annual 

change in its motor sub-score (UMSARS II). UMSARS may become a promising 

scale for SCAs (at least for SCA3/MJD), with an ES=0.23 for UMSARS-II, which is 

similar to ICARS [7]. FARS is a validated scale, most utilized for assessing ataxic 

and non-ataxic signals in FRDA. FARS not only evaluates neurological impairment 



123 
 

and disability, but it also includes other very interesting domains, such as well-known 

quantitative measurements of coordination (PATA and 9HPT), and the T25FW. 

FARS response is reasonable, with a moderate ES (0.34) and a moderate to high 

SRM (0.53-1.04) in FRDA patients, after 12 months of follow-up. But, FARS has 

some drawbacks: first, it is a complex scale and takes more than 30 minutes to 

complete; secondly, it has only been validated and used in FRDA, though it may be 

applied to other inherited ataxias.  

The NESSCA scale also appears to be a promising scale to assess ataxia and non-

ataxia manifestations. Its sensitivity to annual changes is similar to of SARA and 

ICARS, in SCAs (1.25/40 points of change and an ES of 0.22 per 12 months). With 

good reliability and validity parameters, NESSCA has only been validated in 

SCA3/MJD. Regarding only the non-ataxic features, INAS was validated for different 

SCAs, but its responsiveness is not clear, with a mean annual change lower than for 

the former scales (0.37/16 points in one year; SRM=0.26). 

Quantitative performance scores 

The quantitative ataxia scores, either individual or composite, are intended to 

represent more precise measures, easier to perform, and with greater effect sizes. 

Individual scores are the 9HPT, Click test, 8MW, T25FW and PATA test. Composite 

scores are CATSYS 2000; CCFS – including 9HPT and click test; CCFSw – CCFS 

plus the hand writing test; SCAFI – 8MW, 9HPT and PATA; and FARS IV, Z2 and Z3. 

They are all very reliable. Discriminant validity (responsiveness) is not so important 

here, since these tests are intended to detect minimal changes. Quantitative scores, 

however, have the downside of not being feasible in more severely affected patients: 

some may not be able to walk, write, use the pegboard, perform the click test, or 

even talk. The ceiling effects that may be produced are probably unavoidable, and 



124 
 

should preclude the recruitment of more disabled patients for trials using these 

scores.  

The importance of scales in studies of natural history and in future therapeutic 

trials  

Natural history studies bring knowledge about the progression rate of a disease and 

help delineating clinical trials. They have confirmed the slow progression of SCAs 

and FRDA: clinical trials on these disorders thus need to be longer than in other 

diseases. It seems to be clear that low ES or SRM for SCAs and FRDA are mainly 

due to slow disease progression, and not because of the properties of the scales, 

since this is in agreement with the clinical assessment of these patients. For 

instance, it was very clear that UMSARS-II for MSA, a disease with a faster 

progression, showed a larger 12-month ES (1.12) than for SCA3/DMJ (0.23). Another 

issue is that the progression rate of disease in placebo groups will not necessarily be 

the same as that of the natural history, as the placebo effect is quite evident in 

various trials, as was, e.g., in FARS and FRDA: while the mean worsening was 9.5 

points/159 per year in the natural history study, it was 0.6 points/117 per six months 

in a placebo group from a clinical trial [9,12]. This finding stresses the need for 

clinically significant and reliable biomarkers to be used as secondary endpoints, in 

order to derive evidence from phase-II clinical trials. 

Conclusions 

(1) We recommend that all three kinds of scales should be employed in future clinical 

trials, according to the phase of the study. Given the efforts to develop new 

instruments, and the validation criteria already obtained with the scales currently 

available, we do not think that new tools are needed, for the moment. 



125 
 

(2) Quantitative performance scores will be very important to develop evidence from 

phase-II trials, demonstrating a drug's effect in a selected group of patients. The 

composite SCAFI and CCFS, as well as individual scoring tests, will probably be 

useful as secondary endpoints in phase III trials in ataxia, though SCAFI might be 

preferable, since it includes a walking test. Gait ataxia is usually the presenting sign 

and the main disability in SCAs and FRDA. Given its clinical importance, gait 

performance should be measured in phase II trials. The 8MW (or T25FW ) may add 

significant information, although this has been shown only, up to now, in a FRDA 

cohort [37].  

(3) Ataxia scales, such as SARA and ICARS, are the best studied and validated, so 

far: one of them should be used in long-term, multicenter phase III studies, as well as 

serve as the instrument to validate sensitivity to change in phase II trials (where 

performance tools should be used). SARA is simpler and less time-consuming than 

ICARS; moreover, redundant items of ICARS may be a problem. SARA may thus be 

a better choice.  

(4) Ataxia and non-ataxia scores will provide a better view of overall disability and, 

together with tools for quality of life, will be necessary to demonstrate MID. For the 

time being, there seems to be is no clear advantage between NESSCA and 

UMSARS, though it must be noted that NESSCA has been used in the longest 

natural history study ever published [39]. We recommend either NESSCA or 

UMSARS for SCAs, mostly for not giving categorical variables. FARS is quite a 

complete scale, and is the one recommended for studies in FRDA.  

(5) Finally, it is worth reminding that the real MID (which is not clearly measured by 

any of the tools reviewed here), as well as indexes of quality of life, will probably be 

the most important endpoints to measure in future therapeutic trials. 



126 
 

5. ACKNOWLEDGEMENTS 

We are grateful to the Latin-American Science and Technology Development 

Programme (CYTED) (210RT0390) for funding the RIBERMOV network, through 

which initiative this work took form. We thank the reviewers who provided important 

hints and fruitful suggestions that have considerably improved this review. L.B. 

Jardim was supported by CNPq, Brazil, and by INAGEMP, Brazil. 

6.  REFERENCES 

1 Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic 

criteria. Lancet Neurol. 2010;9:94-104. 

2 Kieling C, Morales Saute JA, Jardim LB. When ataxia is not just ataxia. Nat 

Clin Pract Neurol. 2007 May;3:E2. 

3 Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, 

et al. International Cooperative Ataxia Rating Scale for pharmacological 

assessment of the cerebellar syndrome. The Ataxia Neuropharmacology 

Committee of the World Federation of Neurology. J Neurol Sci. 1997;145:205-

11. 

4 Tison F, Yekhlef F, Balestre E, Chrysostome V, Quinn N, Wenning et al. 

Application of the International Cooperative Ataxia Scale rating in multiple 

system atrophy. Mov Disord 2002;17:1248 – 54. 

5 Storey E, Tuck K, Hester R, Hughes A, Churchyard A. Inter-rater reliability of 

the International Cooperative Ataxia Rating Scale (ICARS). Mov Disord. 

2004;19:190-2. 



127 
 

6 Schmitz-Hübsch T, Tezenas du Montcel S, Baliko L, Boesch S, Bonato S, 

Fancellu R, et al. Reliability and validity of the International Cooperative Ataxia 

Rating Scale: a study in 156 spinocerebellar ataxia patients. Mov Disord. 

2006;21:699-704. 

7 D'Abreu A, Franca M Jr, Lopes-Cendes I, Cendes F. The international 

cooperative ataxia rating scale in Machado-Joseph disease. Comparison with 

the unified multiple system atrophy rating scale. Mov Disord. 2007;22:1976-9. 

8 Bürk K, Mälzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hübsch T, et al. 

Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov 

Disord. 2009;24:1779-84. 

9 Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB. How is disease 

progress in Friedreich's ataxia best measured? A study of four rating scales. J 

Neurol Neurosurg Psychiatry. 2007;78:411-.. 

10 França MC Jr, D'Abreu A, Nucci A, Cendes F, Lopes-Cendes I. Progression of 

ataxia in patients with Machado-Joseph disease. Mov Disord. 2009; 24:1387-

90. 

11 Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of 

high-dose idebenone in patients with Friedreich's ataxia: a randomised, 

placebo-controlled trial. Lancet Neurol. 2007;6:878-86. 

12 Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled 

trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67:941-7. 

13 Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, et al. 

Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled 



128 
 

pilot trial. Neurology. 2010;74:839-45. 

14 Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, et al. Effects of 

the oral form of ondansetron on cerebellar dysfunction. A multi-center double-

blind study. J Neurol. 2003;250:693-7. 

15 Mori M, Adachi Y, Mori N, Kurihara S, Kashiwaya Y, Kusumi M, et al. Double-

blind crossover study of branched-chain amino acid therapy in patients with 

spinocerebellar degeneration. J Neurol Sci. 2002;195:149-52. 

16 Heo JH, Lee ST, Chu K, Kim M. The efficacy of combined estrogen and 

buspirone treatment in olivopontocerebellar atrophy. J Neurol Sci. 

2008;271:87-90. 

17 Assadi M, Campellone JV, Janson CG, Veloski JJ, Schwartzman RJ, Leone 

P. Treatment of spinocerebellar ataxia with buspirone. J Neurol Sci. 

2007;260:143-6. 

18 Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 

and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin 

E and coenzyme Q10 therapy. Eur J Neurol. 2008;15:1371-9. 

19 Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone 

treatment in Friedreich patients: one-year-long randomized placebo-controlled 

trial. Neurology. 2003;60:1676-9. 

20 Schöls L, Vorgerd M, Schillings M, Skipka G, Zange J. Idebenone in patients 

with Friedreich ataxia. Neurosci Lett. 2001;306:169-72. 

21 Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt 



129 
 

C, et al. Scale for the assessment and rating of ataxia: development of a new 

clinical scale. Neurology. 2006;66:1717-20. 

22 Braga-Neto P, Godeiro-Junior C, Dutra LA, Pedroso JL, Barsottini OG. 

Translation and validation into Brazilian version of the Scale of the 

Assessment and Rating of Ataxia (SARA). Arq Neuropsiquiatr. 2010;68:228-

30. 

23 Weyer A, Abele M, Schmitz-Hübsch T, Schoch B, Frings M, Timmann D, et al. 

Reliability and validity of the scale for the assessment and rating of ataxia: a 

study in 64 ataxia patients. Mov Disord. 2007;22:1633-7. 

24 Schmitz-Hübsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu 

R, et al. Responsiveness of different rating instruments in spinocerebellar 

ataxia patients. Neurology. 2010;74:678-84. 

25 Chan E, Charles P, Ribai P, Goizet C, Marelli C, Vincitorio CM, et al. 

Quantitative assessment of the evolution of cerebellar signs in spinocerebellar 

ataxias. Mov Disord. 2011. doi: 10.1002/mds.23531. 

26 Gazulla J, Benavente I. Single-blind, placebo-controlled pilot study of 

pregabalin for ataxia in cortical cerebellar atrophy. Acta Neurol Scand. 

2007;116:235-8. 

27 Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a brief 

ataxia rating scale (BARS) based on a modified form of the ICARS. Mov 

Disord. 2009;24:1820-8 

28 Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, et al. Multiple 

System Atrophy Study Group. Development and validation of the Unified 

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Schmahmann%20JD%22%5BAuthor%5D
http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gardner%20R%22%5BAuthor%5D
http://www.ncbi.nlm.nih.gov/pubmed?term=%22MacMore%20J%22%5BAuthor%5D
http://www.ncbi.nlm.nih.gov/pubmed?term=%22Vangel%20MG%22%5BAuthor%5D
javascript:AL_get(this,%20'jour',%20'Mov%20Disord.');
javascript:AL_get(this,%20'jour',%20'Mov%20Disord.');


130 
 

Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19:1391-

402. 

29 Schwab R, England A. Projection technique for evaluating surgery in 

Parkinson‘s disease. In: Gillingham F, Donaldson I, editors. Third symposium 

on Parkinson‘s disease. Edinburgh: Livingstone; 1969. p 152–75. 

30 Geser F, Seppi K, Stampfer-Kountchev M, Köllensperger M, Diem A, 

Ndayisaba JP, et al. The European Multiple System Atrophy-Study Group 

(EMSA-SG). J Neural Transm. 2005;112:1677-86. 

31 Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires 

M, et al. Progression of multiple system atrophy (MSA): a prospective natural 

history study by the European MSA Study Group (EMSA SG). Mov Disord. 

2006;21:179-86. 

32 May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, et al. 

Potential outcome measures and trial design issues for multiple system 

atrophy. Mov Disord. 2007;22:2371-7. 

33 Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. 

Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical 

symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 

2010;25:97-107. 

34 Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn NP, Mathias C, et 

al. Safety and tolerability of growth hormone therapy in multiple system 

atrophy: a double-blind, placebo-controlled study. Mov Disord. 2007;22:1138-

44. 



131 
 

35 Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, et al. 

Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. 

Neurology. 2005;64:1261-2. 

36 Lynch DR, Farmer JM, Tsou AY, Perlman S, Subramony SH, Gomez CM, et 

al. Measuring Friedreich ataxia: complementary features of examination and 

performance measures. Neurology. 2006;66:1711-6. 

37 Friedman LS, Farmer JM, Perlman S, Wilmot G, Gomez CM, Bushara KO, et 

al. Measuring the rate of progression in Friedreich ataxia: implications for 

clinical trial design. Mov Disord. 2010 Mar 15;25(4):426-32. 

38 Kieling C, Rieder CR, Silva AC, Saute JA, Cecchin CR, Monte TL, et al. A 

neurological examination score for the assessment of spinocerebellar ataxia 3 

(SCA3). Eur J Neurol. 2008;15:371-6. 

39 Jardim LB, Hauser L, Kieling C, Saute JA, Xavier R, Rieder CR, et al. 

Progression rate of neurological deficits in a 10-year cohort of SCA3 patients. 

Cerebellum. 2010;9:419-28.  

40 Schmitz-Hübsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. 

Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia 

symptoms. Neurology. 2008;71:982-9. 

41 Després C, Lamoureux D, Beuter A. Standardization of a neuromotor test 

battery: the CATSYS system. Neurotoxicology. 2000 Oct;21(5):725-35. 

42 Aguilar D, Sigford KE, Soontarapornchai K, Nguyen DV, Adams PE, Yuhas 

JM, Tassone F, Hagerman PJ, Hagerman RJ. A quantitative assessment of 

tremor and ataxia in FMR1 premutation carriers using CATSYS. Am J Med 



132 
 

Genet A. 2008 Mar 1;146A(5):629-35. 

43 Allen EG, Juncos J, Letz R, Rusin M, Hamilton D, Novak G, Shubeck L, 

Tinker SW, Sherman SL. Detection of early FXTAS motor symptoms using the 

CATSYS computerised neuromotor test battery. J Med Genet. 2008 

May;45(5):290-7. Epub 2008 Jan 30. 

44 Juncos JL, Lazarus JT, Graves-Allen E, Shubeck L, Rusin M, Novak G, 

Hamilton D, Rohr J, Sherman SL. New clinical findings in the fragile X-

associated tremor ataxia syndrome (FXTAS). Neurogenetics. 2011 

May;12(2):123-35. Epub 2011 Jan 29. 

45 Assadi M, Leone P, Veloski JJ, Schwartzman RJ, Janson CG, Campellone 

JV. Validating an Ataxia Functional Composite Scale in spinocerebellar ataxia.  

J Neurol Sci. 2008 May 15;268(1-2):136-9. Epub 2008 Jan 11. 

46 du Montcel ST, Charles P, Ribai P, Goizet C, Le Bayon A, Labauge P, et al. 

Composite cerebellar functional severity score: validation of a quantitative 

score of cerebellar impairment. Brain. 2008;131:1352-61. 

47 Schmitz-Hübsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Saccà F, et 

al. SCA Functional Index: a useful compound performance measure for 

spinocerebellar ataxia. Neurology. 2008 ;71:486-92. 

48 Cano SJ, Riazi A, Schapira AH, Cooper JM, Hobart JC. Friedreich's ataxia 

impact scale: a new measure striving to provide the flexibility required by 

today's studies. Mov Disord. 2009;24:984-92. 

49 Streiner DL and Norman GR. Health Measurement Scales: A practical guide 



133 
 

to their development and use. Oxford, Oxford University Press, 2008 

50 Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of 

clinical significance employed in randomized controlled trials of drugs for 

dementia. J Am Geriatr Soc. 2009 Mar;57(3):536-46. Epub 2009 Jan 29. 

51 Pulst SM. Ataxia rating scales in the balance. Nat Clin Pract Neurol. 

2007;3:119. 

 

Tables: 

Table 1. Clinical scales used in ataxias: classification, range, validation, time needed 

for application, and studies of natural history, sensitivity to change and clinical trials 

performed with each scale. 

 

  

 

 



134 
 



135 
 

 

  



136 
 

. Capítulo 5 - A randomized, phase 2/3 trial of lithium carbonate 

in Machado-Joseph disease. 

 

  



137 
 

Title: A randomized, phase 2/3 trial of lithium carbonate in Machado-Joseph 

disease. 

Jonas Alex Morales Saute
1,7

, MD, PhD,; Raphael Machado de Castilhos
7,10

, MD, 

MsC; Thais Lampert Monte
8
, MD, MsC; Artur Francisco Schumacher-Schuh

2,8
, MD, 

MsC; Karina Carvalho Donis
7
, MD; Rui D‘Ávila

7
, MD; Gabriele Nunes Souza

7
; Aline 

Dutra Russo
7
; Gabriel Vasata Furtado

2
, MsC; Tailise Conte Gheno

2
, MsC; Diogo 

Onofre Gomes de Souza
4
, MD, PhD; Luis Valmor Cruz Portela

4
, PhD; Maria Luiza 

Saraiva Pereira
2,4,7,10

, PhD; Suzi Camey
3,6

, PhD;  Vanessa Bielefeld Leotti Torman
6
, 

MsC; Carlos R. M. Rieder
1,8,9

, MD, PhD; Laura Bannach Jardim
1,5,7,10*

, MD, PhD.
 

1
Post-Graduate Programs in Medical Sciences, 

2
Genetics and Molecular Biology and 

3
Epidemiology; and  Departments of 

4
Biochemistry, 

5
Internal Medicine and 

6
Statistics, 

Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; 
7
Medical 

Genetics and 
8
Neurology Services, Hospital de Clínicas de Porto Alegre (HCPA), 

Porto Alegre, RS, Brazil; 
9
Neurology Department, Universidade Federal de Ciências 

da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil; 
10

Instituto Nacional 

de Genética Médica Populacional (INAGEMP). 

 

* Corresponding author: Laura Bannach Jardim 

Medical Genetics Service, Hospital de Clínicas de Porto Alegre, 

Rua Ramiro Barcelos 2350, 

Zip Code 90.035-903, Porto Alegre, Brazil 

e-mail: ljardim@hcpa.ufrgs.br  



138 
 

Abstract 

Objective: Based on findings in pre-clinical models of polyglutamine disorders, we 

have assessed safety and effectiveness of lithium carbonate (0.5-0.8mEq/L) in 

patients with MJD/SCA3. 

Methods: A phase 2/3 single center, double-blind, parallel, placebo-controlled trial 

was conducted (ClinicalTrials.gov,NCT01096082). Patients, caregivers, and all study 

staff, but pharmacists and principal investigators, were masked to treatment 

assignment. Between May and September, 2011, independently ambulatory 

MJD/SCA3 patients with ? 10 years of disease duration were randomly assigned 

(1:1, variable size blocks, stratified by CAGexp) by computer-generated 

randomisation sequence. Primary safety end-point (24 weeks) was the difference in 

the total number of adverse events (AE) and of effectiveness (48 weeks), the 

difference in the variation of NESSCA scale between groups. Analysis was by 

intention-to-treat (ITT). 

Findings: Sixty-two patients were assigned to treatment groups (31/31 

placebo/lithium). Sixty patients (31/29 placebo/lithium) were analysed according to 

ITT. After 24 weeks, 169 AE were reported, 50.3% in lithium group (p=1.00). After 48 

weeks, placebo group had a non-significant larger progression in NESSCA (0.35 

points, 95% CI -1.0 to 1.7, p=0.222) and SARA scales (0.96 points, 95% CI -0.46 to 

2.38, p=0.329). Lithium group had significantly slower progression after 48 weeks in 

gait ataxia severity (p=0.008), PATA rate (p=0.002), Click Test ND (p=0.023), SCAFI 

(p=0.015) and CCFS (p=0.029). 

Interpretation: Lithium is safe, but had no significant effect on NESSCA progression 

of MJD/SCA3. In contrast, lithium significantly slowed the progression of several 

secondary outcomes all related to ataxic manifestations. These results open new 

perspectives for treatment of MJD/SCA3 and other polyglutamine disorders. 

 

  



139 
 
Introduction 

Machado-Joseph Disease [OMIM#109150], also known as spinocerebellar ataxia 

type 3 (MJD/SCA3), is an autosomal dominant neurodegenerative disease caused by 

a CAG repeat expansion (CAGexp) at ATXN3 gene.
1
 CAGexp size, as in other 

polyglutamine (polyQ) disorders, inversely correlates with age of disease onset and 

directly correlates with disease severity.
2,3,4

  

MJD/SCA3 is the most common SCA worldwide, affecting 3.5:100,000 individuals in 

South Brazil.
5,6

 The clinical picture is composed of adult-onset cerebellar ataxia 

commonly accompanied by progressive external ophthalmoplegia, dysarthria, 

dysphagia, pyramidal signs, dystonia, rigidity, and distal muscles atrophy.
3,4,7,8

 As 

disease progresses, patients become confined to a wheelchair and later bedridden.
9
 

No effective treatment for SCAs is currently available. Case series and small trials of 

potential symptomatic or disease progression modifier medications, as anxiolytics, 

antidepressants, cholinesterase inhibitors, and antiepileptic drugs, have shown 

limited efficacy or conflicting results. A recent double-blind randomized trial with 

varenicline treatment for twenty SCA3 patients also showed non-conclusive results, 

with a short course of treatment and relatively unbalanced randomized groups.
10 

 

Therapeutic strategies for polyQ diseases might focus on single disease specific 

mechanisms or in class-wide therapeutic targets as the general toxic mechanism 

triggered by expanded polyQ. PolyQ disease proteins share their propensity to 

misfold, oligomerize, and form intracellular aggregates.
8
 Lithium has been shown to 

exert neuroprotective effects in numerous models of neurodegeneration including at 

least two PolyQ diseases: Huntington Disease (HD)
11,12,13,14 

and SCA1.
15

 

Neuroprotective effects of lithium were mainly attributed to the inhibition of glycogen 

synthase kinase-3? (GSK-3?).
14,15,16

 GSK-3? inhibition increases the expression of 

anti-apoptotic proteins and neurotrophins.
17,18,19

 Lithium also acts on cellular protein 

quality control systems increasing expression of chaperones
20

 and promoting 

autophagy;
21

 and on epigenetics mechanisms modulating histone methylation
22

 and 

acetylation.
23

 In an open label trial, high doses of lithium were reported to be 

moderately tolerated in twelve SCA1 patients
24

 and, in a case report, a SCA2 patient 

treated during thirty years with lithium for mood disorder presented a less severe 



140 
 

phenotype than her affected relatives.
25

 In contrast, there are several reports of 

lithium toxicity in non-ataxic patients inducing cerebellar dysfunction.
26

 

Considering the above neuroprotective actions of lithium, we aimed to assess safety 

and effectiveness of lithium carbonate in patients with MJD/SCA3.  

Methods 

Patients 

A randomised, double-blind, parallel, placebo controlled trial of lithium was done in 

patients with MJD/SCA3. From May to September, 2011, patients were enrolled in a 

single center at Hospital de Clínicas de Porto Alegre (HCPA), the only Neurogenetic 

Disorders center in the State of Rio Grande do Sul, the southernmost State of Brazil. 

Patients were recruited from the MJD/SCA3 database of the Neurogenetic and 

Movement Disorders outpatient clinic of HCPA.  

Patients were eligible if they were aged 16 years or more and had a molecular 

diagnosis of MJD/SCA3, as described elsewhere.
27

 Inclusion criteria were the ability 

to provide informed consent and comply with study procedures; disease duration of 

10 years or less from symptoms onset; and being able to walk independently (the 

use of canes, sticks or stroller was allowed). Exclusion criteria were the  presence of 

any of the following: known sensitivity or intolerability to lithium; exposure to any 

investigational drug within the past 30 days; sodium-free diet; previous history of 

thyroid disorder (hyper or hypothyroidism); previous history of other neurologic or 

systemic significant medical disorder (cardiac, pulmonary, renal, hepatic, 

hematological, active malignancy, or infectious disease); being pregnant, breast 

feeding or not agreeing with the use of contraception during the study; current or 

previous alcohol or other drug abuse during the last year, except for cigarette 

smoking; use of thiazide diuretics, ACE inhibitors or angiotensin receptor blockers; 

chronic use of digoxin, indomethacin and piroxicam; use of  aminophylline, 

phenothiazine antipsychotics, haloperidol and sibutramine; plasma levels of thyroid 

stimulating hormone more than 20% above the upper limit of normal range; 

creatinine, alanine transaminase (ALT) or aspartate transaminase (AST) levels 

above the upper limit of normal range; significant cardiac conduction abnormality on 

screening electrocardiogram.  



141 
 
Randomisation and masking 

Patients were assessed for eligibility at the screening visit by the study physicians. 

Eligibility was confirmed by the principal executor investigator (JAMS) after the result 

of laboratory evaluation.  

An independent pharmacist (MLSP) generated the randomisation list with Random 

Allocation Software (Isfahan University of Medical Sciences, Iran).  Patients were 

randomly assigned 1:1, in blocks of variable sizes of 4 or 6, stratified by CAGexp (? 74 

or &gt; 74 CAGs). Two lists of random four-digit number were generated, one for each 

stratum. The Principal Investigators (PIs - LBJ and CRMR) and the responsible for 

study drugs dispensation (GVF and TCG) have access to the randomisation list 

(unmasked), and none of them had direct contact with patients during the study. GVF 

and TCG assigned the treatment by matching the randomisation number to a 

corresponding treatment from the randomisation code sheet and then dispensed 

either lithium carbonate or placebo. Each randomisation code was placed in 

sequentially numbered, opaque, sealed envelopes in accordance with the 

randomisation list, that were open by the principal executor investigator or study 

nurses after patient was considered eligible.  

Patients, caregivers, physicians, nurses, statisticians, with the exception of site 

pharmacists and PIs (MLSP, GVF, TCG LBJ and CRMR) were masked to treatment 

assignment. 

Outcomes 

Primary Outcomes: 

Safety - The difference in total number of AEs between study groups 24 weeks after 

the beginning of maintenance phase.  

Effectiveness- The difference in the variation of NESSCA - Neurological Examination 

Score for the Assessment of Spinocerebellar Ataxia
28

 from baseline to 48 weeks after 

the beginning of maintenance phase between study groups. 

Secondary Outcomes: 



142 
 

Safety – Difference between groups in the: 1) total number of AEs during the 48 

weeks; 2) number of mild, moderate and severe AEs. 

Effectiveness – Difference between groups in the variation of NESSCA from baseline 

to 24 weeks and of the following instruments from baseline to 24 and 48 weeks: 1) 

SARA - Scale for the Assessment and Rating of Ataxia;
29

 2) gait ataxia severity 

defined as 0, absent; 1, minimal: only while walking on toes, heels or in tandem; 2, 

moderate: gait autonomy preserved; 3, inability to walk without help; 4, total inability 

to walk: the patient being wheelchair-bound or bedridden;
28

 3) the z scores of the 

quantitative ataxia instruments 9-Hole Pegboard Test (9-HPT), 8m Walking-time 

(8MW), Click Test and PATA rate;
30

 4) the composite quantitative ataxia scores SCA 

Functional Index (SCAFI)
31 

and Composite Cerebellar Functional Score (CCFS);
32

 5) 

the functional status Barthel Index;
33

 and 6) the Portuguese versions of the quality of 

life instrument WHOQOL bref
34

 and of (BDI) Beck Depression Inventory.
35

 Difference 

between groups in the mean Patients‘ Clinical Global Impression of change (PGI) 

was assessed after 48 weeks.
36

 The comparison of disease serum biomarkers 

between groups was also performed during 12, 24 and 48 weeks of treatment and 

will be reported separately. 

Other planned analysis – to analyze the interaction of the number of CAGexp, 

according to randomization strata, and of lithium serum levels with patient response 

to treatments in NESSCA, SARA and composite quantitative ataxia scores. 

Procedures 

Each patient had two responsible physicians during the study. The research assistant 

physician, who evaluated adverse events and reviewed laboratory exams (except for 

serum lithium levels), and the evaluating physician, who only performed the 

effectiveness outcome instruments evaluations. No changes of physicians were 

allowed. Each assistant and evaluating physician were trained on study procedures 

and on evaluation instruments before the study start.  

After being assigned as eligible, patients returned for the baseline visit when they 

received randomisation and study numbers. Vital signs, weight, NESSCA, SARA, 

gait ataxia severity, 9-HPT, 8MW, Click Test, PATA rate, Barthel Index, WHOQOL 

bref and BDI were assessed at the baseline visit. For patients who were unable to 

perform 8MW the 10-fold value of the maximal performance time was attributed (i.e., 



143 
 

1,800s).
31 

After baseline, patients entered the titration phase which consisted of every 

week visits with lithium dosage until the patient achieved the target (real or sham). A 

maximum of seven weeks for this phase was established. When completed titration 

the maintenance phase started (Week 0) which consisted of telephone calls by the 

assistant physician to assess AEs every 2 weeks until week 12. At week 12, patient 

came for consultation and repeated safety laboratory exams and serum lithium 

levels, which were repeated thereafter every 12 weeks. After week 12 until the end of 

week 48 the assistant physician performed a telephone call monthly. At week 24 and 

48 the evaluating physician performed the same protocol assessed at baseline visit. 

A maximum variation of ± 4 weeks from the planned evaluation date was allowed. 

Intervention 

Lithium Carbonate (Carbolitium®) was donated by Eurofarma (São Paulo, Brazil) and 

dispensed as 300mg tablets. Identical matching placebo tablets were produced and 

purchased from the Central Pharmacy of Hospital das Clínicas, Faculty of Medicine, 

University of Sao Paulo.   

Patients were initially given one tablet of the study drug at night; when taking more 

than one tablet, the study drug was given twice daily. Drug concentrations were 

measured weekly in the titration phase to achieve a serum lithium concentration of 

0.5–0.8mEq/L and afterwards every three months. Lithium concentrations were 

recorded for all patients 11:30-12:30hrs after the last dose. Lithium doses were 

adjusted centrally by the unmasked PIs and were not available to other study and 

hospital staff. If concentrations were less than 0.5mEq/L, dose was increased by one 

tablet per day. For patients taking an odd number of tablets, the extra tablet was 

taken in the evening. If concentrations were between 0.8mEq/L and 1.2mEq/L, the 

dose was decreased by half or one tablet.  If concentrations were greater than 

1.2mEq/L, treatment would be suspended and lithium concentrations would be tested 

3–5 days later, at which time treatment was either restarted at half the previous dose. 

To maintain masking of patients and investigators throughout the study, sham dose 

modifications were done by LBJ and CRMR for patients assigned to placebo. When 

patient achieved the target (or sham) dosage, lithium serum levels were repeated 

after one week in order to confirm stable levels. Every dosage change was 

communicated by the PIs to two nurses (GNS e ADR) who were blind to treatment 

assignment and communicate the posology change to patients. Patient‘s assistant 



144 
 

physician could also change the dosage of study drug in accordance to adverse 

events (AEs). After any study drug changes during the study, lithium levels were 

repeated after one week.  

During titration phase each individual received a recipient with sufficient tablets for a 

month plus 20% additional tablets. During maintenance phase each individual 

received a recipient with sufficient tablets for three months plus 20% additional 

tablets. For per-protocol analysis the individual was considered adherent if he/she 

ingested 80 to 120% of the estimated number of tablets for the period.   

Sample Size 

The trial was designed to have 80% power to detect a 50% decrease in the rate of 

decline in NESSCA, considering a standardized response mean (SRM) of 0.8 and a 

Type I error of 5%, if 52 patients were recruited in total. However it should be stated 

that there is no previous data on SRM for NESSCA and that scales showing a similar 

rate of progression, as SARA, in subsequent studies showed a SRM of 0.41 after 1 

year.
30

 Therefore the study power might have been overestimated.  

Statistical Analysis  

Distributions of baseline characteristics, adverse events, and laboratory 

abnormalities were compared using chi-square or Fisher‘s exact test and t tests. 

Analysis was by intention to treat (ITT) and per-protocol. All randomized patients who 

received at least one dose of study drug and who came to at least one follow-up 

endpoint assessment were eligible for inclusion in the primary effectiveness analysis 

on ITT. Per protocol analysis was performed with patients who took the study drug 

during the whole study, maintained lithium levels of 0.5 to 0.8mEq/L (only for lithium 

group) and were considered adherent. Patients who were unable to perform the 

8MW task in all evaluations (baseline, 24 weeks and 48 weeks) were excluded from 

the ITT and per-protocol analysis for this end-point as well as for SCAFI.  

Analysis was made by Generalized Estimation Equation (GEE) analysis treating the 

measures in 24 and 48 weeks as response and adjusting by baseline measures. To 

incorporate correlation between measures of the same patient, the exchangeable 

structure was considered for the working correlation matrix. For subgroup analyses, 

the interactions between the subgroups and groups and time were added to the 



145 
 

model. Bonferroni correction was used for multiple comparisons. Correlations of 

serum lithium levels with effectiveness outcomes were performed with Pearson 

correlation test. 

All analysis was made by two statisticians (VBLT, SC) who were blind for treatment 

allocation. After the final analysis of the primary end-point at 48 weeks the 

statisticians were unblinded in order to perform the analysis of the interaction of 

lithium serum levels and patient response to treatment.  

The estimated responses in 72 weeks were predicted considering the mean change 

from baseline to 48 weeks for each group. Then the GEE model was adjusted for the 

primary endpoint to see if statistical significance would be reached, if not, then the 

study would be stopped for futility related to study design. 

SPSS/PASW version 18 was utilized for all analysis. 

Ethics and Registration 

The study was approved by the institutional (GPPG-HCPA) and the Brazilian 

National Bioethics Commission (CONEP) and all subjects provided written consent 

before commencement of study procedures. The study is registered at 

ClinicalTrials.gov, NCT01096082. 

Role of funding source 

The financial support for the study came from the Brazilian funding agencies 

FAPERGS, CNPq and FIPE-HCPA. The pharmaceutical company Eurofarma only 

donated lithium carbonate tablets, with no further support to the study. Eurofarma 

and the public Brazilian agencies had no involvement in the study design and 

protocol, collection, analysis, and interpretation of data, in the writing of the report, or 

in the decision to submit the paper for publication. JAMS, CRMR and LBJ had full 

access to all the final data in the study and had final responsibility for the decision to 

submit for publication.  

Results 

Between May and September, 2011, 92 MJD/SCA3 patients were screened (Fig 1) 

and 62 were randomly assigned to receive lithium (n=31) or placebo (n=31). 

Demographic characteristics, clinical features and values of primary and secondary 



146 
 

outcome variables were similar in the treatment groups at baseline (Table 1). 

Concomitant use of other medical treatments was also similar between groups 

(Supplemental Table 1). Patients were followed for at least 48 weeks until the study 

was stopped for futility, in November, 2012. The study would be underpowered with 

the current population and design to detect a significant effect in the primary 

effectiveness endpoint if continued until 72 weeks.  

Safety Outcomes:  

Primary Endpoint  

The total number of AEs, at 24 weeks after the beginning of maintenance phase was 

of 85 (50.3%) in the lithium group and 84 (49.7%) in the placebo group (p=1.00).  As 

lithium carbonate was proved to be safe in MJD/SCA3 patients at this point, the study 

continued, aiming to assess lithium effectiveness after 48 weeks of treatment. 

Secondary Endpoints 

The total number of AEs after 48 weeks was of 95 events (50.8 %) in the lithium 

group and 92 events (49.2 %) in the placebo (p=0.884). There was also no significant 

difference among AEs severity between groups (Table 2). The frequency of most 

common AEs (present in &gt;5 of patients) were also similar between lithium and 

placebo treated patients (p=0.427), with the exception of thyroid and erectile 

dysfunction and falls, that seemed to occur more frequently in the lithium group 

(Supplemental Table 2).   

Four serious AE were reported. Two of them were related to the increase of 

depressive symptoms. One patient presented worsening of BDI and suicidal ideation 

(placebo group) with significant risk and another an unsuccessful suicide attempt 

(lithium group) with a major intake of benzodiazepines. Both patients were offered 

psychiatric consultation and management with symptom improvement. As depression 

is one of the commonest non-motor MJD/SCA3 manifestations
37

 and both events had 

no clear temporal association with the study drugs, they were considered unrelated 

AEs. Two falls with significant injuries were also reported. The first one happened 

during enrollment and prior to drug start, resulting in shoulder dislocation (lithium 

group). The other was in the first week of the titration phase, and resulted in coccyx 

fracture (lithium group). Titration was suspended until the patient was discharged 



147 
 

from hospital, and then restarted, with no further related falls. Both AE were also 

considered unrelated to the study drug. 

Protocol adhesion 

Six patients discontinued the allocated drug. Two withdrew informed consent soon 

after baseline assessment for reasons unrelated to AE and were excluded from all 

analysis (both on lithium group). Demographic characteristics between groups 

remained similar with these two exclusions. The other four completed all follow ups. 

Two of them stopped the study medication in the end of titration and beginning of 

maintenance phases due to muscular pain (lithium group) and balance worsening 

(placebo). One patient on lithium and one on placebo group discontinued treatment 

due to personal reasons, unrelated to AEs.  

Two additional patients in the lithium group were not included on per-protocol 

analysis. One of them remained without taking or with lithium levels under the target 

for 75 days (22% of maintenance phase) due to leg pain (severe, non-serious and 

probably drug-related AE). The second patient has only tolerated lithium levels of 

0.3mEq/L or less, with higher concentrations being associated with tremor (severe, 

non-serious and definitely drug-related AE). Therefore per-protocol analysis was 

done on 54 patients (87% of randomized patients), 25 on lithium and 29 on placebo 

treatment. ITT analysis included 60 patients (97% of randomized patients), 29 on 

lithium and 31 on placebo treatment.  

 The mean lithium dose was of 990 (600 to 1650) mg/day or 3.3 (2 to 5.5) 

tablets/day. The mean placebo dose was of 3.4 (2 to 5) tablets/day. During 

maintenance phase, plasma concentrations of lithium for both groups were measured 

on average 5.5 ± 0.7 times per patient. The mean lithium concentration was of 0.57 ± 

0.09 (range: 0.3 to 1.4); mean value per patient ranged: 0.3 to 0.68mEq/L) in the 

lithium group. No traces of serum lithium levels were found in the placebo group. In 

one occasion, lithium concentration reached a toxic level (1.4mEq/L) that was time 

related to the onset of tremor, which subsided three months after dosage correction. 

Patient‘s adherence was adequate: lithium and placebo groups ingested 89 and 93% 

of the estimated number of tablets (p=0.10) 

Effectiveness Outcomes 



148 
 

Table 3 details the main results on ITT after 24 and 48 weeks assessments for the 

primary and secondary effectiveness outcomes.  

In the next section, we will describe the results of the ITT analysis. Per protocol data 

will be mentioned for the primary endpoint and afterwards only when results differ 

from ITT. For detailed per-protocol analysis results see Supplemental Table 3.  

Primary Endpoint 

NESSCA 

Although placebo group has worsened more than lithium after 24 and 48 weeks - 

0.93 (95% CI -0.12 to 1.98) and 0.35 points (95% CI -1.0 to 1.7), respectively -, these 

differences were not significant (p=0.222 - Fig 2A). On per-protocol analysis, the 

overall 48 weeks differences in NESSCA between groups remained non-significant 

(p=0.116). After 24 weeks, there was an increase in NESSCA progression of 0.91 

(95% CI -0.15 to 1.97) and after 48 weeks of 0.72 points (95% CI -0.65 to 2.09) 

larger in placebo than in lithium-treated group. 

Futility analysis 

The futility analysis estimated that NESSCA would worsen 0.56 points (95% CI -0.51 

to 1.69) more in the placebo than in the lithium group, a non-statistically significant 

difference, after 72 weeks (p=0.295).  

Secondary Endpoints 

SARA and Gait Ataxia Severity 

After 24 and 48 weeks of treatment, the placebo group worsened 0.26 (95% CI -1.02 

to 1.53) and 0.96 points (95% CI -0.46 to 2.38) more than the lithium group in SARA 

(Fig 2B). However, these differences were not statistically significant (p=0.329). 

Severity of gait ataxia progressed significantly less in lithium-treated group in the 

overall 48 weeks (p=0.008). After 24 and 48 weeks, the worsening of gait ataxia 

severity was 0.26 (95% CI 0.03 to 0.48) and 0.32 points (95% CI 0.07 to 0.57) larger 

in placebo than in lithium group (Fig 2C).  

Quantitative functional tasks (8MW, PATA rate, 9HPT, Click Test) 



149 
 

8MW worsened faster in placebo than in lithium group after 24 (3.62 z scores, 95% 

CI -11.4 to 18.66) and 48 weeks of treatment (14.63 z scores, 95% CI -3.09 to 

32.36), although not statistically significant (p=0.244, Fig 3A). On per-protocol 

analysis these differences became significant (p=0.026), with a faster progression in 

placebo group after 48 weeks (19.39 z scores, 95% CI 4.37 to 34.41, Supplementary 

Table 3). PATA rate progressed differently between groups in the overall 48 weeks 

(p=0.002). After 24 (-0.37 z scores, 95% CI -0.65 to -0.08) and 48 weeks (-0.44 z 

scores, 95% CI -0.73 to -0.14), the placebo group worsened more than lithium group 

(Fig 3B). No significant difference between groups on dominant (9HPT D; p=0.074, 

Fig 3C) and non-dominant hand 9HPT (9HPT ND; p=0.619) was found. A near 

significant dominant (p=0.051) and a significant non-dominant hand Click Test (Click 

Test ND - p=0.023, Fig 3D) progression was found in the overall 48 weeks between 

groups. Click Test ND seemed to worsen faster in placebo than in lithium group after 

24 (0.57, 95% CI -0.03 to 1.17) and 48 weeks (0.38, 95% CI -0.06 to 0.82). On per-

protocol analysis, the differences in Click Test D (p=0.210) and Click Test ND 

(p=0.137) between groups were not significant. 

Composite Scores (SCAFI, CCFS) 

The mean SCAFI progression was significantly different between groups in the 

overall 48 weeks (p=0.015, Fig 3E). After 24 weeks of treatment there was less 

worsening (0.20, 95% CI -0.003 to 0.41) in lithium than in placebo group, which 

became significant after 48 weeks (0.32, 95% CI 0.06 to 0.57). CCFS progressed 

differently between groups in the overall 48 weeks (p=0.029, Fig 3F). After 24 weeks 

of treatment, there was a mean worsening of 0.03 (95% CI -0.002 to 0.06) units 

larger in placebo than in lithium group that became significant after 48 weeks (95% 

CI 0.003 to 0.05). On per-protocol analysis, the difference between groups in CCFS 

progression was not observed (p=0.155). 

Mood, disability and Quality of Life (BDI, Barthel Index and WHOQOL-bref) 

During the 48 weeks of follow up, there were no significant differences between 

groups on BDI (p=0.420), Barthel Index (p=0.780) and in the physical (p=0.442), 

psychological (p=0.402), social relationships (p=0.209) and environment (p=0.948) 

domains of WHOQOL-bref.  

Patients’ Clinical Global Impression of change (PGI) 



150 
 

After completing 48 weeks of treatment, mean PGI scores of lithium (3.59±1.15) were 

lower than of placebo-treated patients (4.45±1.26) on both ITT (p=0.007, Fig 2D) and 

per-protocol analysis (p=0.042).  

Differences in the slope of progression from 24 to 48 weeks. 

A time-group interaction model showed no differences in the slope of progression 

between groups from 24 to 48 weeks of treatment, for all variables, except 9HPTND 

(p=0.050). These results indicated that the effects (positive, negative or null) were 

already present after 24 weeks of treatment, remaining similar.  

Exploratory analysis 

In order to explore the possibility of a heterogenic pattern of response to lithium 

therapy in the different neurological systems, we performed further analysis on 

NESSCA and SARA items (Table 4).  

NESSCA was subdivided in the following clinically defined sub scores: cerebellar 

(gait ataxia plus limb ataxia); oculomotor (nystagmus plus progressive external 

ophthalmoplegia); pyramidal (pyramidal findings); extrapyramidal (dystonia, rigidity, 

bradykinesia, eyelid retraction plus blepharospasm) and peripheral (fasciculation, 

sensory loss plus distal amyotrophies). The cerebellar sub score of NESSCA 

worsened more in placebo than in lithium group during the overall 48 weeks on ITT 

(p&lt;0.001). After 24 and 48 weeks of treatment, there was a mean progression in 

cerebellar NESSCA of 0.81 (95% CI 0.44 to 1.18, p&lt;0.001) and 0.64 points (95% CI 

0.23 to 1.05, p=0.002) faster in placebo than in lithium group. Neither other NESSCA 

sub scores nor SARA items presented different progressions during the study period, 

see Table 4.  

Planned analysis of interactions 

CAGexp repeats – The randomization strata of ?74 or &gt;74 CAGexp were analyzed 

against the primary and secondary effectiveness outcomes.  

CAGexp strata interacted significantly with NESSCA progression between groups 

(p=0.007). Patients with ?74 CAGexp (n=18) progressed significantly less in the 

lithium group after 24 weeks (-2.87, CI 95% 1.51 to 4.23, p=&lt;0.001), with a trend 

after 48 weeks (-1.87, CI -3.77 to 0.03, p=0.054). There was no difference between 



151 
 

groups in NESSCA progression in patients with &gt;74 CAGexp (N=42) after 24 

(p=0.894) or 48 weeks (p=0.709). However, no significant interaction of NESSCA sub 

scores with CAG strata was found. For instance, cerebellar NESSCA progressed 

significantly less in lithium group both in patients with ? 74 CAGexp (p&lt;0.001 and 

p=0.066; after 24 and 48 weeks, respectively) and &gt;74 CAGexp (p=0.016 and 

p=0.011; after 24 and 48 weeks, respectively). 

There was a trend for the z score of Click Test D to interacted with CAGexp strata 

(p=0.053). Patients with ? 74 CAGexp progressed significantly less in the lithium than 

in the placebo group after 48 weeks (1.03, CI 95% 0.33 to 1.74, p=0.004). There was 

no difference between groups in patients with &gt; 74 CAG exp after 24 (p=0.415) or 48 

weeks (p=0.651). The z score of Click Test ND did not interact with CAGexp strata 

(p=0.468). There was a trend for a CCFS interaction with CAGexp (p=0.069). Only 

patients with ? 74 CAGexp progressed significantly less in the lithium than in the 

placebo group, with a trend after 24 weeks (0.05, CI 95% -0.006 to 0.12, p=0.076) 

that became significant after 48 weeks of treatment (0.70, CI 95% 0.02 to 0.12, 

p=0.004).  

The only result that significantly favored placebo in the study was the interaction of 

Barthel index with CAGexp (p=0.013). Patients with ? 74 CAGexp progressed 

significantly less in the placebo group than the lithium group only after 48 weeks (-

6.68, CI 95% -11.98 to -1.39, p=0.013). 

There was no significant interaction of CAGexp with the progressions of SARA 

(p=0.293), gait ataxia severity (p=0.934), 8MW (p=0.184), PATA rate (p=0.808), 

9HPTD (p=0.824) and 9HPTND (p=0.684), SCAFI (p=0.345), BDI (p=0.421) and the 

physical (p=0.484), psychological (p=0.816), social relationships (p=0.597) and 

environment (p=0.668) domains of WHOQOL-bref.  

Lithium levels 

Average lithium levels obtained in per-protocol population under lithium therapy were 

tested against all outcomes under study. The only associations found were those 

with total NESSCA (R=0.41, p=0.037, Pearson) and its extrapyramidal subscores 

(R=0.40, p=0.04) progressions. In other words, the higher the average lithium levels 

of a given patient, the faster was the worsening in the extrapyramidal subscore of 

NESSCA. 



152 
 

Blinding 

Eleven months after the study beginning, the research assistant physicians where 

asked about their impression of which drug each of their patients was taking. In the 

lithium group, 51.7% were judged as taking lithium and 48.3% placebo. In the 

placebo group 32.3% were judged as taking lithium and 67.7% as taking placebo 

(p=0.2), indicating that study masking was effective.  

Discussion 

Lithium carbonate was safe in patients with MJD/SCA3 but did not substantially 

modify the disease progression as measured by NESSCA. The study was completed 

after 48 weeks of follow up, and it was stopped based on a futility analysis related to 

the study design. This was a single center study in which the maximum capacity of 

following patients with the chosen eligibility criteria was close to the number of the 

recruited patients. Considering this, our futility analysis was performed in a time 

based perspective rather than increasing the number of participants. This analysis 

concluded that the study would be underpowered with the current population and 

design to detect a significant effect in the primary effectiveness endpoint if continued 

until 72 weeks. However, even being a single center trial, the present study is the 

largest and longest randomized clinical ever performed for MJD/SCA3. 

We have not found a significant effect of lithium treatment in the semiquantitative 

scales NESSCA - a multisystem neurological-examination based evaluation - and 

SARA - a scale based only on ataxic manifestation. However, both scales depicted a 

trend for an effect favoring lithium. The quantitative ataxia scores of gait (8MW, on 

per-protocol analysis), word speed (PATA rate), and non-dominant finger pointing 

coordination (Click Test ND), all had significant slower progressions with lithium 

treatment after 48 weeks. And in consequence, both composite scores of the 

quantitative measures, SCAFI (based on 8MW, 9HPT and PATA rate) and CCFS 

(based on Click Test D and 9HPTD) also showed a slower progression in the lithium 

group during the same period. The main advantage of these quantitative 

performance ataxia scales is to reliably detect small clinical changes over time, in a 

continuous measure, that theoretically provide better sensitivity and responsiveness 

to the scale. Lithium-treated patients also reported lower (better) PGI scores than 

placebo indicating that a subjective difference in disease progression between 



153 
 

groups was felt by patients and that the results obtained with quantitative ataxia 

scales may be clinically relevant.  

Gait ataxia severity also progressed slowly in lithium treated patients during both 24 

and 48 weeks. In the exploratory analysis of NESSCA, the cerebellar sub score also 

presented a slower progression in the lithium group. These results are in accordance 

to those obtained with the quantitative ataxia scores, and strongly suggest that 

lithium might be effective in cerebellar function. In contrast, lithium had no significant 

effect on oculomotor, pyramidal, extrapyramidal and peripheral subscores of 

NESSCA.  The lack of effectiveness on these domains might explain the non-

significant result in the total scale. Of note, cerebellar NESSCA accounted for 32.4% 

and 23.6% of total NESSCA for patients with ?74 and &gt;74 CAGexp, respectively. This 

difference may explain why lithium was effective in total NESSCA only for patients 

with ?74 CAGexp, while in cerebellar NESSCA lithium was effective for both strata. 

After 48 weeks, the mean progression of NESSCA in the placebo group was 1.45 

points. While in this period cerebellar NESSCA (range: 0-7, 2 items) progressed 0.74 

(SE 0.13) points, the sum of pyramidal, extrapyramidal and peripheral NESSCA 

(range: 0-19, 9 items) only progressed 0.23 (SE 0.47) points in the placebo group. 

Therefore, we could not exclude a lithium effect in some of these symptoms since 

they did not progressed significantly during the study. Extracerebellar signs in SCAs 

contribute importantly to patients‘ handicap, which was one of the reasons for 

choosing NESSCA as the primary effectiveness endpoint. Recent evidence from the 

Inventory of Non-Ataxia Signs (INAS) showed that extracerebellar features, and not 

necessarily the scales, present an unsatisfactory responsiveness
38,39

 and therefore 

should be assessed in future clinical trials only as secondary outcomes. Importantly, 

higher lithium concentrations (&gt; than 0.6 mEq/L) were related to a faster progression 

in the extrapyramidal subscore of NESSCA which might have contributed to the 

negative result on the total score. These data indicate that lower lithium 

concentrations ranges should be chosen in future studies.   

The cerebellar function instruments presented similar progression rates in the 

placebo group than the reported natural history of SCAs.
4,38,40

 Negative findings 

occurred with Barthel index and all domains of WHOQOL bref. It is worth to mention 

that lithium showed no effect in BDI, what excludes the possibility that motor 



154 
 

improvements seen in quantitative cerebellar scores could be attributed to an 

antidepressant effect.  

A small number of patients were lost during follow-up. The study dropout rate was 

lower than previous trials with lithium in neurodegenerative disorders, even with 

similar serum levels target.
41

 Most patients were considered adherent, which was 

confirmed with frequent lithium serum levels evaluations in both groups and with the 

counting of the number of tablets that were taken. Therefore, most of ITT and per-

protocol analysis results were similar.  

In conclusion, this randomised, double-blind, placebo controlled trial demonstrated 

safety of lithium treatment in MJD/SCA3 patients, but failed to show a significant 

modification of disease progression in the primary endpoint NESSCA. Several 

secondary outcomes, all related to ataxic manifestations such as gait ataxia severity, 

quantitative tasks and composite scores, presented slower progressions with lithium 

treatment, after 48 weeks. Although a symptomatic effect could not be excluded, 

these results strongly suggest that lithium might be effective against ataxia 

progression in MJD/SCA3. 

Lithium acts on different neuroprotective pathways that may interfere with polyQ 

class-wide pathogenic routes. Future cellular, animal and clinical studies will play a 

significant role to uncover these mechanisms. The present results open the 

perspectives for an effective treatment for MJD/SCA3 and other polyQ disorders. A 

multicentric, randomized clinical trial is warrant in a near future, aiming to confirm 

lithium effectiveness in reducing the progression rate of cerebellar ataxia. 

Contributors 

JAMS and LBJ participated in conception and design of the study. GNS, ADR and 

JAMS provided project management. AFSS, KCD, JAMS, RMC, RD, TLM were the 

research assistant and evaluating physicians. GVF, TCG and MLSP were 

responsible for dispensing medications and provided the molecular diagnoses of 

patients. CRMR and LBJ were responsible for the dosage changes in the study 

drugs. LBJ, DOGS and LVCP were responsible for the study financial support. 

JAMS, LBJ, VBLT and SC contributed to analysis and interpretation of data, and 

writing of the paper. All authors reviewed the paper. 



155 
 
Acknowledgments 

We thank the patients who participated in the study and also the ones who were not 

eligible. We thank HCPA and its Postgraduate Research Group (GPPG) that not only 

provided financial support to the study, but also indirectly turn its realization possible 

by constructing the Center for Clinical Research building. We are grateful to 

Eurofarma for donating lithium carbonate tablets used in this study. We had to thank 

specially to the following workers of HCPA: Andrea Ramos Rambo, Cleber Ferrari, 

Rodrigo Pires de Medeiros, Suzete Guterres Coelho, Tania Alves Braga, Joíza Lins 

Camargo and Rafael Zimmer. We thank José Roberto Goldim for all additional 

ethical consultations and advices during the study.  This study was supported by 

FAPERGS (09/0078-5), CNPq (478888/2010-4), and FIPE-HCPA (09-418). JAMS 

and GVF were supported by CAPES. TCG, ADR, DOGS, LVP, MLSP, CRMR and 

LBJ were supported by CNPq. 

Conflicts of interest 

We have no conflicts of interest. 

 

References  

 

1.  Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene 

for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994;8:221–

228.  

2. Maciel P, Gaspar C, DeStefano AL, et al. Correlation between CAG repeat 

length and clinical features in Machado-Joseph disease. Am J Hum Genet 

1995;57:54–61.  

3. Jardim LB, Pereira ML, Silveira I, et al. Neurologic findings in Machado-Joseph 

disease: relation with disease duration, subtypes, and (CAG)n. Arch Neurol 

2001;58:899–904.  

4. Jardim LB, Hauser L, Kieling C, et al. Progression rate of neurological deficits in 

a 10-year cohort of SCA3 patients. Cerebellum 2010; 9:419–428.  

5. Prestes PR, Saraiva-Pereira ML, Silveira I, et al. Machado-Joseph disease 

enhances genetic fitness: a comparison between affected and unaffected 

women and between MJD and the general population. Ann Hum Genet 2008; 



156 
 

72:57–64.  

6. Sequeiros J, Martins S, Silveira I. Epidemiology and population genetics of 

degenerative ataxias. Handb Clin Neurol 2012;103:227–251.  

7. Dürr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado-

Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 

1996;39:490–499. 

8. Costa M do C, Paulson HL. Toward understanding Machado-Joseph disease. 

Prog Neurobiol 2012;97:239–257.  

9. Kieling C, Prestes PR, Saraiva-Pereira ML, Jardim LB. Survival estimates for 

patients with Machado-Joseph disease (SCA3). Clin Genet 2007;72:543–545.  

10. Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of 

varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. 

Neurology 2012;78:545–550. 

11. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-

3beta inhibitors prevent cellular polyglutamine toxicity caused by the 

Huntington‘s disease mutation. J Biol Chem 2002;277:33791–798.  

12. Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on 

motor behaviour and survival of mice transgenic for the Huntington‘s disease 

mutation. Brain Res Bull 2003;61:375–383.  

13. Berger Z, Ttofi EK, Michel CH, et al. Lithium rescues toxicity of aggregate-prone 

proteins in Drosophila by perturbing Wnt pathway. Hum Mol Genet 

2005;14:3003–3011.  

14. Pouladi MA, Brillaud E, Xie Y, et al. NP03, a novel low-dose lithium formulation, 

is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol 

Dis 2012;48:282–289.  

15. Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, et al. 

Lithium therapy improves neurological function and hippocampal dendritic 

arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 

2007;4:e182.  

16. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen 

synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol 

Sci 2009;110:14–28.  

17. Chuang D-M. The antiapoptotic actions of mood stabilizers: molecular 

mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005;1053:195–204. 

18. Leyhe T, Eschweiler GW, Stransky E, et al. Increase of BDNF serum 



157 
 

concentration in lithium treated patients with early Alzheimer‘s disease. J 

Alzheimers Dis 2009;16:649–56.  

19. De Sousa RT, Van de Bilt MT, Diniz BS, et al. Lithium increases plasma brain-

derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. 

Neurosci Lett 2011;494:54–56. 

20. Bijur GN, Jope RS. Opposing actions of phosphatidylinositol 3-kinase and 

glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J 

Neurochem 2000;75:2401–2408.  

21. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic 

lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052–2057. 

22. McColl G, Killilea DW, Hubbard AE, et al. Pharmacogenetic analysis of lithium-

induced delayed aging in Caenorhabditis elegans. J Biol Chem 2008;283:350–

357.  

23. Kwon B, Houpt TA. Phospho-acetylation of histone H3 in the amygdala after 

acute lithium chloride. Brain Res 2010;1333:36–47.  

24. Lopez GJ, McElroy BA, Considine E, et al. Safety and tolerability of lithium 

carbonate in spinocerebellar ataxia   type 1 (SCA1) patients: Lessons from a 

feasibility study. Mov Disord 2010;25:S194–S194. 

25. Hering S, Achmüller C, Köhler A, et al. Phenotype variability in spinocerebellar 

ataxia type 2: a longitudinal family survey and a case featuring an unusual 

benign course of disease. Mov Disord 2009;24:774–777.  

26. Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-

effectuated neurotoxicity. Clin Neuropharmacol 2005;28:38–49.  

27. Bauer PO, Kotliarova SE, Matoska V, et al. Fluorescent multiplex PCR--fast 

method for autosomal dominant spinocerebellar ataxias screening. Genetika 

2005;41:830–837.  

28. Kieling C, Rieder CRM, Silva ACF, et al. A neurological examination score for 

the assessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 2008;15:371–

376.  

29. Schmitz-Hübsch T, Du Montcel ST, Baliko L, et al. Scale for the assessment and 

rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717–

1720. 

30. Saute JAM, Donis KC, Serrano-Munuera C, et al. Ataxia rating scales--

psychometric profiles, natural history and their application in clinical trials. 

Cerebellum 2012;11:488–504.  



158 
 

31. Schmitz-Hübsch T, Giunti P, Stephenson DA, et al. SCA Functional Index: a 

useful compound performance measure for spinocerebellar ataxia. Neurology 

2008;71:486–492. 

32. Du Montcel ST, Charles P, Ribai P, et al. Composite cerebellar functional 

severity score: validation of a quantitative score of cerebellar impairment. Brain 

2008;131:1352–1361.  

33. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State 

Med J 1965;14:61–65.  

34. Fleck MP, Louzada S, Xavier M, et al. Application of the Portuguese version of 

the abbreviated instrument of quality life WHOQOL-bref. Rev Saude Publica 

2000;34:178–183. 

35. Gorenstein C, Andrade L. Validation of a Portuguese version of the Beck 

Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. 

Braz J Med Biol Res 1996;29:453–457.  

36. Guy W. ECDEU Assessment Manual for Psychopharmacology, rev. ed. 

Rockville (Maryland), National Institute of Mental Health, 1976. 

37. Saute JAM, Da Silva ACF, Donis KC, Vedolin L, Saraiva-Pereira ML, Jardim LB. 

Depressive mood is associated with ataxic and non-ataxic neurological 

dysfunction in SCA3 patients. Cerebellum 2010;9:603–605; author reply 606–

607.  

38. Schmitz-Hübsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different 

rating instruments in spinocerebellar ataxia patients. Neurology 2010;74:678–

84. 

39. Jacobi H, Rakowicz M, Rola R, et al. Inventory of Non-Ataxia Signs (INAS): 

Validation of a New Clinical Assessment Instrument. Cerebellum 2012 Oct 23. 

40. Chan E, Charles P, Ribai P, et al. Quantitative assessment of the evolution of 

cerebellar signs in spinocerebellar ataxias. Mov Disord 2011;26:534–538. 

41. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in 

combination with riluzole for treatment of amyotrophic lateral sclerosis: a 

randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:481–

488. 

 

  



159 
 
Figures Subtitles 

Figure 1 - Trial Flow Diagram 

Figure 2 – Mean progression of semiquantitative SCA scales  

A. Mean progression of NESSCA, ITT. B. Mean progression of NESSCA, per-protocol. C. Mean progression of 

SARA, ITT. D. Mean progression of gait ataxia severity, ITT. Bars are SE. ITT= Intention-to-treat. NESSCA= 

Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. SARA= Scale for the 

Assessment and Rating of Ataxia. 

Figure 3 – Mean progression of individual and composite quantitative ataxia scores 

A. Mean progression of 8MW. B. Mean progression of PATA rate. C. Mean progression of 9HPTD. D. Mean 

progression of non-dominant hand Click Test. E. Mean progression of SCAFI. F. Mean progression of CCFS. 

Bars are SE. 8MW= 8m Walking-time. 9HPTD= Dominant hand 9-Hole Pegboard Test. SCAFI= SCA 

Functional Index. CCFS= Composite Cerebellar Functional Score.  

 

Tables 

Table 1 - Demografics and Baseline Characteristics 

 

Data are mean (SD), median (25
th
 to 75

th
 percentile) or number (%). CAGn= number of expanded CAG repeats. 

NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. SARA= Scale for the 

Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard Test. D= dominant hand. 

ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite Cerebellar Functional Score. BDI= 

Beck Depression Inventory. All functional scores were shown as z-scores. 

 

Table 2 – Adverse events after 48 weeks.  

Data are number of events (%). AE = Adverse events 

 

Table 3 – Intention-to-treat analysis: lithium carbonate effectiveness in MJD/SCA3  



160 
 
1
Overall 48 weeks difference between groups in GEE model; 

2
Effect related to the difference in progression of 

placebo to lithium groups; 
# 

N=51, see methods for explanation.*p&lt;0.05, **p&lt;0.01. All functional scores were 

shown as z-scores. NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. 

SARA= Scale for the Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard 

Test. D= dominant hand. ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite 

Cerebellar Functional Score. BDI= Beck Depression Inventory. 

 

Table 4 – NESSCA and SARA exploratory analysis 

1
Overall 48 weeks difference between groups in GEE model on ITT;

 2
 Effect related to the difference in 

progression of placebo to lithium groups. ***p&lt;0.001. NESSCA= Neurological Examination Score for the 

Assessment of Spinocerebellar Ataxia. SARA= Scale for the Assessment and Rating of Ataxia. 

 

Supplemental Material 

 

Supplemental table 1 – Other medical treatments 

Data are the total number of patients taking other medical treatments at baseline visit. 
1
Vitamins, nutritional 

supplements and antioxidants included: coenzyme Q10, isoflavone, omega 3, tryptophan and vitamins C and E. 

PPI= Proton-Pump Inhibitors. SNRI= Serotonin–Norepinephrine Reuptake Inhibitors. SSRI= 

Selective Serotonin Reuptake Inhibitors.  

 

Supplemental Table 2 – Most frequent adverse events after 48 weeks  

Data are number of events (%). AE = Adverse events. ECG = electrocardiogram. TSH= thyroid stimulating 

hormone.  

 

Supplemental Table 3 – Per-protocol analysis: lithium carbonate efficacy in MJD/SCA3  



161 
 
1
 Overall 48 weeks difference between groups in GEE model; 

2
 Effect related to the difference in progression of 

placebo to lithium groups; 
# 

N=48, see methods for explanation. *p&lt;0.05, **p&lt;0.01. All functional scores were 

shown as z-scores. NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. 

SARA= Scale for the Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard 

Test. D= dominant hand. ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite 

Cerebellar Functional Score. BDI= Beck Depression Inventory. 

 

 

 

 

 

 

 

  



162 
 

 
Placebo (n=31) Lithium (n=31) 

Women 17 (54%) 15 (48%) 

Age at Baseline 40.4 (9.2) 40.5 (9.6) 

Age at Onset 34.5 (9) 34.5 (8.8) 

Duration 6.1 (2.5) 6 (2.6) 

CAGn 75.4 (2.8) 75.3 (3.3) 

NESSCA 14.7 (4.7) 13.8 (4.7) 

SARA 11.4 (3.7) 10.3 (4.3) 

Gait Ataxia 

Severity 

1 3 (10%) 5 (16%) 

2 19 (61%) 18 (58%) 

3 9 (29%) 8 (26%) 

8MW 8.48 (7.0 to 14.2) 7.3 (5.9 to 12.7) 

PATA rate 25.6 (5.8) 26.3 (7.3) 

9HPT D 17.8 (2.9) 18.9 (6.0) 

9HPT ND 20.37 (4.0) 20.7 (6.7) 

Click Test D 20.35 (3.8) 20.9 (4.8) 

Click Test ND 20.55 (3.6) 21.1(5.7) 

SCAFI -0.19 (0.62) -0.02 (1.11) 

CCFS 1.07 (0.06) 1.08 (0.08) 

Barthel 95 (6.58) 93.4 (9.8) 

BDI 13.23 (9.6) 11.4 (8.5) 

WHOQOL-bref 

Physical 
50.58 (15.27) 57.6 (17.6) 

WHOQOL-bref 

Psychological 
60.35 (17.0) 65.7 (15.7) 

WHOQOL-bref 

Social 
69.09 (17.10) 70.1 (17.3) 

WHOQOL-bref 

Environment 
60.9 (16.57) 61.6 (13.0) 

Physical Therapy 14 (45%) 14 (45%) 

Phonotherapy 6 (19%) 3 (10%) 

 

 

Table 1 - Demografics and Baseline Characteristics 

Data are mean (SD), median (25
th
 to 75

th
 percentile) or number (%). CAGn= number of expanded CAG repeats. 

NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. SARA= Scale for the 

Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard Test. D= dominant hand. 

ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite Cerebellar Functional Score. BDI= 

Beck Depression Inventory. All functional scores were shown as z-scores. 

 



163 
 
AE Placebo Lithium Total p 

Total 92 (49.7%) 95 (50.3%) 187 0.884 

Mild 59 (50.4%) 58 (49.6%) 117 (62.6%) 

0.913 Moderate 28 (47.5%) 31 (52.5%) 59 (31.6%) 

Severe 5 (45.5%) 6 (54.5%) 11 (5.9%) 

Serious 1 (1.1%) 3 (3.2%) 4 (2.1%) 0.621 

 

Table 2 – Adverse events after 48 weeks  

Data are number of events (%). AE = Adverse events 

  



164 
 

N=60 p
1
 Favoring Effect

2
 95% CI 

NESSCA 0.222 Lithium 
24w 0.93 [-0.12;1.98] 

48w 0.35 [-1.0; 1.70] 

SARA 0.329 Lithium 
24w 0.26 [-1.02;1.53] 

48w 0.96 [-0.46;2.38] 

Ataxia Severity 0.008** Lithium 
24w 0.26* [0.03;0.48] 

48w 0.32* [0.07;0.57] 

8MW
#
 0.244 Lithium 

24w 3.62 [-11.4;18.66] 

48w 14.63 [-3.09;32.36] 

PATA rate 0.002** Lithium 
24w -0.37* [-0.65;-0.08] 

48w -0.44** [-0.73;-0.14] 

9HPT D 0.074 Lithium 
24w 0.31 [-0.06;0.68] 

48w 0.34 [-0.07;0.76] 

9HPT ND 0.619 
Lithium 24w 0.14 [-0.19;0.48] 

Placebo 48w -0.33 [-0.84;0.18] 

Click Test D 0.051 Lithium 
24w 0.42 [-0.08;0.93] 

48w 0.38 [-0.006;0.76] 

Click Test ND 0.023* Lithium 
24w 0.57 [-0.03;1.17] 

48w 0.38 [-0.06;0.82] 

SCAFI
#
 0.015* Lithium 

24w -0.20 [-0.41;0.003] 

48w -0.32* [-0.57;-0.06] 

CCFS 0.029* Lithium 
24w 0.03 [-0.002;0.06] 

48w 0.03* [0.003;0.05] 

Barthel 0.780 Lithium 
24w -0.68 [-4.37;3.00] 

48w -0.23 [-3.74;3.28] 

BDI 0.420 Lithium 
24w 1.58 [-1.50;4.66] 

48w 0.39 [-1.87;2.66] 

WHOQOL-bref 

Physical 
0.442 Lithium 

24w -0.95 [-8.85;6.95] 

48w -4.24 [-11.29;2.80] 

WHOQOL-bref 

Psychological 
0.402 Placebo 

24w 0.61 [-6.27;7.49] 

48w 3.97 [-1.81;9.76] 

WHOQOL-bref 

Social 
0.209 Placebo 

24w 5.69 [-2.59;13.97] 

48w 3.16 [-5.10;11.43] 

WHOQOL-bref 

Environment 
0.948 

Placebo 24w 0.57 [-5.44;6.59] 

Lithium 48w -0.25 [-6.05;5.54] 

 

Table 3 – Intention-to-treat analysis: lithium carbonate effectiveness in MJD/SCA3  

1
Overall 48 weeks difference between groups in GEE model; 

2
Effect related to the difference in progression of 

placebo to lithium groups; 
# 

N=51, see methods for explanation.*p&lt;0.05, **p&lt;0.01. All functional scores were 

shown as z-scores. NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. 

SARA= Scale for the Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard Test. 

D= dominant hand. ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite Cerebellar 

Functional Score. BDI= Beck Depression Inventory. 



165 
 

Variable p
1
 Favoring Effect

2
 95% CI 

NESSCA sub scores     

NESSCA cerebellar &amp;lt;0.001*** Lithium 
24w 0.81*** [0.44;1.18] 

48w 0.64** [0.23; 1.05] 

NESSCA oculomotor 0.685 Lithium 
24w 0.09 [-0.23;0.41] 

48w 0.02 [-0.28;0.31] 

NESSCA pyramidal 0.788 Placebo 
24w -0.01 [-0.38;0.36] 

48w -0.07 [-0.41;0.26] 

NESSCA 

extrapyramidal 
0.766 

Lithium 24w 0.074 [-0.52;0.67] 

Placebo 48w -0.240 [-0.84;0.36] 

NESSCA peripheral 0.912 
Placebo 24w -0.048 [-0.47;0.37] 

Lithium 48w 0.005 [-0.53;0.54] 

SARA items      

Gait 0.176 Lithium 
24w 0.227 [-0.16;0.61] 

48w 0.299 [-0.16;0.76] 

Stance 0.181 Lithium 
24w 0.293 [-0.20;0.78] 

48w 0.288 [-0.19;0.77] 

Sitting 0.756 Lithium 
24w 0.67 [-0.15;0.29] 

48w 0.002 [-0.28;0.28] 

Speech 0.913 
Placebo 24w -0.112 [-0.47;0.25] 

Lithium 48w 0.077 [-0.25;0.41] 

Finger chase 0.271 Lithium 
24w 0.050 [-0.16;0.26] 

48w 0.139 [-0.05;0.33] 

Nose-finger  0.920 
Placebo 24w -0.081 [-0.27;0.11] 

Lithium 48w 0.098 [-0.10;0.30] 

Fast alternating 

movements 
0.230 Lithium 

24w 0.149 [-0.21;0.51] 

48w 0.269 [-0.13;0.67] 

Heel-shin  0.869 
Placebo 24w -0.006 [-2.43;3.36] 

Lithium 48w 0.46 [-1.87;2.66] 

 

Table 4 – NESSCA and SARA exploratory analysis 

1
Overall 48 weeks difference between groups in GEE model on ITT;

 2
 Effect related to the difference in 

progression of placebo to lithium groups. ***p&lt;0.001. NESSCA= Neurological Examination Score for the 

Assessment of Spinocerebellar Ataxia. SARA= Scale for the Assessment and Rating of Ataxia. 

 

 

 



166 
 

 

  



167 
 



168 
 

 

 

 

  



169 
 

Drug Class Placebo Lithium 

SSRI 8 8 

Tricyclic antidepressants 6 4 

Hormonal contraceptives 3 4 

Benzodiazepines 2 4 

Vitamins, nutritional 

supplements and 

antioxidants1 

3 3 

Muscle relaxant / analgesics 3 2 

PPI 1 4 

Anticholinergics 2 1 

Beta-blockers 1 2 

Calcium channel blockers 1 1 

?-agonists 0 1 

Levodopa 1 0 

SNRI 1 0 

Statins 1 0 

 
Supplemental table 1 – Other medical treatments 

Data are the total number of patients taking other medical treatments at baseline visit. 
1
Vitamins, nutritional 

supplements and antioxidants included: coenzyme Q10, isoflavone, omega 3, tryptophan and vitamins C and E. 

PPI= Proton-Pump Inhibitors. SNRI= Serotonin–Norepinephrine Reuptake Inhibitors. SSRI= 

Selective Serotonin Reuptake Inhibitors.  

 

  



170 
 

AE Placebo Lithium Total 

Minor ECG 

abnormalities 
6 (50%) 6 (50%) 12 

Muscular pain 7 (63.6%) 4 (36.4%) 11 

Headache 4 (44.4%) 5 (55.6%) 9 

TSH elevation 1 (12.5%) 7 (87.5%) 8 

Falls 2 (25%) 6 (75%) 8 

Somnolence 4 (50%) 4 (50%) 8 

Mild transaminases 

elevation 
5 (71.4%) 2 (28.6%) 7 

Diarrhea 2 (33.2%) 4 (66.7%) 6 

Erectile dysfunction 1 (16.7%) 5 (83.3%) 6 

Microscopic hematuria 4 (66.7%) 2 (33.3%) 6 

Heart burn 2 (40%) 3 (60%) 5 

Insomnia 3 (60%) 2 (40%) 5 

 

Supplemental Table 2 – Most frequent adverse events after 48 weeks  

Data are number of events (%). AE = Adverse events. ECG = electrocardiogram. TSH= thyroid stimulating 

hormone.  

 

  



171 
 

 

 

 

 

 

 

 

 

Supplemental Table 3 – Per-protocol analysis: lithium carbonate efficacy in MJD/SCA3  

1
 Overall 48 weeks difference between groups in GEE model; 

2
 Effect related to the difference in progression of 

placebo to lithium groups; 
# 

N=48, see methods for explanation. *p&lt;0.05, **p&lt;0.01. All functional scores were 

shown as z-scores. NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. 

SARA= Scale for the Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard Test. 

D= dominant hand. ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite Cerebellar 

Functional Score. BDI= Beck Depression Inventory. 

N=54 p
1
 Favoring Effect

2
 95% CI 

NESSCA 0.116 Lithium 
24w 0.91 [-0.15;1.97] 

48w 0.72 [-0.65;2.09] 

SARA 0.557 
Placebo 24w -0.10 [-1.33;1.14] 

Lithium 48w 0.81 [-0.61;2.24] 

Ataxia Severity 0.010** Lithium 
24w 0.28* [0.05;0.51] 

48w 0.30* [0.03;0.58] 

8MW
#
 0.026* Lithium 

24w 8.49 [-3.41;20.4] 

48w 19.39* [4.37;34.41] 

PATA rate 0.010** Lithium 
24w -0.28 [-0.58;0.01] 

48w -0.44* [-0.74;-0.13] 

9HPT D
#
 0.117 Lithium 

24w 0.36 [-0.02;0.75] 

48w 0.24 [-0.19;0.68] 

9HPT ND
#
 0.184 

Lithium 24w 0.01 [-0.33;0.35] 

Placebo 48w -0.49 [-1.02;0.03] 

Click Test D 0.210 Lithium 
24w 0.23 [-0.27;0.75] 

48w 0.26 [-0.10;0.63] 

Click Test ND 0.137 Lithium 
24w 0.45 [-0.18;1.10] 

48w 0.17 [-0.23;0.58] 

SCAFI 0.015* Lithium 
24w -0.21 [-0.43;0.007] 

48w -0.33* [-0.59;-0.07] 

CCFS 0.155 Lithium 
24w 0.02 [-0.01;0.05] 

48w 0.02 [-0.006;0.01] 

Barthel 0.945 Lithium 
24w -0.14 [-4.11;3.84] 

48w -0.10 [-3.71;3.50] 

BDI 0.827 
Lithium 24w 0.62 [-2.58;3.82] 

Placebo 48w -0.08 [-2.30;2.13] 

WHOQOL-bref 

Physical 
0.527 Lithium 

24w -0.70 [-8.73;7.33] 

48w -3.78 [-11.24;3.68] 

WHOQOL-bref 

Psychological 
0.271 Placebo 

24w 2.08 [-5.32;9.49] 

48w 4.50 [-1.97;10.98] 

WHOQOL-bref 

Social 
0.110 Placebo 

24w 7.98 [-0.74;16.7] 

48w 3.56 [-4.83;11.96] 

WHOQOL-bref 

Environment 
0.841 Lithium 

24w -0.420 [-6.19;5.35] 

48w -0.558 [-6.78;5.67] 



172 
 
 

 

6 CONSIDERAÇÕES FINAIS 
 

Este trabalho produziu informações originais sobre aspectos nutricionais e 

hormonais e sobre a segurança e a eficácia do carbonato de lítio na DMJ/SCA3. 

Ademais, trouxe mais compreensão sobre quais podem ser os melhores desfechos 

clínicos (as escalas revisadas) e os melhores delineamentos, em futuros ensaios 

clínicos para a condição. 

 É da natureza da investigação científica que uma linha nunca se encerre e 

que os seus resultados gerem novas hipóteses para os passos a seguir. A 

descoberta científica é um processo – e não uma revelação – e uma de suas 

belezas é justamente o seu caráter especulativo em relação ao que ainda não se 

sabe e que reside, por ora, no futuro. Nossos resultados levantaram diversas 

hipóteses, que por sua vez se impõem como novos desafios a serem testados da 

melhor maneira possível. 

 Nossas conclusões, ou evidências principais, e sua incompletude, são as 

seguintes: 

1) Os sintomas depressivos são frequentes em pacientes com DMJ/SCA3 e 

estão intimamente relacionados tanto com a gravidade das manifestações 

cerebelares quanto extracerebelares. Estes sintomas representam significativo 

impacto negativo sobre a qualidade de vida dos indivíduos, e são tratáveis. A 

avaliação dos demais fatores relacionados à redução da qualidade de vida dos 

pacientes com DMJ/SCA3 não está bem elucidada, assim como a definição dos 

melhores instrumentos para sua avaliação. A análise de validação e responsividade 

no presente ECR do questionário WHOQOL-bref está em fase de execução e será 

relatada nos próximos meses.    

2) A DMJ/SCA3 está associada definitivamente à perda de peso. Ao contrário 

das previsões, este emagrecimento associou-se muito claramente à mutação (ao 

tamanho da repetição expandida) e não exatamente à progressão da doença – à 

disfagia e outras incapacidades. Esse resultado sugere que a ATXN3 mutada produz 

algum efeito sistêmico, possivelmente de origem extraneuronal, que provoca 

primariamente o emagrecimento. Uma taxa metabólica basal elevada é a primeira 

explicação que se apresenta. Ademais, resta confirmar com mais robustez que a 



173 
 

disfagia terá de fato um papel irrelevante nesse achado. Um estudo caso-controle 

sobre o metabolismo basal e avaliação de peptídeos reguladores do apetite em 

pacientes com início recente dos sintomas e em indivíduos pré-sintomáticos; e um 

outro que correlacione o grau de disfagia – medido por seu melhor instrumento, a 

videofluoroscopia da deglutição – com o emagrecimento poderiam responder a 

essas dúvidas. Ambos estão sendo planejados e serão realizados na sequência 

desta tese. 

3) A expansão CAG no ATXN3 está associada a alterações nos níveis séricos 

da proteína ligante do IGF-1, a IGFBP-1. Esse dado é outra evidência de um efeito 

sistêmico, extraneuronal, da ATXN3 mutada e coloca a IGFBP-1 como possível 

biomarcador da DMJ/SCA3. Como este efeito é mediado e quais são suas 

consequências são as perguntas que levantamos. Um novo estudo, que meça a 

expressão da IGFBP-1 e a correlacione com a CAG expandida, poderá ajudar a 

esclarecer se este efeito é devido a uma expressão aumentada ou a uma redução 

de sua degradação. Esse estudo, em consequência desta tese, já está em 

andamento. Uma melhor definição do papel da IGFBP-1 como biomarcador da 

doença e a avaliação da relevância clínica deste achado será realizada no estudo de 

biomarcadores aninhado ao ECR com carbonato de lítio. 

4) A DMJ/SCA3 está associada a um aumento da sensibilidade periférica à 

insulina que leva a redução de seus níveis séricos e manutenção da glicemia.  A 

maior sensibilidade periférica à insulina ocorreu em indivíduos com idades de inicio 

mais precoces e de forma independente do tamanho da CAG expandida, seu 

principal preditor. Apesar de a redução da sinalização intracelular de insulina poder 

resultar em Diabetes Mellitus, ela também pode aumentar a longevidade e atrasar o 

processo de toxicidade mediada pela agregação proteica (Cohen e Dillin, 2009). 

Esse cenário é o oposto do que encontramos para DMJ/SCA3 e gera hipóteses 

iniciais sobre os mecanismos do provável efeito modificador da doença que 

descrevemos para a insulina. Como e quando estas alterações iniciam e se existe 

potencial terapêutico na modulação destas vias, são algumas das perguntas a 

serem respondidas. Um estudo avaliando o sistema insulina/IGF-1 em estágios pré-

sintomáticos e precoces da doença poderá começar a responder à questão. Esse 

estudo, consequência desta tese, já está em andamento.  



174 
 

 5) A progressão da NESSCA possivelmente não foi capaz de demonstrar a 

efetividade do tratamento com carbonato de lítio em 60 pacientes com DMJ/SCA3. 

Ainda que vários desfechos secundários tenham apresentado melhora significativa, 

não resultam em nível de evidência suficiente para recomendar o uso deste 

medicamento. Estes resultados indicam a necessidade de um segundo ECR, que 

use outro desfecho primário e que utilize os dados do ensaio anterior para aprimorar 

o seu delineamento. Os dados essenciais seriam conhecer a progressão do 

desfecho no tempo e ter uma estimativa mais próxima do tamanho do efeito a ser 

buscado. Estudos de história natural podem ser uteis neste sentido, contudo os 

dados do presente ECR serão certamente de maior valia para o planejamento de 

futuros estudos com lítio e com outros medicamentos, pois demonstram a evolução 

das principais escalas clínicas de SCAs já descritas considerando a presença do 

efeito placebo e de um maior efeito Hawthorne, relacionado ao acompanhamento 

controlado de um ensaio clínico. Duas classes de desfecho poderão ser eleitas: 

escalas clínicas ou biomarcadores. Para a questão dos biomarcadores, nós nos 

preparamos e colhemos uma série deles nos três tempos do ECR – baseline, 6 e 12 

meses – e poderemos ver como eles progrediram. Entre eles, estão o IGF-1, 

Insulina, IGFBP-1, NSE e BDNF. Esses resultados serão analisados em 2013 e 

podem levar à sugestão de biomarcadores mais sensíveis à resposta terapêutica. 

Por outro lado, vimos que vários instrumentos de medida da ataxia melhoraram em 

12 meses. Seria essa resposta observada espúria? Um ECR usando uma delas 

como desfecho primário poderá dar convicção completa. Será necessário nos 

próximos meses analisar em detalhes os desfechos que utilizamos no ECR 

apresentado, bem como as subpopulações em que se sugere um maior benefício, a 

fim de calcularmos os tamanhos amostrais necessários para cada um dos 

instrumentos. Certamente um número ainda maior de pacientes será necessário 

para provar a efetividade do carbonato de lítio em reduzir a progressão da 

DMJ/SCA3, havendo a necessidade deste segundo ECR ser multicêntrico, e é essa 

a nossa proposição final. 

 

 

 

 



175 
 

7 APÊNDICES 

7.1 Termos de consentimento livre e esclarecido  

 

PROJETO: O PAPEL DO FATOR SEMELHANTE À INSULINA TIPO I (IGF-1) NA DOENÇA DE MACHADO-

JOSEPH 

INFORMAÇÕES AOS INDIVÍDUOS CONVIDADOS A PARTICIPAR DO ESTUDO (CASOS). 

 

 

Esta é uma pesquisa que tem por objetivo principal analisar se uma substância 

natural e circulante no sangue e nos tecidos das pessoas, um neuroprotetor, conhecido pelo 

nome de ?Sistema do Fator de Crescimento semelhante à Insulina do Tipo 1 (IGF-1)?,  está  

alterado nos pacientes com a Doença de Machado-Joseph. A intenção é a de se 

compreender melhor os mecanismos dessa doença e, talvez, buscar a aquisição de 

conhecimento que possibilite um futuro tratamento eficaz para os pacientes afetados por 

esse problema de saúde. Serão dosadas várias substâncias no seu sangue ou plasma: os 

níveis séricos de IGF-1, IGFBP-1 e 3, Albumina, Insulina, Colesterol Total, Colesterol HDL, 

Triglicerídeos, Glicose, Creatinina, Bilirrubinas e Tempo de Protrombina. Essas substâncias 

serão dosadas em dois grupos de pessoas: nos doentes portadores da Doença de 

Machado-Joseph e em pessoas sadias, que servirão de comparação. É necessário estudar 

um grupo de pessoas que não possuam a doença para comparar seus resultados com os do 

grupo de pacientes portadores da Doença de Machado-Jospeh.  

Você está sendo convidado a participar dessa pesquisa, por ser portador da Doença 

de Machado-Joseph. Sua participação, caso estiver de acordo com ela, envolverá (1) uma 

entrevista clínica; (2) o preenchimento de um questionário para avaliar se você tem 

manifestações depressivas; (3) a realização de exames físicos neurológicos padronizados; e 

(4) a coleta de duas amostras de sangue (20 mL). Entretanto, tudo isso somente será feito, 

depois de você autorizar a sua participação nesse estudo, entregando um documento 

assinado por si ou por seu representante legal. 

 O sangue coletado será armazenado, para fins dessa pesquisa. Ele poderá ser 

utilizado para outros fins somente mediante a sua autorização por escrito, tanto no presente 

termo de consentimento, como em documentos futuros. Solicitaremos sua autorização 

expressa para qualquer nova pesquisa para a qual cogitarmos em aproveitar seu material 

armazenado. Por isso, ficaremos com seu endereço e telefone.  Novos projetos de pesquisa 

que aparecerem no futuro, para os quais eventualmente solicitarmos sua aprovação para o 



176 
 
aproveitamento do seu material estocado, também deverão obter aprovação prévia da 

Comissão de Ética Local (chamada de GPPG) e da Comissão Nacional de Pesquisa 

(chamada de CONEP). 

Os riscos envolvidos nessa pesquisa são: mal-estar passageiro ou mancha roxa no 

local da coleta de sangue e cansaço. Seu nome será mantido em sigilo pelos pesquisadores 

envolvidos no estudo, sendo estes dados utilizados apenas para esta pesquisa.  

Os resultados definitivos não terão prazo para sua liberação, pois dependem de 

análises bioquímicas em implementação no laboratório. Esses resultados também não terão 

uma interpretação direta: ou seja, não serão ?bons? ou ?maus?. Mesmo assim, se você o 

desejar, podemos entregá-los assim que ficarem prontos. Se assim o desejar, por favor, 

assinale na folha do Termo de Consentimento. 

Os resultados dos exames realizados no seu material ficarão guardados em bancos 

de dados protegidos, aos quais terão acesso somente os pesquisadores envolvidos. 

Nenhum resultado seu será divulgado ou liberado para terceiros. São considerados dados 

sigilosos, e estarão apenas à sua disposição ou de seu representante legal.  

 

 

Pesquisador Responsável:      Pesquisador Executor: 

Drª Laura Bannach Jardim                                                   Jonas A. M. Saute ou 

Andrew Chaves 

 

Endereço e telefone da pesquisadora responsável, Laura Bannach Jardim, 

Serviço de Genética Médica do HCPA 

Hospital de Clínicas de Porto Alegre 

Rua Ramiro Barcelos 2350 

90035-903 Porto Alegre, RS, Brasil 

Tel.: (51) 2101-8011 

Fax: (51) 2101-8010 



177 
 

PROJETO: O PAPEL DO FATOR SEMELHANTE À INSULINA TIPO I (IGF-1) NA DOENÇA DE MACHADO-

JOSEPH 

INFORMAÇÕES AOS INDIVÍDUOS CONVIDADOS A PARTICIPAR DO ESTUDO, COMO CONTROLES 

SAUDÁVEIS. 

 

 

Esta é uma pesquisa que tem por objetivo principal analisar se uma substância 

natural e circulante no sangue e nos tecidos das pessoas, um neuroprotetor, conhecido pelo 

nome de ?Sistema do Fator de Crescimento semelhante à Insulina do Tipo 1 (IGF-1)?,  está  

alterada nos pacientes com a Doença de Machado-Joseph. A intenção é a de se 

compreender melhor os mecanismos dessa doença e, talvez, buscar a aquisição de 

conhecimento que possibilite um futuro tratamento eficaz para os pacientes afetados por 

esse problema de saúde. Serão dosadas várias substâncias no seu sangue ou plasma: os 

níveis séricos de IGF-1, IGFBP-1 e 3, Albumina, Insulina, Colesterol Total, Colesterol HDL, 

Triglicerídeos, Glicose, Creatinina, Bilirrubinas e Tempo de Protrombina. Essas substâncias 

serão dosadas em dois grupos de pessoas: nos doentes portadores da Doença de 

Machado-Joseph e em pessoas sadias, que servirão de comparação. É necessário estudar 

um grupo de pessoas que não possuam a doença para comparar seus resultados com os do 

grupo de pacientes portadores da Doença de Machado-Jospeh.  

Você está sendo convidado a participar dessa pesquisa, por não ter a Doença de 

Machado-Joseph e ser um possível ?controle?, ou seja, saudável. Sua participação, caso 

estiver de acordo com ela, envolverá (1) uma entrevista clínica; (2) o preenchimento de um 

questionário para avaliar se você tem manifestações depressivas; e (3) a coleta de duas 

amostras de sangue (20 mL). Entretanto, tudo isso somente será feito, depois de você 

autorizar a sua participação nesse estudo, entregando um documento assinado por si ou por 

seu representante legal. 

 O sangue coletado será armazenado, para fins dessa pesquisa. Ele poderá ser 

utilizado para outros fins somente mediante a sua autorização por escrito, tanto no presente 

termo de consentimento, como em documentos futuros. Solicitaremos sua autorização 

expressa para qualquer nova pesquisa para a qual cogitarmos em aproveitar seu material 

armazenado. Por isso, ficaremos com seu endereço e telefone.  Novos projetos de pesquisa 

que aparecerem no futuro, para os quais eventualmente solicitarmos sua aprovação para o 

aproveitamento do seu material estocado, também deverão obter aprovação prévia da 

Comissão de Ética Local (chamada de GPPG) e da Comissão Nacional de Pesquisa 

(chamada de CONEP). 



178 
 

Os riscos envolvidos nessa pesquisa são: mal-estar passageiro ou mancha roxa no 

local da coleta de sangue e cansaço. Seu nome será mantido em sigilo pelos pesquisadores 

envolvidos no estudo, sendo estes dados utilizados apenas para esta pesquisa.  

Os resultados definitivos não terão prazo para sua liberação, pois dependem de 

análises bioquímicas em implementação no laboratório. Esses resultados também não terão 

uma interpretação direta: ou seja, não serão ?bons? ou ?maus?. Mesmo assim, se você o 

desejar, podemos entregá-los assim que ficarem prontos. Se assim o desejar, por favor, 

assinale na folha do Termo de Consentimento. 

Os resultados dos exames realizados no seu material ficarão guardados em bancos 

de dados protegidos, aos quais terão acesso somente os pesquisadores envolvidos. 

Nenhum resultado seu será divulgado ou liberado para terceiros. São considerados dados 

sigilosos, e estarão apenas à sua disposição ou de seu representante legal. 

 

 

 

 

 

Pesquisador Responsável:      Pesquisador Executor: 

Drª Laura Bannach Jardim                                                    Jonas A. M. Saute ou 

                                                                Andrew Chaves 

 

Endereço e telefone da pesquisadora responsável, Laura Bannach Jardim, 

Serviço de Genética Médica do HCPA 

Hospital de Clínicas de Porto Alegre 

Rua Ramiro Barcelos 2350 

90035-903 Porto Alegre, RS, Brasil 

Tel.: (51) 2101-8011 

Fax: (51) 2101-8010 

 



179 
 

 

TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO 

PROJETO: O PAPEL DO FATOR SEMELHANTE À INSULINA TIPO I (IGF-1) NA DOENÇA 

DE MACHADO-JOSEPH 

(uma cópia para o Serviço Executor e outra para o indivíduo) 

 

Responsáveis:  Professores Diogo Souza e Laura Bannach Jardim 

Serviço de Genética Médica do Hospital de Clínicas de Porto Alegre; e 

Universidade Federal do Rio Grande do Sul. 

 

1. Você teve acesso às informações dadas pelo  

 laboratório que vai realizar a pesquisa?  

 Ficou com essas informações?       

          Sim Não 

 

2.   Você pôde fazer perguntas a respeito do teste?   Sim Não 

 

3. As respostas que lhe deram foram satisfatórias?   Sim Não 

 

4. Você entendeu que o resultado será sigiloso e  

 somente entregue a você ou a seu representante   

 legal?         Sim Não 

 

5. Você entendeu que não há prazo para a entrega 

dos resultados de seus exames, pois os testes  

serão feitos como pesquisa? 

Sim Não 

  

6.  Você concorda que a sua amostra seja aproveitada 

 em outras pesquisas, futuras, e para isso seja  

 guardada  no laboratório que vai fazer a pesquisa?  Sim Não 



180 
 
  

 Quais médicos e estudantes conversaram com você  

 sobre esses testes e estudos?       

 …………. ………………………… 

 …………………………………………………………….  

  

7.   Você entendeu que você está livre para sair do estudo 

 

 a qualquer momento?      Sim Não 

 sem precisar dar qualquer explicação?    Sim Não 

 sem que isso afete o seu atendimento médico aqui?  Sim Não 

 

8.   Você deseja receber os resultados das análises, 

          quando ficarem prontos?      Sim Não 

 

9..   Você concorda em participar desse estudo?   Sim Não 

 

 

Assinatura ………………………………………………        Data ………………. 

Nome por extenso …………………………………………………. 

    Paciente ou Responsável legal 

 

Endereço: 

 

Telefone: 

 

Médico …………………………………………………………………………. 

   Assinatura    Nome por extenso 

 

O médico preenche:    (          ) caso    (        ) controle 



181 
 
 

Serviço de Genética Médica do HCPA 

Hospital de Clínicas de Porto Alegre 

Rua Ramiro Barcelos 2350 

90035-903 Porto Alegre, RS, Brasil 

Tel.: (51) 2101-8011 

Fax: (51) 2101-8010 

 

Data:  



182 
 
TERMO DE CONSENTIMENTO 

Projeto: Ensaio clínico randomizado, duplo-cego, placebo-controlado, para determinar 

a segurança e a eficácia  do tratamento com Carbonato de Lítio em pacientes com a 

Doença de Machado-Joseph 

 

Uma cópia para o paciente e outra para o pesquisador 

 

Pesquisadora responsável: Profa. Laura Bannach Jardim 

Hospital de Clínicas de Porto Alegre 

Rua Ramiro Barcelos 2350 

90035-903 Porto Alegre, RS, Brasil 

Tel.: (51) 3359-8000    

Fax: (51) 3359-8001 

 

Pesquisadores executores:  

Médicos: Jonas Alex Morales Saute, Carlos Roberto de Melo Rieder, Thais Lampert Monte e  
Raphael Machado de Castilhos 

Estudantes de medicina: Rafael Faraco e Karina Donis 

 

Telefones para contato:  

- (51) 3359-8309 (Serviço de Genética Médica - HCPA)  

- (51) 3359-8520 (Serviço de Neurologia – HCPA) 

 

Você está sendo convidado a participar de um estudo que testará a medicação Cabonato de 

Lítio em pacientes com a Doença de Machado-Joseph. Esta medicação já é utilizada há 

muitos anos para outras doenças com poucos efeitos adversos. 

Temos como objetivo principal avaliar se o Carbonato de Lítio é seguro para pacientes com 

Doença de Machado-Joseph. Aproveitaremos para também analisar se seus efeitos serão 

eficazes sobre a evolução da doença. Para tanto, precisamos comparar os resultados de 

quem usa-lo com os resultados de quem não usá-lo. Por isso, no início do estudo, metade 

dos indivíduos usará a medicação e a outra metade, usará um placebo. Um placebo é um 

comprimido no qual falta o agente farmacológico. Cada paciente que concordar em 

participar desse estudo poderá ser sorteado a entrar em qualquer um dos dois grupos: o do 

fármaco ou o do placebo. No entanto, nem você, nem os médicos que lhe atenderão 

saberão em qual grupo você entrou. Ou se você está ou não está tomando a medicação 

verdadeiramente. O sorteio será realizado por uma pessoa que não terá contato direto com 

os doentes que entrarem no estudo. 



183 
 
A pesquisa sobre a eficácia dos remédios precisa ser assim: nem o médico, nem o paciente 

devem saber se ele está recebendo o medicamento ou o placebo. É assim que 

conseguimos evitar que as nossas emoções influenciem a nossa leitura dos resultados, nos 

exames físicos dos pacientes. Tanto médicos como pacientes naturalmente desejam que o 

remédio funcione, e podem ver resultados lá onde eles talvez sejam apenas ilusões. 

O estudo terá duração de 12 meses, se tudo correr bem. Existe um coordenador do estudo 

que fiscalizará tanto se vai haver resultados positivos antes do término dos 12 meses, como 

se acontecerem eventos indesejados. Em qualquer eventualidade que coloque o grupo de 

pacientes em risco, o estudo será interrompido ou modificado, ou mesmo aberto. No caso 

de o estudo ser aberto, todos os pacientes receberão a prescrição do remédio ativo. 

Os efeitos colaterais possíveis causados pelo medicamento em estudo são: alterações na 

função da tireóide e nos níveis de glicose e cálcio no sangue; aumento de peso, perda de 

apetite, sede; sonolência, alteração de memória, tremor, alteração do equilíbrio, diminuição 

de sensibilidade do tato, disfunção sexual; arritmias cardíacas, inchaço nas pernas; 

náuseas, vômitos, boca seca; queda de cabelos, coceira no corpo, vermelhidão na pele; 

dores nas articulações e musculares. Durante o estudo será coletado sangue para 

realização de exames que avaliam a presença desses efeitos colaterais. Também serão 

realizados questionários para avaliar a evolução da doença.  

O sangue e as informações coletadas serão continuadamente monitorizados. Se algum 

evento adverso acontecer, seu médico irá contactá-lo imediatamente. Duas coisas poderão 

ser indicadas, se houver evento adverso: ou a medicação será reduzida, ou suspensa.  

Você deverá comparecer a muitas consultas, para que essa monitorização seja segura: 

serão entre 4 e 7 consultas previstas nas primeiras semanas, para acertar a dose do seu 

medicamento. Depois disso, você deverá voltar ao Hospital mais quatro vezes, no correr de 

um ano. Além dessas consultas, vamos combinar telefonemas de quinze em quinze dias 

para saber se tudo está correndo bem. 

Esses contatos são diferentes do atendimento habitual que você recebe, pois estamos 

fazendo um estudo cientifico. Ademais, se eventos indesejados e que tragam risco à sua 

saúde acontecerem, somente saberemos se mantivermos esses contatos freqüentes com 

você.  Se for necessário interromper a administração do remédio, ainda assim as consultas 

acontecerão, para sua segurança. 

A participação neste estudo é voluntária e você está livre para retirar-se dela a qualquer 

momento. 

Durante a pesquisa você poderá entrar em contados com os pesquisadores através destes 

números:  

- (51) 3359-8309 (Serviço de Genética Médica - HCPA) 

- (51) 3359-8520 (Serviço de Neurologia – HCPA) 

 

A seguir, leia atentamente estas perguntas e responda como você julgar melhor. 

1. Você teve acesso às informações dadas por quem vai realizar a pesquisa?  



184 
 
 Ficou com essas informações?       

          Sim Não 

 

2.   Você pôde fazer perguntas a respeito da pesquisa?  Sim Não 

 

3. As respostas que lhe deram foram satisfatórias?   Sim Não 

 

4. Você entendeu que o resultado será confidencial e  

 somente entregue a você ou a seu representante   

 legal?         Sim Não 

 

5. Você entendeu que o objetivo principal deste estudo 

 é definir se o medicamento Carbonato de Lítio é seguro?   Sim Não  

  

6.  Você entendeu que, nos primeiros seis meses,  

 você não saberá se estará tomando o medicamento 

 ou um comprimido neutro, sem efeito (Placebo)? 

 Você concorda com isso?      Sim Não 

7. Você entendeu que ao menos 9 consultas serão 

 agendadas nos primeiros 6 meses, e que a sua 

 assiduidade será muito importante?     Sim Não 

 

8. Quais médicos e estudantes conversaram com você  

 sobre esses testes e estudos?       

 …………. ………………………… … … … … … … … 

9.  Você entendeu que você está livre para sair do estudo 

 a qualquer momento?      Sim Não 

 sem precisar dar qualquer explicação?    Sim Não 

 sem que isso afete o seu atendimento médico aqui?  Sim Não 

 



185 
 
10.   Você entendeu que os organizadores desse estudo  

 podem decidir interromper o estudo a qualquer momento, 

 por razões de segurança?      Sim Não 

 

11.   Você concorda em participar desse estudo?   Sim Não 

 

Assinatura ………………………………………………        Data ………………. 

Nome por extenso …………………………………………………. 

    Paciente ou Responsável legal 

Endereço: 

Telefone: 

Médico …………………………………………………………………………. 

   Assinatura    Nome por extenso 

Data:  

 

 

 

 

 

 

 

  



186 
 

8 ANEXOS 

8.1 Escalas de Ataxias 

- NESSCA 

- SARA 

- Escalas Quantitativas 

- Barthel  

- BDI 

- WHOQOL-bref 
  



187 
 
NESSCA    Nome:                          Data: __ __ / __ __ / __ __ 

Avaliador:     (Circular)  Baseline      6 meses    12meses 

Item  Proofs  Severity Score 

Gait ataxia - Walking spontaneously, ten 
steps, parallel to a wall, and 

including a half-turn 

- Walking on toes, on heels, 

and in tandem 

Absent 0 

Minimal: only while walking on toes, heels, or in 

tandem 

1 

Moderate: gait autonomy preserved 2 

Inability to walk without help 3 

Wheelchair bound or bedridden 4 

Limb ataxia 

(bilateral) 

- Finger-to-nose test 

- Test for dysdiadochokinesia 

(fast alternating pronation 

and supination of hands, 

elbows fixed to his/her sides) 

- Rebound test of Gordon-
Holmes 

Absent 0 

Minimal: one single altered proof 1 

Moderate: two altered proofs 2 

Important: three altered proofs 

Proofs: (a) dysmetria, (b) fast alternating hand 

movements, and (c) upper limb rebound. Positive 
findings can be uni or bilateral. 

3 

 

Nistagmus  Absent 0 

On extreme gaze; or circular, after saccades 1 

Permanent 2 

Progressive 

external 

ophthalmoplegia 

 Absent 0 

Supranuclear: medial longitudinal fasciculus 

syndrome; or limitation in upward gaze or 

convergence 

1 

Nuclear ophthalmoplegia, with strabismus 2 

Pyramidal 

findings  

- Limb reflexes, including 

patellar and ankle clonus test  

- Plantar reflex 

- Muscle tone examination 

- Motor strength proofs: 
extended arms and 

Mingazzini test ( 60 sec each) 

Absent 0 

Few brisk reflexes 1 

General hyperreflexia; or clonus; or Babinski sign 2 

Three findings: (a) general hyperreflexia, (b) 

spasticity, (c) clonus, (d) Babinski sign; (e) paresis 

3 

Four or five of the above mentioned signs 4 

Dysarthria  Absent 0 

Mild: Impaired speech, but easy to understand  1 

Moderate: speech understandable, but with 

difficulty  

2 

Severe: speech hardly understandable 3 

Anarthria 4 

Dysfagia  Absent 0 

Mild 1 

Important: occuring every day 2 

 

 

Fasciculations  Absent 0 

Contraction fasciculation in the face  1 



188 
 

Diffuse, or in other parts of the body 2 

Sensory loss (a) Vibratory sense in the 
first toes; normal: &gt;11 sec. 

(b) Discrimination between 

tactile and algesic stimuli 

using a needle; 10 trials per 
foot (tpf). 

(c) Discrimination between 

cold (10
o
C) and warm (40-

60
o
C) water; 10 tpf 

Absent 0 

One altered proof: Reduction in (a) or (b) or (c): 

two to four mistakes, on average of both feet 

1 

Two altered proofs 2 

Total loss of vibratory sense in toes; or 5 or more 

mistakes in one of discriminating proofs; or three 

altered proofs 

 

3 

Dystonia  Absent 0 

Mild, triggered by voluntary movements  1 

Moderate,  impairing, in some degree, voluntary 

movements (vm) 

2 

Almost constant, severely impairing vm 3 

Rigidity  Absent 0 

Moderate: does not prevent total, passive 

mobilization  

1 

Important: prevent total, passive mobilization 2 

Bradykinesia 

 

- Patient is asked to perform 

10 cycles of repetitive 

opposition (extension and 

flexion) of the second finger 

against the thumb 

Absent 0 

Slow movements, with reduction in amplitude 1 

Movements can hardly be done 2 

Eyelid 

retraction 

 Absent 0 

Present 1 

Blepharospasm   Absent  0 

Present  1 

Distal 

amyotrophies 

- Inspection of the interossei, 

tenar and hypotenar muscles 

Absent 0 

Present  1 

Sphincter 

function 

 Normal 0 

Urgency 1 

Incontinence 2 

Cramps   Absent 0 

Present  1 

Vertigo  Absent 0 

Present 1 

Total score   

 

 



189 
 

Scale for the assessment and rating of ataxia (SARA) 

Paciente: 

Data: __ __ / __ __ / __ __ 

Avaliador: 

Avaliação (Circular) Baseline 6 meses 12 meses 

1) Gait 

Proband is asked (1) to walk at a safe distance parallel to a 

wall including a half-turn (turn around to face the opposite 

direction of gait) and (2) to walk in tandem (heels to toes) 

without support.  

 
0 Normal, no difficulties in walking, turning and walking tandem 

(up to one misstep allowed) 

1 Slight difficulties, only visible when walking 10  consecutive 

steps in tandem 

2 Clearly abnormal, tandem walking &gt;10 steps not possible 

3 Considerable staggering, difficulties in half-turn, but  without 

support 

4 Marked staggering, intermittent support of the wall required 

5 Severe staggering, permanent support of one stick or light 

support by one arm required 

6 Walking &gt; 10 m only with strong support (two special sticks or 

stroller or accompanying person)  

7 Walking &amp;lt;10 m only with strong support (two  special sticks or 

stroller or accompanying person) 

8 Unable to walk, even supported 

2) Stance 

Proband is asked to stand (1) in natural position, (2) with feet 

together in parallel (big toes touching each other) and (3) in 

tandem (both feet on one line, no space between heel and toe). 

Proband does not wear shoes, eyes are open. For each condition, 

three trials are allowed. Best trial is rated. 

 
0 Normal, able to stand in tandem for &gt; 10 s 

1 Able to stand with feet together without sway, but not in tandem 

for &gt; 10s 

2 Able to stand with feet together for &gt; 10 s, but only with sway 

3 Able to stand for &gt; 10 s without support in natural position, but  

not with feet together 

4 Able to stand for &gt;10 s in natural position only with intermittent 

support 

5 Able to stand &gt;10 s in natural position only with constant support 

of one arm 

6 Unable to stand for &gt;10 s even with constant support  

          of one arm 

 

 

  Score    Score  

3) Sitting 

Proband is asked to sit on an examination bed without support 

of feet, eyes open and arms outstretched to the front. 

 
0 Normal, no difficulties sitting &gt;10 sec 

1 Slight difficulties, intermittent sway 

2 Constant sway, but able to sit &gt; 10 s without support 

3 Able to sit for &gt; 10 s only with intermittent support 

4 Unable to sit for &gt;10 s without continuous support 

 

4) Speech disturbance 

Speech is assessed during normal conversation. 

 
0 Normal 

1 Suggestion of speech disturbance 

2 Impaired speech, but easy to understand 

3 Occasional words difficult to understand 

4 Many words difficult to understand 

5 Only single words understandable 

6 Speech unintelligible / anarthria 

  Score     Score  



190 
 

 

Escore Total:

5) Finger chase  

Rated separately for each side 

Proband sits comfortably. If necessary, support of feet and 

trunk is allowed. Examiner sits in front of proband and 

performs 5 consecutive sudden and fast pointing movements in 

unpredictable directions in a frontal plane, at about 50 % of 

proband´s reach. Movements have an amplitude of 30 cm and 

a frequency of 1 movement every 2 s. Proband is asked to 

follow the movements with his index finger, as fast and 

precisely as possible. Average performance of last 3 movements 

is rated.  

 
   0     No dysmetria  

   1     Dysmetria, under/ overshooting target&amp;lt;5 cm 

   2     Dysmetria, under/ overshooting target &amp;lt;15 cm  

   3     Dysmetria, under/ overshooting target &gt; 15 cm 

   4     Unable to perform 5 pointing movements 

 

6) Nose-finger test  

Rated separately for each side 

Proband sits comfortably. If necessary, support of feet and 

trunk is allowed. Proband is asked to point repeatedly with his 

index finger from his nose to examiner’s finger which is in 

front of the proband at about 90 % of proband’s reach. 

Movements are performed at moderate speed. Average 

performance of movements is rated according to the amplitude 

of the kinetic tremor.  

 

 

 
   0     No tremor  

   1     Tremor with an amplitude &amp;lt;2 cm 

   2     Tremor with an amplitude &amp;lt;5 cm  

   3     Tremor with an amplitude &gt; 5 cm  

   4     Unable to perform 5 pointing movements  

Score Right Left Score Right Left 

mean of both sides (R+L)/2  mean of both sides (R+L)/2  

7) Fast alternating hand movements  

Rated separately for each side  

Proband sits comfortably. If necessary, support of feet and 

trunk is allowed. Proband is asked to perform 10 cycles of 

repetitive alternation of pro- and supinations of the hand on 

his/her thigh as fast and as precise as possible. Movement is 

demonstrated by examiner at a speed of approx. 10 cycles 

within 7 s. Exact times for movement execution have to be 

taken. 

 
0 Normal, no irregularities (performs&amp;lt;10s) 

1 Slightly irregular (performs&amp;lt;10s) 

2 Clearly irregular, single movements difficult to distinguish or 

relevant interruptions, but performs&amp;lt;10s 

3 Very irregular, single movements difficult to distinguish or 

relevant interruptions, performs &gt;10s 

4 Unable to complete 10 cycles 

  

8) Heel-shin slide  

Rated separately for each side 

Proband lies on examination bed, without sight of his legs. 

Proband is asked to lift one leg, point with the heel to the 

opposite knee, slide down along the shin to the ankle, and lay 

the leg back on the examination bed. The task is performed 3 

times. Slide-down movements should be performed within 1 s. 

If proband slides down without contact to shin in all three 

trials, rate 4.  
 

0 Normal 

1 Slightly abnormal, contact to shin maintained  

2 Clearly abnormal, goes off shin up to 3 times during 3 cycles 

3 Severely abnormal, goes off shin 4 or more times during 3  

cycles 

4 Unable to perform the task 

 

      Score Right Left   Score Right Left 

  mean of both sides (R+L)/2    mean of both sides (R+L) / 2  



191 
 

Paciente: 

Data: __ __ / __ __ / __ __ 

Avaliador: 

Avaliação (Circular) Baseline 6 meses 12 meses 

 

Teste de caminhada de 8 metros (8-MW) 

Instruções: É realizada a medida do tempo levado pelo paciente para caminhar 8 metros 

podendo utilizar qualquer aparelho (bengala, andador), porém sem o auxilio de outra pessoa 

ou da parede para realizar o teste. É dada a instrução de o mesmo realizar a tarefa o mais 

rápido possível, mas de forma segura. Ao iniciar o teste o paciente deve estar com os pés 

atrás da linha de largada, sendo permitido que o aparelho que o auxilia esteja à frente desta 

linha. Realizar o teste 2 vezes e anotar os valores. Se o paciente não conseguir, anotar que 

foi incapaz de realizar o teste. 

                                              

8 - MW Tempo (s) 

Tempo 1 (s):  

Tempo 2 (s):  

 

 

 

Medida PATA  

 

Instruções: Contar o quão freqüente o paciente consegue repetir as sílabas ?PATA? em 10 

segundos. Realizar o teste 2 vezes e anotar os valores 
 
 
 

PATA rate Tempo (s) 

Tempo 1 (s):  

Tempo 2 (s):  

 

  



192 
 

Paciente: 

Data: __ __ / __ __ / __ __ 

Avaliador: 

Avaliação (Circular) Baseline 6 meses 12 meses 

 

9-Hole Pegboard Test 

Instruções: O paciente, que está sentado, segura nove cilindros (9mm de diametro e 32mm 

de comprimento) em uma da mãos e os coloca arbitrariamente, um por um, com a mão 

contrária em uma prancha de madeira com 9 buracos. O cronômetro deve ser iniciado 

quando o primeiro cilindro é colocado corretamente em um buraco e termina quando o 

último cilindro tiver sido colocado. O examinador deve segurar firmemente a prancha 

durante o teste. Uma tentativa é desempenhada para cada mão. Se o paciente deixar cair 

um cilindro o examinador pára o cronômetro e o paciente reinicia o teste desde o seu início. 

                                              

9-Hole Pegboard Tempo 1 (s)   Tempo 2 (s) 

Mão dominante  

Mão não-dominante   

 

 

Click Test 

Instruções: O paciente fica sentado de frente para o examinador com o contador 
posicionado sobre a mesa com os números voltados para o examinador. O paciente deve 
utilizar o seu dedo indicador para pressionar o botão do contador, alternadamente, 10 
vezes. O tempo inicia quando o primeiro botão for apertado e encerra quando o segundo 
contador marcar 10. O teste é realizado apenas 1x para cada mão. 
 
 

Click Test Tempo 1 (s)   Tempo 2 (s) 

Mão dominante  

Mão não-dominante   

 

(ATENÇÃO: Anotar esquerda ou direita para todos e especificar se ambidestro) 



193 
 

ÍNDICE DE BARTHEL 

Paciente: 

Data: __ __ / __ __ / __ __ 

Avaliador: 

Avaliação (Circular) Baseline 6 meses 12 meses 

 

Como você realiza as suas refeições? 

(   ) 10 – Independente. Capaz de comer por si só em tempo razoável. A comida pode ser 

cozida ou servida por outra pessoa. 

(  ) 5 – Necessita de ajuda para se cortar a carne, passar a manteiga, porém é capaz de 

comer sozinho. 

(  ) 0 – Dependente. Necessita ser alimentado por outra pessoa. 

Como você toma seu banho? 

(  ) 5 - Independente. Capaz de se lavar inteiro, de entrar e sair do banho sem ajuda e de 

fazê-lo sem que outra pessoa supervisione. 

(  ) 0 – Dependente.Necessita de algum tipo de ajuda ou supervisão. 

Como você se veste? (parte superior e inferior do corpo) 

(  ) 10 - Independente. Capaz de vestir-se e despir-se sem ajuda. 

(  ) 5 – Necessita de ajuda. Realiza todas as atividades pessoais sem ajuda mais da metade 

das tarefas em tempo razoável. 

(  ) 0 - Dependente.Necessita de algum tipo de ajudA 

Como você realiza seus asseios? 

(  ) 5 – Independente. Realiza todas as atividades pessoais sem  nenhuma ajuda, os 

componentes necessários podem ser providos por alguma pessoa. 

(  ) 0 -  Dependente.Necessita de algum tipo de ajuda. 

Como é sua evacuação? 

(  ) 10 – Continente. Não apresenta episódios de incontinência. 

(  ) 5 – Acidente ocasional. Menos de uma vez por semana necessita de ajuda para colocar 

enemas ou supositórios. 

(  ) 0 – Incontinente. Mais de um episódio semanal. 



194 
 

Como é sua micção. Como você a realiza? 

(  ) 10 – Continente. Não apresenta episódios. Capaz de utilizar qualquer dispositivo por si 

só (sonda, urinol, garrafa). 

(  ) 5 – Acidente ocasional. Apresenta no máximo um episódio em 24 e requer ajuda para 

manipulação de sondas ou de outros dispositivos. 

(  ) 0 – Incontinente. Mais de um episódio em 24 horas. 

Como você vai ao banheiro? 

(  ) 10 – Independente. Entra e sai sozinho e não necessita de ajuda por parte de outra 

pessoa. 

(  ) 5 – Necessita de ajuda. Capaz de mover-se com uma pequena ajuda; é capaz de usar o 

banheiro. Pode limpar-se sozinho. 

(  ) 0 – Dependente. Incapaz de ter acesso a ele ou de utilizá-lo sem ajuda maior 

Como você realiza as suas transferência (cama, poltrona, cadeira de rodas)? 

(  ) 15 – Independente. Não requer ajuda para sentar-se ou levantar-se de uma cadeira nem 

para entrar ou sair da cama. 

(  ) 10 – Mínima ajuda. Incluindo uma supervisão ou uma pequena ajuda física. 

(  ) 5 – Grande ajuda. Precisa de uma pessoa forte e treinada. 

(  ) 0 – Dependente necessita um apoio ou ser levantado por duas pessoas. É incapaz de 

permanecer sentada. 

Como você realiza a deambulação (locomoção, caminhar) 

(  ) 15 – Independente. Pode andar 50 metros ou seu equivalente em casa sem ajuda ou 

supervisão. Pode utilizar qualquer ajuda mecânica exceto andador. SE utilizar uma prótese, 

pode colocar a prótese nela e tirar sozinha. 

(  ) 10 - Necessita ajuda. Necessita supervisão ou uma pequena ajuda por parte de outra 

pessoa ou utiliza andador. 

Como você realiza a subida e descida de escadas? 

(  ) 10 – Independente. Capaz de subir e descer um piso sem ajuda ou supervisão de outra 

pessoa. 

(  ) 5  - Necessita ajuda. Necessita ajuda e supervisão. 

(  ) 0 – Dependente. É incapaz de subir e descer degraus. 

Valores: Muito grave:  45 pontos;  Grave: 45 – 49 pontos 

Moderada: 60-80 pontos;   Leve: 80 – 100 pontos                                                                 

Pontuação total: _______________________ 



195 
 

BECK DEPRESSION INVENTORY 

Paciente: 

Data: __ __ / __ __ / __ __ 

Avaliador: 

Avaliação (Circular) Baseline 6 meses 12 meses 

 

Este questionário consiste em 21 grupos de afirmações. Depois de ler cuidadosamente cada 

grupo, faça um círculo em torno do número (0, 1, 2 ou 3) diante da afirmação, em cada 

grupo, que descreve melhor a maneira como você tem se sentido nesta semana, incluindo 

hoje. Se várias afirmações num grupo parecerem se aplicar igualmente bem, faça um 

círculo em cada uma. Tome o cuidado de ler todas as afirmações, em cada grupo, antes de 

fazer a sua escolha. 

1. 0 Não me sinto triste. 

    1 Eu me sinto triste. 

    2 Estou sempre triste e não consigo sair disso. 

    3 Estou tão triste ou infeliz que não consigo suportar. 

2. 0 Não estou especialmente desanimado quanto ao futuro. 

    1 Eu me sinto desanimado quanto ao futuro. 

    2 Acho que nada tenho a esperar. 

    3 Acho o futuro sem esperança e tenho a impressão de que as coisas não podem 

melhorar. 

3. 0 Não me sinto um fracasso. 

    1 Acho que fracassei mais do que uma pessoa comum. 

    2 Quando olho para trás, na minha vida, tudo o que posso ver é um monte de fracassos. 

    3 Acho que, como pessoa, sou um completo fracasso. 

4. 0 Tenho tanto prazer em tudo como antes. 

    1 Não sinto mais prazer nas coisas como antes. 

    2 Não encontro um prazer real em mais nada. 

    3 Estou insatisfeito ou aborrecido com tudo. 

5. 0 Não me sinto especialmente culpado. 

    1 Eu me sinto culpado às vezes. 

    2 Eu me sinto culpado na maior parte do tempo. 

    3 Eu me sinto sempre culpado. 

6. 0 Não acho que esteja sendo punido. 

    1 Acho que posso ser punido. 

    2 Creio que vou ser punido.  

    3 Acho que estou sendo punido. 

7. 0 Não me sinto decepcionado comigo mesmo. 

    1 Estou decepcionado comigo mesmo. 



196 
 

    2 Estou enojado de mim. 

    3 Eu me odeio. 

8. 0 Não me sinto de qualquer modo pior que os outros. 

    1 Sou crítico em relação a mim devido a minhas fraquezas ou meus erros. 

    2 Eu me culpo sempre por minhas falhas. 

    3 Eu me culpo por tudo de mal que acontece. 

9. 0 Não tenho quaisquer idéias de me matar. 

    1 Tenho idéias de me matar, mas não as executaria. 

    2 Gostaria de me matar. 

    3 Eu me mataria se tivesse oportunidade. 

10. 0 Não choro mais que o habitual. 

      1 Choro mais agora do que costumava. 

      2 Agora, choro o tempo todo. 

      3 Costumava ser capaz de chorar, mas agora não consigo mesmo que o queira. 

11. 0 Não sou mais irritado agora do que já fui. 

      1 Fico molestado ou irritado mais facilmente do que costumava. 

      2 Atualmente me sinto irritado o tempo todo. 

      3 Absolutamente não me irrito com as coisas que costumavam irritar-me. 

12. 0 Não perdi o interesse nas outras pessoas. 

      1 Interesso-me menos do que costumava pelas outras pessoas. 

      2 Perdi a maior parte do meu interesse nas outras pessoas. 

      3 Perdi todo o meu interesse nas outras pessoas. 

13. 0 Tomo decisões mais ou menos tão bem como em outra época. 

      1 Adio minhas decisões mais do que costumava.  

      2 Tenho maior dificuldade em tomar decisões do que antes. 

      3 Não consigo mais tomar decisões. 

14. 0 Não sinto que minha aparência seja pior do que costumava ser.  

      1 Preocupo-me por estar parecendo velho ou sem atrativos.  

      2 Sinto que há mudanças permanentes em minha aparência que me fazem parecer sem 

atrativos. 

      3 Considero-me feio. 

15. 0 Posso trabalhar mais ou menos tão bem quanto antes. 

      1 Preciso de um esforço extra para começar qualquer coisa. 

      2 Tenho de me esforçar muito até fazer qualquer coisa. 

      3 Não consigo fazer nenhum trabalho. 

16. 0 Durmo tão bem quanto de hábito. 

      1 Não durmo tão bem quanto costumava. 

      2 Acordo uma ou duas horas mais cedo do que de hábito e tenho dificuldade para voltar 

a dormir. 

      3 Acordo várias horas mais cedo do que costumava e tenho dificuldade para voltar a 

dormir. 



197 
 

17. 0 Não fico mais cansado que de hábito. 

      1 Fico cansado com mais facilidade do que costumava. 

      2 Sinto-me cansado ao fazer quase qualquer coisa. 

      3 Estou cansado demais para fazer qualquer coisa. 

18. 0 Meu apetite não está pior do que de hábito.  

      1 Meu apetite não é tão bom quanto costumava ser.  

      2 Meu apetite está muito pior agora.  

      3 Não tenho mais nenhum apetite. 

19. 0 Não perdi muito peso, se é que perdi algum ultimamente.  

      1 Perdi mais de 2,5 Kg. 

      2 Perdi mais de 5,0 Kg. 

      3 Perdi mais de 7,5 Kg. 

Estou deliberadamente tentando perder peso, comendo menos: SIM ( ) NÃO ( ) 

20. 0 Não me preocupo mais que o de hábito com minha saúde. 

      1 Preocupo-me com problemas físicos como dores e aflições ou perturbações no 

estômago ou prisão de ventre. 

      2 Estou muito preocupado com problemas físicos e é difícil pensar em outra coisa que 

não isso. 

      3 Estou tão preocupado com meus problemas físicos que não consigo pensar em outra 

coisa. 

21.0 Não tenho observado qualquer mudança recente em meu interesse sexual.  

     1 Estou menos interessado por sexo que costumava. 

     2 Estou bem menos interessado em sexo atualmente.  

     3 Perdi completamente o interesse por sexo. 

 

Escore Total:  __ __ 



198 
 

WHOQOL-BREF 

Paciente: 

Data: __ __ / __ __ / __ __ 

Avaliador: 

Avaliação (Circular) Baseline 6 meses 12 meses 

 

Instruções 

Este questionário é sobre como você se sente a respeito de sua qualidade de vida, saúde 

e outras áreas de sua vida. Por favor responda a todas as questões. Se você não tem 

certeza sobre que resposta dar em uma questão, por favor, escolha entre as alternativas a 

que lhe parece mais apropriada. Esta, muitas vezes, poderá ser sua primeira escolha.  

Por favor, tenha em mente seus valores, aspirações, prazeres e preocupações. Nós 

estamos perguntando o que você acha de sua vida, tomando como como referência as 

duas últimas semanas. Por exemplo, pensando nas últimas duas semanas, uma questão 

poderia ser:  

 Nada 
Muito  

pouco 
médio Muito 

Completa

mente 

Você recebe dos outros o apoio de que 

necessita? 
1 2 3 4 5 

 

Você deve circular o número que melhor corresponde ao quanto você recebe dos  

outros o apoio de que necessita nestas últimas duas semanas.  

Portanto, você deve circular o número 4 se você recebeu "muito" apoio como abaixo.  

 Nada 
Muito 

pouco 
médio Muito 

completa

mente 

Você recebe dos outros o apoio de que 

necessita? 
1 2 3  5 

Você deve circular o número 1 se você não recebeu "nada" de apoio.  



199 
 

Por favor, leia cada questão, veja o que você acha e circule no número e lhe parece a 

melhor resposta.  

  
muito 

ruim 
Ruim 

Nem 

ruim 

nem 

boa 

boa 
muito 

boa 

1 
Como você avaliaria sua qualidade 

de vida?  
1 2 3 4 5 

 

  

Muito 

insa-

tisfeito 

Insatis-

feito 

nem 

satisfeito 

nem 

insatisfeito 

Satis-

feito 

Muito 

satisfeito 

2 
Quão satisfeito(a) você 

está com a sua saúde? 
1 2 3 4 5 

 

As questões seguintes são sobre o quanto você 

tem sentido algumas coisas nas últimas duas semanas. 

  nada 
muito 

pouco 

mais ou 

menos 

Bas-

tante 

Extrema-

mente 

3 

Em que medida você acha que 

sua dor (física) impede você de 

fazer o que você precisa? 

1 2 3 4 5 

4 

O quanto você precisa de algum 

tratamento médico para levar sua 

vida diária? 

1 2 3 4 5 

5 O quanto você aproveita a vida? 1 2 3 4 5 

6 
Em que medida você acha que a 

sua vida tem sentido? 
1 2 3 4 5 

7 
O quanto você consegue se 

concentrar? 
1 2 3 4 5 

8 
Quão seguro(a) você se sente 

em sua vida diária? 
1 2 3 4 5 

9 

Quão saudável é o seu ambiente 

físico (clima, barulho, poluição, 

atrativos)? 

1 2 3 4 5 



200 
 

 

As questões seguintes perguntam sobre quão completamente você tem sentido ou é 

capaz de fazer certas coisas nestas últimas duas semanas. 

  nada 
muito 

pouco 
médio Muito 

completa

mente 

1

0 

Você tem energia suficiente para 

seu dia-a- dia? 
1 2 3 4 5 

1

1 

Você é capaz de aceitar sua 

aparência física? 
1 2 3 4 5 

1

2 

Você tem dinheiro suficiente para 

satisfazer suas necessidades? 
1 2 3 4 5 

1

3 

Quão disponíveis para você 

estão as informações que precisa 

no seu dia-a-dia? 

1 2 3 4 5 

1

4 

Em que medida você tem 

oportunidades de atividade de 

lazer? 

1 2 3 4 5 

 

As questões seguintes perguntam sobre quão bem ou satisfeito você se sentiu a respeito 

de vários aspectos de sua vida nas últimas duas semanas.  

  
Muito 

ruim 
ruim 

nem 

ruim 

nem 

bom 

bom 
muito 

bom 

1

5 

Quão bem você é capaz de se 

locomover? 
1 2 3 4 5 

  

Muito 

insati

sfeito 

Insati

sfeito 

nem 

satisfeit

o nem 

insatisf

eito 

satisfe

ito 

Muito 

satisfeito 

1

6 

Quão satisfeito(a) você está com 

o seu sono?  
1 2 3 4 5 

1

7 

Quão satisfeito(a) você está com 

sua capacidade de desempenhar 

as atividades do seu dia-a-dia? 

1 2 3 4 5 



201 
 

1

8 

Quão satisfeito(a) você está com 

sua capacidade para o trabalho? 
1 2 3 4 5 

1

9 

Quão satisfeito(a) você está 

consigo mesmo? 
1 2 3 4 5 

2

0 

Quão satisfeito(a) você está com 

suas relações pessoais (amigos, 

parentes, conhecidos, colegas)? 

1 2 3 4 5 

2

1 

Quão satisfeito(a) você está com 

sua vida sexual? 
1 2 3 4 5 

2

2 

Quão satisfeito(a) você está com  

o apoio que você recebe de seus 

amigos? 

1 2 3 4 5 

2

3 

Quão satisfeito(a) você está com  

as condições do local onde 

mora? 

1 2 3 4 5 

 

2

4 

 

Quão satisfeito(a) você está com 

o  

seu acesso aos serviços de 

saúde? 

1 2 3 4 5 

2

5 

Quão satisfeito(a) você está com 

o seu meio de transporte? 
1 2 3 4 5 

 

As questões seguintes referem-se a com que freqüência você sentiu ou experimentou certas 

coisas nas últimas duas semanas.  

  Nunca 
Algumas 

vezes 

freqüen

tement

e 

Muito 

freqüen

temente 

sempre 

2

6 

Com que freqüência você 

tem sentimentos negativos 

tais como mau humor, 

desespero, ansiedade, 

depressão? 

1 2 3 4 5 

 

Alguém lhe ajudou a preencher este questionário? 

Quanto tempo você levou para preencher este questionário?  

Você tem algum comentário sobre o questionário?  

OBRIGADO PELA SUA 
COLABORAÇÃO 


</field>
	</doc>
</add>